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The prostate was first described by Niccolò Massa in 1536, and illustrated by Andreas Vesa-
lius in 1538. However, prostate cancer was not identified until 1853 by J. Adams, a surgeon 
at The London Hospital.1 He noted in his report that this condition was ‘a very rare disease’. 
The first treatment modality for prostate cancer was surgery to relieve urinary obstruction.2 
Removal of the entire gland (radical perineal prostatectomy) was first performed in 1904 by 
Hugh Young at Johns Hopkins Hospital.3 The operation involved removal of the entire pros-
tate gland, the seminal vesicles, and a small cuff of bladder, with the bladder then sutured to 
the cut end of the urethra. This became the surgery of choice until the 1940s. By that time, 
prostate cancer was increasingly being detected and the typical patient was a man in his early 
seventies who was diagnosed with metastases to the bone and/or soft tissues. Diagnosis at 
such an advanced disease status was a death sentence, with patients dying within 1–2 years. 
In 1941 Charles B. Huggins (figure 1.1) discovered that metastatic prostate cancer responds 
to androgen-ablation therapy through orchiectomy, which heralded the beginning of a new 
era of prostate cancer therapy.4 The discovery of ‘chemical castration’ won Huggins the 1966 
Nobel Prize in Medicine.
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Figure 1.1 Charles B. Huggins
The next surgical advance came in 1945 when Terrence Millin introduced the retropubic ap-
proach for prostate enucleation.5 This approach offered significant advantage over the perineal 
approach because it was easier to learn and allowed access to the pelvic lymph nodes, which 
is useful for tumor staging. Although minor improvements in technique were made over the 
next 40 years, prostatectomy was not commonly performed because almost all patients were 
left impotent by the procedure. A significant advance occurred in 1983 when Patrick Walsh 
(figure 1.2) developed a modified technique for radical retropubic prostatectomy on the basis 
of an anatomical approach to enhance control of bleeding. This approach aims to avoid in-
jury to the neurovascular bundles that innervate the corpora cavernosa of the penis, thereby 
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allowing erectile function and sexual potency to be maintained without compromising the 
adequacy of surgical margins.6
External beam radiotherapy was initially used only as an adjunct to interstitial radium because 
the kilovoltage delivery systems were not adequate to allow definitive treatment of most 
deep-seated neoplasms such as prostate cancer. With the discovery of androgen-ablation 
therapy in the early 1940s, radiation therapy lost popularity as a treatment modality for pros-
tate cancer. Renewed interest in radiation therapy returned in the 1950s when higher-energy 
cobalt machines were developed, whose photon beams could penetrate to deeper levels. The 
first reported series of prostate cancer patients who were treated with 60Co(cobalt) therapy 
focused on patients with unresectable disease.7 Soon after, Juan Del Regato reported on a 
small number of patients who were apparently cured following 60Co-therapy.8 In the late 
1950s, pioneering work by Malcolm Bagshaw and others revealed the possibility of radiation 
curability of prostate cancer.9,10 The past decade has witnessed widespread acceptance and use 
of prostate brachytherapy. Interest in the procedure first appeared almost 90 years ago, and 
noted clinicians performed hundreds of implants in the first quarter of the 20th century.11
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Figure 1.2 Patrick C. Walsh
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SCREENING FOR PROSTATE CANCER
Rationale of screening
Screening for diseases, especially cancer, has become part of modern medicine. Screening 
for breast, cervical and colorectal cancer is already normal practice in some countries, and 
will probably become routine in other countries in the future.12-16 Screening for malignant 
melanoma, prostate and lung cancer are subject to ongoing studies.17-20 The rationale behind 
screening is simple: to detect cancers at an early stage, when they are still curable. Screening 
is currently performed using one of three methods: mass screening (i.e. large scale screening 
of an entire population), selective screening (i.e. screening high-risk populations) or opportu-
nistic screening (e.g. incorporated as part of a medical consultation). Diagnostic testing differs 
from screening because it attempts to identify the disease in the presence of symptoms, while 
screening is offered to symptom-free individuals.
In any population screened for cancer, however, four basic groups of patients exist: Those 
diagnosed with cancer who would not have developed cancer symptoms during their lifetime 
(overdiagnosis). Those diagnosed with cancer at an early stage that might otherwise have led 
to symptoms and/or the need for more aggressive curative treatment. Those diagnosed with 
cancer at a curable stage with aggressive disease that might otherwise have progressed to 
metastatic disease at the time of diagnosis; and those whose cancer is diagnosed by screening 
at the same stage as it would have been diagnosed through clinical routines. The window of 
opportunity for decreasing cancer-mortality by screening for cancer lies with the third group. 
Randomized clinical trials, considered the gold standard for the evaluation of a screening test, 
have to show how sizeable that window is.
European Randomized study of Screening for Prostate Cancer (ERSPC)
At present, two large randomized screening trials for prostate cancer are underway: the ERSPC 
in Europe, and the Prostate, Lung, Colorectal and Ovary cancer (PLCO) trial in the US.18 The 
ERSPC has recruited more than 250,000 men in eight European countries, in order to determine 
whether the price of reducing prostate cancer mortality through population-based screening 
is acceptable in terms of quality-of-life consequences and costs.21 The answer, based on trial 
evidence, will not be available before 2008-2010.
Prostate specific antigen (PSA)
PSA is a glycoprotein manufactured almost exclusively by the prostate gland. It is a serine 
protease enzyme, the gene of which is located on the nineteenth chromosome (19q13).22 In-
creased levels of PSA may suggest the presence of prostate cancer. However, prostate cancer 
can also be present in the complete absence of an elevated PSA level.23
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Prostate cancer incidence
Since the potential value of PSA for the early detection of prostate cancer was described in 
the early 1990s, both prostate cancer incidence and mortality rates have changed profoundly 
(figure 2.1).24 Between 1989 and 2003, for example, the age-standardized incidence rate of 
prostate cancer increased by 48.4% in The Netherlands, reaching an incidence of 93.2 cases per 
100,000 men or 7,902 in total. Based on rates from 2001-2003, 17.1% of U.S. men born today 
will be diagnosed with cancer of the prostate at some time during their lifetime.25 It is now the 
most frequently diagnosed non-cutaneous cancer with 225,000 new cases reported each year 
in Europe alone.26 Moreover, autopsy studies have revealed that prostate cancer occurs in an 
even larger proportion of men: 55% of men in their fifties, and 64% of men in their seventies.27 
If the current trends toward using lower PSA thresholds to determine the need for biopsy, and 
taking more core samples per biopsy continues, the number of living men diagnosed with 
prostate cancer will increase even further.28-30 Based on the data from the control arm of the 
Prostate Cancer Prevention Trial (PCPT) it can be calculated that if all U.S. men with PSA levels 
2.5 ng/mL or more would be biopsied 775,000 cancers would be diagnosed, which is 542,910 
more than the estimated 232,090 cases to be diagnosed in 2005 in the United States and 25.6 
times more than the 30,350 men expected to die of the disease.23,30,31
 Inc_mort  
Figure 2.1. Prostate cancer incidence and mortality trends in the Netherlands.
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Prostate cancer mortality
Despite this rising incidence, the age-standardized prostate cancer mortality rate in The 
Netherlands fell by 11% between 1989 and 2003, to 28.4 deaths per 100,000 men or 2,349 
in total.32 Whether this decrease is the result of screening or of improvements in treatment is 
controversial. Currently, one in four deaths in the United States is due to cancer. Of those, 9.4% 
is due to prostate cancer, which makes it the most important cause of death in males after 
lung cancer and colorectal cancer with an expected number of 27,350 deaths in 2006.33
Screening and stage migration
Screening results in the more frequent detection of small volume, low grade and organ con-
fined prostate cancers, which are diagnosed earlier in their course.24 It is however unclear 
whether the stage and grade migration results in a reduction in the mortality, although 
case-control studies with conflicting results are available.34-36 Lead time is defined as the time 
period from screening detection to diagnosis in absence of screening. If the patient dies 
during the lead-time period of the tumor, the lead-time is indefinite and therefore equal to 
overdiagnosis.
Overdiagnosis
Overdiagnosis occurs when screening detects small tumors that would otherwise remain 
clinically unrecognized until the individual died from other causes. It is not known whether 
the shift towards diagnosis of aggressive cancers at a favorable stage justifies the amount of 
overdiagnosis and the costs associated with screening.
The impact of overdiagnosis and unnecessary treatment and of its side effects on patient 
health is also unclear; however, application of a mathematical model (the Miscan model) on 
data from the ERSPC has shown that, in an annual screening program for men aged 55 to 67 
years, 56% of diagnosed cases would constitute instances of overdiagnosis.37 If this estimate 
proves to be realistic, nationwide screening programs may not be acceptable using the pres-
ent screening regimens, even if benefits in terms of mortality reduction were shown. Research 
aimed at the development of more selective screening tools is therefore very important.
Morbidity
Although the risk of complications from an individual prostate biopsy is very small,38 the cu-
mulative risk posed by repeated prostate biopsies in a large population could become quan-
titatively important, specifically for overdiagnosed cases. Furthermore, besides the medical 
consequences of screening tests, the emotional consequences of screened men must also be 
considered.
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Quality of life
Research suggests that, overall, other than during the short period related to the screening 
process and to the biopsy procedure, screening does not adversely influence patients’ short-
term health.39 Indeed, many men report feeling reassured as a result of screening, especially 
after receiving a ‘normal’ result. However, a diagnosis of prostate cancer, which occurs more 
frequently in a screening setting (i.e. overdiagnosis), has a negative influence on the quality 
of life.40
It is still too soon to say whether population-based prostate cancer screening is a useful tool. 
We must wait until the results of ongoing prostate cancer screening trials are available. Until 
then, opportunistic screening should not be encouraged and those men who do want a PSA 
test should participate in a carefully designed, balanced information program.41 Even if PSA 
screening is found to reduce prostate cancer-specific mortality, levels of overdiagnosis may 
remain unacceptable for population based screening. Thus, research into mechanisms to 
reduce overdiagnosis including new markers is urgently needed. Until alternative screening 
tools are found, PSA will continue to be used, and overdiagnosis will remain an unavoidable 
drawback of prostate cancer screening. The current challenge is to ensure that overdiagnosis 
does not result in overtreatment. To this end, research efforts presently focus on clarifying 
which cancers can be managed through active surveillance.
ACTIVE SURVEILLANCE
Ways out of the dilemma of overtreatment
Because not all cancers diagnosed require treatment, one of the major challenges for the fu-
ture is to determine which diagnosed cancers should be treated, and which can be managed 
by active surveillance. Active surveillance manages selected men with prostate cancer expec-
tantly with curative intent. This means men are carefully selected and subsequently actively 
observed in order to have the possibility to offer them deferred curative treatment once the 
tumor seems to progress. Active surveillance should be clearly differentiated from watchful 
waiting. Watchful waiting entails a strategy for all men who are managed expectantly, whereas 
active surveillance focuses on men for whom therapy is delayed until the tumor becomes pro-
gressive and curative treatment can be offered. The stage migration that screening provides 
has resulted in an over-representation of low-risk cancers. Therefore, studies which validate 
monitoring algorithms in active surveillance regimens are ongoing.42,43
Arguments to elect active surveillance include the prevention of overtreatment, the side-
effects of prostate cancer treatment modalities, quality of life issues, costs associated with 
treatment and ethical arguments.
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Overtreatment
The increasing use of PSA as a screening test due to a higher awareness of the disease, the in-
creasing number of biopsies, the increasing number of cores per biopsy and the increasing life 
expectancy have resulted in a more frequent diagnosis of prostate cancers, which are of lower 
grade and stage.44-46 The majority of these (screen-detected) prostate cancers have a good 
long-term survival, especially when only a small number of cores with well-differentiated pros-
tate cancer was diagnosed.47,48 Screening diagnoses prostate cancers which would not have 
been diagnosed in the absence of screening (i.e. overdiagnosis).48 As mentioned above, the 
amount of overdiagnosis is subject to investigation. Etzioni et al. applied a computer model 
to the SEER data on prostate cancer incidence from 1988 through 1998. Those were consistent 
with overdiagnosis rates of approximately 29% for whites and 44% for blacks among men 
with prostate cancers detected by PSA screening.48 With the increasing screening use of PSA, it 
is remarkable that the amount of U.S. men initially managed with watchful waiting increased 
from 7.5% in 1989 to 1991 to 9.5% in 1992 to 1994, and then decreased significantly during 
the next 6 years to 5.5% in 1998 to 2000.49
Side effects of treatment
Treatment for prostate cancer may involve surgery, external beam radiation therapy, 
brachytherapy, high intensity focused ultrasound (HIFU), watchful waiting, active surveil-
lance, chemotherapy, cryosurgery, hormonal therapy, or combinations. The most frequently 
applied treatments for organ confined prostate cancer are radical prostatectomy, external 
beam radiotherapy and brachytherapy.49
Although severe or life-threatening complications with radical prostatectomy are rare, the 
adverse effects of greatest concern are damage to the urinary sphincter and erectile nerves 
(nervi erigenti), resulting in urinary incontinence and impotence, respectively. Complete in-
continence is uncommon after radical prostatectomy, although a significant number of men 
experience some degree of stress urinary incontinence.50-52 In the Prostate Cancer Outcomes 
Study, a population-based study of 1,291 men who underwent radical prostatectomy for local-
ized prostate cancer and were followed for two years, 1.6 percent reported no urinary control 
at 24 months following surgery (compared with 0.7 percent at baseline prior to surgery), while 
7 and 42 percent reported frequent and occasional leakage, respectively (compared with 2 
and 9 percent at baseline).51 Age had an impact on the degree of incontinence; 14 percent of 
men ages 75 to 79 years experienced the highest level of incontinence compared with 0.7 to 4 
percent of younger men. In the Prostate Cancer Outcomes Study, 42 percent of men reported 
that sexual performance was a moderate to large problem at 24 months (compared with 18 
percent at baseline); 60 percent were not able to have erections firm enough for sexual inter-
course (compared with 16 percent at baseline).51 At 24 months postoperatively, men over the 
age of 60 were more likely to be impotent than younger men (78 to 85 versus 61 percent).
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Complications after external beam radiotherapy include bladder irritation (urgency, pain, 
frequency) in up to 5 percent of men, and impotence in 40 to 50 percent.53 In contrast to 
surgery, these complications tend to increase over time. The reported incidence of radiation 
proctitis ranges from 2 to 39 percent, depending upon the definition used, and the dose field, 
and technique of radiotherapy. Prostate inflammation and swelling can occur acutely following 
brachytherapy, suggesting that men with significant urinary symptoms or a large prostate are 
not good candidates. Urinary retention can be severe enough to require self-catheterization; 
transurethral resection to improve micturition is contraindicated until a substantial portion of 
the radioactivity (usually 5 half-lives) has dissipated because of the risk of incontinence and 
radiation risks to the surgeon and pathologist. Later complications include irritative voiding 
symptoms, urinary retention, rectal urgency, bowel frequency, rectal bleeding or ulceration, 
and prostatorectal fistulas.54-56 The incidence of erectile dysfunction ranges from 14 to 52 per-
cent, depending on whether it is physician- or patient-reported.
Quality of life
The more immediate, though stable, side effects associated with surgery should be weighed 
against the increasing incidence of symptoms and use of treatments after the progression of 
disease in active surveillance.57 Published empirical studies on prostate cancer specific and 
generic health related quality of life (HRQoL) in patients on active surveillance of localized 
prostate cancer are scarce. Many studies have a cross-sectional design resulting in limited 
comparability largely due to uncertainty about the selection of patients and seemingly con-
tradictory results. Still the evidence supports hypotheses that being on active surveillance 
causes uncertainty and distress and may have negative effects on generic HRQoL.58 In the 
series reported by Choo, 14 out of 69 men who discontinued the active surveillance protocol 
did so without signs of disease progression. The benefit of prevention of side effects of active 
therapy must be weighed against the impact of anxiety and uncertainty in patients on active 
surveillance.59,60
In a study among 326 participants randomized to either radical prostatectomy or watchful 
waiting, mental health and overall well-being were similar in both groups after a median fol-
low-up of 4 years.61 The CaPSURE study showed that mental health remained stable over time 
among watchful waiting patients, but that physical scores and sexual function decreased more 
than expected from the aging process alone.62 Mental scores were slightly worse compared 
to radical prostatectomy patients, but better than patients who underwent radiotherapy.63 In 
men receiving no active treatment satisfaction was less than in actively treated men.64
Steginga found moderate distress around diagnosis in a prospective study among patients 
undergoing prostatectomy, radiotherapy or watchful waiting, which decreased afterwards. 
42% of men still experienced decision-related distress after 12 months.65 In a review on anxiety 
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in prostate cancer, Dale concluded that many years after initial therapy, high anxiety levels 
were less prevalent after prostatectomy (23%) than in watchful waiting (31%).66 Daubenmier 
evaluated the effect of a lifestyle intervention among men on active surveillance. Generic 
HRQoL remained high in the intervention group. Men in the intervention group perceived 
less stress, suggesting that diet, exercise and stress management is beneficial in men on ac-
tive surveillance.67 In men receiving no active treatment, satisfaction was less than in actively 
treated men.64
One as yet unpublished Dutch population-based study among long term survivors of 
prostate cancer showed comparable generic HRQoL scores among patients who underwent 
radiotherapy or watchful waiting, with patients after prostatectomy showing better scores. 
However, the choice of watchful waiting seemed to be the policy for very old patients.68 
Knowledge of the mechanisms behind treatment choices in localized prostate cancer is 
limited. Knowledge and understanding of prostate cancer and of the uncertainty of benefit 
from active treatment, as well as active support from medical professionals, seems pivotal for 
patients to consider active surveillance.69 Fear of future consequences of progressive prostate 
cancer may be the most common reason to reject active surveillance.70 A study on patient 
education needs of men on active surveillance is ongoing at the University of California in San 
Francisco.
Costs
Another argument for active surveillance is the costs of treatment. Although no literature is 
available, it seems rational that active surveillance is less expensive than immediate treat-
ment. An unpublished study originating from Erasmus MC has revealed that the cost-savings 
for a system which has incorporated active surveillance as an important treatment modality 
are substantial. This analysis takes into account the medical consequences from treatment, 
but leaves social and quality of life consequences out of consideration.
Ethical aspect
The most important argument for active surveillance is probably an ethical one: one can 
wonder what number needed-to-treat to prevent one prostate cancer death our profession 
is prepared to accept. Based on the Swedish randomized trial of radical prostatectomy versus 
watchful waiting, the Connecticut observation series, and the Toronto active surveillance 
experience, an analysis of the benefit of radical treatment of all newly diagnosed favorable-
risk prostate cancer patients, compared with a strategy of active surveillance with selective 
delayed intervention, has been presented by Klotz.71 This number needed to treat analysis 
suggests that approximately 73 patients will require radical treatment for each prostate can-
cer death averted. This translates into a 3- to 4-week survival benefit, unadjusted for quality of 
life. If any, the number of life-years gained can be expected to be small, also because prostate 
cancer is a disease of older age. This should be contrasted to the side-effects of all applied 
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treatments. As a minimum, the number of men needed to treat should be higher than the 
number of men dying from intervention related causes.
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The introduction of the PSA test and its use as a screening test have led to a marked in-
crease in the number of newly diagnosed prostate cancers in countries where screening is 
prevalent.24,25,72,73 Whether screening affects prostate cancer mortality is still unclear, but is 
the main research question for the ERSPC and the PLCO to answer.18 Whatever these trials 
conclude, it is likely that opportunistic PSA screening will continue to be used for screening, 
although a positive effect of screening on the mortality will make a population based screen-
ing program more likely. The performance of the PSA test together with the high incidence-
to-mortality ratio and the high prevalence of the disease in older men have confronted the 
medical community and especially the urological world with new dilemmas. Basic research 
endeavors have led to the discovery of new, more specific markers for prostate cancers, but 
not to a new standard for the detection of prostate cancer which offer the possibility for risk 
stratification.74,75
Until new predictors for the detection of only the significant prostate cancers become avail-
able, the high incidence, the serious side effects of prostate cancer treatments, the costs and 
especially ethical aspects oblige us to cope with the side-effects of screening for prostate can-
cer, such as overdiagnosis. This thesis focuses on one way out of the PSA screening dilemma 
described above, namely active surveillance. It would be preferential to prevent the detec-
tion of insignificant cancers, but that is for the present impossible and is beyond the scope 
of this thesis. For this thesis, a situation is therefore accepted in which men are diagnosed 
with insignificant prostate cancer. It is further explored what kind of cancers are diagnosed 
by screening, how to subsequently risk-stratify them and what the best strategy is for active 
surveillance of a subset of these cancers.
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ABSTRACT
Introduction
The European Randomized study of Screening for Prostate Cancer (ERSPC) investigates the 
feasibility of population-based screening. This report compares the preliminary outcome of 
cancers detected in the screen and the control arm of its Rotterdam section, by means of 
biochemical progression rates.
Patients & Methods
In the screen arm of this study (21,210 men), screening was applied according to well-es-
tablished protocols, and a 4-year screen interval was chosen. Widely accepted biochemical 
progression-criteria were used to evaluate the diagnosed cancers over time.
Results
Although more cancers were detected in the screen than in the control arm (1,339 vs. 298, 
P<0.001), their clinico-pathological features were more favorable. Furthermore, screened men 
had higher 5-year survival rates for biochemical progression after surgery (84.4% vs. 58.9% in 
controls), radiotherapy (71.0% vs. 58.0%), and endocrine therapy (40.5% vs. 16.3%).
Conclusion
The higher biochemical progression-free survival can at least in part be explained by lead and 
length-time. How screening will affect the mortality remains unclear.
Biochemical progression rates in the screen arm compared to the control arm
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INTRODUCTION
Since prostate-specific antigen (PSA) screening for prostate cancer became available in the 
late 1980s,24 both prostate cancer incidence and mortality rates have changed profoundly. 
Between 1989 and 2002, for example, the age standardized incidence rate of prostate cancer 
increased by 38.7% in the Netherlands (reaching 87.1/100,000) and by 21.3% in the United 
States (reaching 176.3/ 100,000).32,73 It is now the most frequently diagnosed non-cutaneous 
cancer, with 225,000 new cases occurring each year in Europe alone.26 Between 1989 and 2002 
in the Netherlands, however, the age standardized prostate cancer mortality rate fell by 8.5% 
to 29.2/100,000,while in the USA it fell by 17.6% to 28.1/100,000 during the same period.32,73 
Whether this decrease is the result of screening or of improvements in the therapy admin-
istered is still a matter of debate. At present, two large randomized clinical screening trials 
for prostate cancer are ongoing: The European Randomized study of Screening for Prostate 
Cancer (ERSPC) in Europe, and the Prostate Lung Colorectal and Ovary cancer (PLCO) trial in 
the USA.18 The first of these (the ERSPC) has recruited and randomized approximately 250,000 
men in eight European countries in order to determine the feasibility of reducing prostate 
cancer mortality through population-based screening, and whether this is acceptable in terms 
of quality of life and cost.76 Although prostate cancer screening leads to the diagnosis of men 
with smaller volume,77 lower grade, earlier stage tumors,49 it also results in overdiagnosis and 
overtreatment. The results of screening studies are subject to lead-time bias and length-time 
bias. Lead-time is the time period from screen diagnosis to the moment the patient would 
have developed symptoms in the absence of screening. The associated overdiagnosis, which 
is inherent to screening, is defined as the detection of small tumors that would otherwise 
remain clinically covert until the patient died from other causes. Overdiagnosis by definition 
occurs when the lead-time is larger than the life expectancy. Length time bias is introduced 
by screening because it detects many indolent cancers, with a slow natural course, which 
would have remained subclinical in a non-screened population. Whether the down-staging of 
tumors, with the expected survival benefit, is balanced by the created overdiagnosis with its 
consequences has to be evidenced by studies such as the PLCO and/or the ERSPC. Although 
the definitive results of the ERSPC are not expected before 2008, this report provides bio-
chemical progression parameters from the Rotterdam section of the ERSPC.
PATIENTS & METHODS
Between November 1993 and January 2000, a total of 42,376 men, aged 55–74, were ran-
domized in the Rotterdam section of the ERSPC. The conditions and algorithm of the ERSPC 
are described in greater detail elsewhere.78 In short, of 21,210 men randomized to the screen 
arm, 19,970 (94.2%) were actually screened. From November 1993 through May 1997 all men 
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with suspect findings on digital rectal examination and/or trans-rectal ultrasound and all men 
with a PSA ≤ 4.0 ng/mL were biopsied. Later on, digital rectal examination and trans-rectal 
ultrasound were omitted as an indication for sextant biopsy and the PSA-threshold value for 
biopsy was lowered to 3.0 ng/mL. All men in the screen arm who were still eligible for screen-
ing after 4 years were reinvited for repeat screening. The 21,166 men in the control arm of 
the ERSPC received standard medical care, which meant that the evaluation of symptoms, a 
diagnosis of prostate cancer and subsequent treatment, or refrainment from it, was provided 
by general practitioners and local urologists. Men with prostate cancer in the control arm 
were identified through a linkage with the Comprehensive Cancer Registry (CCR).79 For this 
report, the cut-off date for diagnosed prostate cancers was January 2001 in both the screen 
and the control arm.
Follow-Up
Follow-up data were obtained by reviewing patients’ charts every 6 months for the first 5 years 
following diagnosis and annually thereafter. Medical history, physical examination, dissemina-
tion studies, and PSA tests were registered. Endpoint in this study was PSA-progression. This 
was defined as two consecutive PSA values of 0.2 ng/mL or higher after radical prostatectomy; 
three consecutive PSA increases meant progression after radiotherapy, following the criteria 
of the American Society for Therapeutic Radiology and Oncology (ASTRO-criteria).80 The time 
of PSA progression was backdated to the date between the first rise and the previous PSA 
test-date. The criteria described by Collette et al. were used for PSA progression in men with 
metastatic disease receiving endocrine treatment (e.g. a first PSA increase of 20% over nadir, 
each to a value>4.0 ng/mL).81 Clinical staging is done throughout the whole study according 
to the 1992 UICC TNM classification.82 No progression rates were calculated for watchful wait-
ing because no widely accepted definition for disease progression exists and most watchful 
waiters will receive treatment once their PSA values increase too rapidly.
Histology
Sextant biopsy was performed as described by Eskew et al.83 Biopsy Gleason scores of all 
screen-detected prostate cancers were provided by a single genito-urinary pathologist.84 Af-
ter the identification of men with prostate cancer in the control group, the histological slides 
with prostate cancer were retrieved from the pathologic storage facilities of all hospitals, and 
the Gleason scores were reviewed for all cases.
Statistics
All statistical tests were performed using the Statistical Package for the Social Sciences (SPSS 
version 12.0.1; SPSS incorporated, Chicago, IL). Statistical significance was defined as a P-value 
<0.05.
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RESULTS
From the start of this screening study (1993) to the end of the year 1999, 1,339 of 19,970 (6.7%) 
men screened were diagnosed with prostate cancer in the screen arm. Of those, 1,014 were 
diagnosed in the prevalence screen (i.e., the first round). In the control arm 298 men (1.4% 
of 21,202) were diagnosed. The number of cancers per 1,000 randomized men was 67.1 for 
the screen arm and 14.1 for the control arm (P-value <0.0001). Interval carcinomas are those 
tumors that are clinically detected in between the screen rounds. During the 4-year screen 
interval in our study 54 of those carcinomas were detected. As table 4.1 shows, screened men 
have a lower age at diagnosis (67.0 vs. 69.0 years, P-value <0.0001), have lower biopsy Gleason-
scores and they have lower PSA levels at the time of diagnosis (median 5.5 ng/mL vs. 11.7 ng/
mL, P<0.0001). The clinical T-stage in the screen group was more favorable, and less nodular 
metastases (1.5% vs. 4.0%, P<0.0001) and distant metastases (1.0% vs. 8.7%, P<0.0001) at di-
agnosis were found. In the control arm, significantly more men were treated with endocrine 
therapy as their initial therapy (3.0% vs. 20.1%, P-value <0.0001), while prostate cancers found 
by screening were more often managed by radical prostatectomy (37.0% vs. 19.1%, P-value 
<0.0001).
Table 4.1 Demographics
Screen arm Control arm P-value
Randomized No. 21,210 21,166
PC No. 1,339 (6.3%) 298 (1.4%) <0.001
Median age at
diagnosis (range)
Years 67.0 (53.4-80.7) 69.0 (55.2-80.2) <0.001
PSA at diagnosis (range) Ng/mL 5.5 (0.3-578.0) 11.7 (0.6-2970.0) <0.001
Biopsy Gleason sum
<7 840 (67.1%) 97 (42.9%)
<0.001
=7 322 (25.7%) 73 (32.3%)
>7 89 (7.1%) 56 (24.8%)
missing 88 72
T stage
T1C 569 (42.5%) 94 (31.5%)
<0.001T2 503 (37.5%) 96 (32.2%)
≥T3 228 (17.0%) 80 (26.8%)
N stage N+ 20 (1.5%) 12 (4.0%) 0.007
M stage M+ 14 (1.0%) 26 (8.7%) <0.001
Treatment
RP 495 (37.0%) 57 (19.1%)
<0.001
RT 608 (45.4%) 131 (44.0%)
WW 196 (14.6%) 50 (16.8%)
ET 40 (3.0%) 60 (20.1%)
Follow-up (range) months 60.8 (3.1-217.6) 49.5 (2.4-212.7)
RP= Radical prostatectomy; RT=Radiotherapy;
WW=Watchful Waiting; ET= Endocrine Treatment
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Table 4.2 Radical prostatectomy versus radiotherapy
RP RT P-value
Screen Control Screen Control
PC No. 495 57 608 131
Median age at
diagnosis
years
64.3
(55.0-75.3)
66.6
(55.4-73.5)
69.0
(55.2-78.0)
69.4
(55.9-78.1)
<0.001
PSA at diagnosis
Ng/mL
(range)
5.3
(0.6-55.0)
9.3
(2.5-94.0)
6.2
(0.3-259.8)
11.7
(1.3-68.6)
<0.001
Biopsy Gleason sum
<7 350 (72.8%) 31 (66.0%) 335 (58.1%) 47 (43.1%)
<0.001
=7 113 (23.5%) 12 (25.5%) 184 (31.9%) 36 (33.0%)
>7 18 (3.7%) 4 (7.0%) 58 (9.5%) 26 (23.9%)
NA 14 10 31 22
T stage
T1C 224 (45.3%) 22 (38.6%) 215 (35.4%) 44 (33.6%)
<0.001T2 231 (46.7%) 31 (54.5%) 222 (36.5%) 40 (30.5%)
≥T3 31 (6.2%) 3 (5.3%) 168 (27.7%) 41 (32.2%)
Follow-up
Years
(range)
5.5
(0.1-10.7)
4.9
(0.2-9.9)
4.9
(0.3-10.0)
4.2
(0.2-10.7)
<0.001
PSA-progression No. 78 (15.8%) 21 (36.8%) 142 (23.4%) 39 (29.8%) <0.001
Median time from
diagnosis to progression
Years
(range)
2.3
(0.5-8.8)
1.7
(0.4-4.1)
2.2
(0.6-7.4)
2.3
(0.7-5.8)
n.s.
RP=Radical Prostatectomy; RT=Radiotherapy; NA=not available
0,00 2,00 4,00 6,00 8,00 10,00 12,00
Time since treatment (years)
0,0
0,2
0,4
0,6
0,8
1,0
PS
A
 p
ro
gr
es
si
on
 fr
ee
 s
ur
vi
va
l
radical prostatectomy
 
Fig4.1 Figure 4.1 Kaplan-Meier projection of the biochemical (PSA-) progression free survival after radical prostatectomy in the screen group (top line) 
and in the control group (bottom line) as a curve of the time period since diagnosis in years.
Men at risk
0 2 4 6 8 10
screen 495 444 333 162 63 5
control 57 42 23 12 4 1
P-value < 0.001
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PSA recurrence rates after radical prostatectomy were significantly lower in the screen arm 
than in the control arm (15.8% vs. 36.8%, P-value <0.0001; table 4.2). Also after radiotherapy 
less biochemical progression occurred in screened men than in controls (23.4% vs. 29.8%, 
P-value 0.01).
As the Kaplan–Meier graphs in figures 4.1–4.3 show, the 5-year PSA-progression free sur-
vival rates for radical prostatectomy (84.4% vs. 58.9%; P-value <0.0001), radiotherapy (71.0% 
vs. 58.0%; P-value 0.01) and endocrine treatment (40.5% vs. 16.3%; P-value 0.04) were signifi-
cantly higher in screened men than in controls. The median time from diagnosis to progres-
sion after radical prostatectomy was 2.3 years (mean 2.5; range 0.5–8.8) in screened men and 
1.7 years (mean 1.9; range 0.4–4.1) in controls (P-value 0.4). After radiotherapy the median 
time to progression was 2.2 years (mean 2.5; range 0.6–7.4) in screened men and 2.3 years 
(mean 2.3; range 0.7–5.8) in controls (P-value 0.31). After endocrine therapy these times were 
1.4 years (mean 1.6; range 0.4–4.1) in screened men and 1.2 years (mean 1.6; range 0.4–4.8) in 
controls (P-value 0.45).
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Fig 4.2 
 
Figure 4.2 Kaplan-Meier projection of the biochemical (PSA-) progression free survival after radiotherapy in the screen group (top line) and in 
the control group (bottom line) as a curve of the time period since diagnosis in years.
Men at risk
0 2 4 6 8 10
screen 608 501 371 228 82 3
control 131 121 84 57 25 2
P-value 0.01
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DISCUSSION
Although the expected result of screening for prostate cancer, with its shift toward more 
favorable stages, is a better survival, there are at least two confounders; namely lead-time 
and length-time bias.37,44,48,85 Because screening detects cancers before symptoms would 
have developed, the time period from early diagnosis by screening to death due to prostate 
cancer is longer than for clinically diagnosed cancers, falsely suggesting a better survival in 
the screened population (i.e., lead time bias). Calculating the time from randomization to 
progression could correct for lead-time and this method can be regarded appropriate for the 
endpoints metastatic disease and prostate cancer-mortality. PSA-progression may be a sur-
rogate endpoint and it is not known whether this method can be used for this purpose.
In the screen arm of this study, 4.8 times more men were diagnosed with prostate cancer 
than in the control arm. While screening will in the beginning result in the diagnosis of more 
cancers, an increasing proportion of those cancers will be diagnosed later during the study 
period (i.e., at a higher age) in the control arm. Although the difference in the number of men 
diagnosed will become smaller once the follow-up period becomes longer, the difference 
in the incidence of prostate cancer suggests overdiagnosis, which may be acceptable if it is 
balanced by a decreasing mortality. This however is not known at present. A mathematical 
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Fig. 4.3 Figure 4.3 Kaplan-Meier projection of the biochemical (PSA-) progression free survival after endocrine treatment in the screen group (top line) 
and in the control group (bottom line) as a curve of the time period since diagnosis in years.
Men at risk
0 2 4 6 8
screen 40 21 10 3 1
control 60 20 6 1 0
P-value 0.04
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model based on data from the ERSPC has shown that the mean lead time for prostate can-
cer is estimated to be 6–12 years, depending on patients’ age.37 This same model estimated 
that for an annual screening program for 55- to 67-year-olds, 50% of diagnosed cases would 
constitute instances of overdiagnosis. As a result of length-time bias, the higher incidence of 
screen-detected prostate cancers can be partly explained by the number of men who are di-
agnosed with indolent prostate cancer. Those are likely to be more frequent in the screen arm, 
which dilutes the total group of diagnosed cancers. Because those cancers do not progress, 
the survival rates in this group are higher as well.
Krygiel et al. found that of 1,939 screen-detected patients 17% had evidence of cancer pro-
gression.86 The percentage with progression-free survival at 5 years for radical prostatectomy 
was 84%, and for radiotherapy 80%. In our screened population, the progression-free survival 
after 5 years for radical prostatectomy was 84.4% and for radiotherapy was 71.0%, using the 
same definitions for biochemical progression. In our study, biochemical recurrence occurred 
at a median of 2.6 years (mean 2.9; range 0.7–9.1) after surgery of men diagnosed in the screen 
arm. In the control arm the median time period from surgery to biochemical recurrence was 
1.4 years (mean 1.9; range 0.5–4.6). These time periods from treatment to progression cor-
roborate with the recent findings of Freedland et al., who described an American cohort of 
prostate cancer patients and found a median time from surgery to biochemical recurrence of 
2.0 years (mean 3.5).87 They also reported that the time period between surgery and biochemi-
cal recurrence (<3 vs. >3 years) was an independent prognostic factor for prostate cancer 
specific-survival.
Khuntia et al. reported about 1,352 men diagnosed with T1-T3 prostate cancers after 1987 
who were all treated with external beam radiotherapy. Of those men, 63% had no sign of 
biochemical relapse after 5 years. Our 5-year PSA-progression free survival was 71.0% among 
screened men and 58.0% among controls.
Albertsen et al. reported that in a cohort of initially untreated men with localized prostate 
cancer, its mortality persisted to increase even 20 years after diagnosis. Therefore, our follow-
up period might be too short, especially considering that Albertsen et al. and others mainly 
described the natural history of cancers diagnosed before the PSA era. Our study, however, 
describes a group of cancers found by screening and a control group of men diagnosed during 
the PSA era. As a result of screening, men diagnosed with prostate cancer are younger and the 
created lead time will probably result in an even longer time from diagnosis to progression, 
although this effect was not significant in our study.
Although the use of PSA-progression as an intermediate endpoint is debatable, Pound et 
al. reported that not a single man who had undergone a radical prostatectomy developed 
metastases or died of prostate cancer with an undetectable PSA.88 Freedland et al. reported 
on 379 men who elected radical prostatectomy and subsequently developed biochemical 
progression.87 The 15-year prostate cancer-specific survival since biochemical progression 
was 55%. The study population of Freedland et al. is collected over a time-span of 18 years, 
including some before the PSA era. Nowadays, screening is widely accepted in the US and the 
population which was studied is a mixture of screened men and those who were not. It is not 
known to what extent those data are comparable to either the screen arm or the control arm 
of our study. In general, the PSA-progression free survival can not give a definite indication of 
the proportion of men dying of prostate cancer, but serves mainly as a tool of comparison.
PSA-testing of asymptomatic men in the control arm of the trial for whatever reason (i.e., 
contamination) must be closely monitored, because the rate of contamination in the control 
arm may adversely affect the power of the trial.76 Otto et al. described that opportunistic PSA 
testing in the control arm reached a peak within the first months of randomization, after 
which it decreased.89 In the control arm of the Rotterdam section of the ERSPC, PSA testing 
was high, but was not followed by a substantial increase in prostate biopsies. Thus, effective 
PSA contamination in the Rotterdam section of the ERSPC is low and not likely to jeopardize 
the power of the trial.89
CONCLUSIONS
PSA-screening increases the incidence of prostate cancer and causes a shift toward cancers 
with more favorable prognostic factors. To what extend the higher PSA progression free sur-
vival rates in this study are a result of that shift, and the influence of lead and length-time on 
these rates is not known. If, and to what extend screening lowers the prostate cancer specific-
mortality, and whether this will be in proportion to the burden of screening can not be an-
swered at this moment. Therefore, the definitive results of the ERSPC, which are not expected 
before 2008, are essential to judge whether population-based screening for prostate cancer 
is a feasible undertaking.
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ABSTRACT
Objectives
This population-based study provides comparisons of prostate cancer characteristics at diag-
nosis of two cohorts of men from two well-defined geographical areas exposed to different 
intensities of prostate cancer screening. Overall survival in both cohorts was compared to that 
in the general population.
Patients & Methods
A cohort of 822 men randomized to the intervention arm of a prostate cancer screening trial, 
and subsequently diagnosed with prostate cancer, was compared to a non-randomized co-
hort of 947 men whom were clinically diagnosed with prostate cancer in a geographically 
neighboring region. In both cohorts, cases were diagnosed with prostate cancer between 
January 1989 and December 1997. A partitioning of overall survival by variables associated 
with cancer onset such as age-at-diagnosis, stage-at-diagnosis, and grade-at-diagnosis was 
performed.
Results
Age-at-diagnosis, tumor extent-at-diagnosis, and grade-at-diagnosis were significantly dif-
ferent between the screened and clinically diagnosed cohort. Five-and-ten year survival was 
higher in the screened cohort than in the clinically diagnosed cohort (88.8% versus 52.4%, 
and 68.4% versus 29.6%, respectively). Significant differences in survival were evident for all 
age-, stage-, and grade subgroups, except for metastatic disease-at-diagnosis.
Conclusions
Differences in overall survival favoring the screened population were observed for all base-
line characteristics (age-, stage-, and grade-of-disease), and these variables may all explain 
differences in overall survival as screening achieves early diagnosis as well as a stage-and 
grade shift. As observed survival rates in the screened population mirrored those within the 
general population, the contribution of lead time and overdiagnosis to final patient outcome 
is considered to be large as well.
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INTRODUCTION
In previous decades, 50-85% of men with advanced prostate cancer were to die from their 
disease depending on the age and extent of disease at diagnosis.90,91 From the early 1990s 
onwards, the prostate cancer mortality rates have slowly declined in the United States, and 
in some European countries.33,92-95 Some have argued that this decrease is due to the appli-
cation of the serum prostate-specific antigen (PSA) test as a tool for the early detection of 
prostate cancer.96,97 Indeed, PSA-determination in serum has contributed to a rapid increase 
in the incidence of prostate cancer, and a concurrent stage and grade migration to earlier 
stages and lower grades of disease. However, this effect of screening on grade and stage does 
not necessarily translate into a reduction of disease-specific mortality as has been shown for 
lung cancer.98 Until present, no beneficial effect of prostate cancer screening on mortality 
using the serum-PSA test, and its subsequent diagnostic and therapeutic sequelae, has been 
established in properly performed randomized controlled trials.
This study was performed to compare the distribution of prognostic factors at diagnosis 
in two cohorts of men subjected to different intensities of prostate cancer screening. Further-
more, overall survival in both cohorts was compared to that in the general population. Through 
this methodology of the expected survival, the magnitude of lead time and overdiagnosis of 
disease can be estimated. Baseline characteristics of 822 men diagnosed with prostate cancer 
in the intervention arm of the Dutch section of the European Randomized study of Screening 
for Prostate Cancer (ERSPC) were compared to those in 947 men clinically diagnosed with 
prostate cancer in a neighboring geographical region in which prostate cancer screening was 
not common practice. Cases were diagnosed with prostate cancer during periods of time of 
similar duration. A partitioning of overall survival by variables associated with cancer onset 
such as age-at-diagnosis, stage-at-diagnosis, and grade-at-diagnosis was performed in both 
cohorts.99,100
PATIENTS & METHODS
Intervention arm of ERSPC
The ERSPC was designed to study the effect of population-based screening for prostate can-
cer on prostate cancer mortality and quality-of-life. Between December 1993 and May 1997, 
in Rotterdam alone, a total of 20,643 men aged 55-75 years were identified in the popula-
tion registry, invited to participate, and after providing informed consent, randomized to the 
screening study. A total of 10,456 men were randomized to the intervention arm. Men with a 
prior diagnosis of prostate cancer were excluded. All participants allocated to the screening 
arm underwent a serum PSA-test, digital rectal examination (DRE) and transrectal ultrasound 
(TRUS). A biopsy was advised in those with PSA ≥4.0 ng/mL and/or in those with a finding 
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suspicious for cancer on DRE and/or TRUS at low PSA-values (0.0–3.9 ng/mL). A systematic 
lateralized sextant needle biopsy was performed, and one or two additional biopsy cores were 
taken from hypo-echoic lesions when present. Treatment decisions were at the discretion of 
the treating urologists thereby considering biopsy tumor features, patient preferences, and 
life expectancy. A detailed description of the methodology of the screening trial is reviewed 
by Roobol et al.101
Four years after prevalence screen, men were invited to undergo repeated screening (sec-
ond screening round). At repeat screening, only PSA ≥3.0 ng/mL prompted a biopsy, irrespec-
tive of DRE/TRUS-findings.102 Cancers diagnosed in between the two screening intervals due 
to opportunistic screening, transurethral resection of the prostate for benign disease, and 
cystoprostatectomy (i.e., ‘interval cancers’) were considered as well.103
Clinically diagnosed cohort
The clinically diagnosed cohort consisted of men diagnosed with prostate cancer in a well-
defined, neighboring geographical area, in the province of ‘Zeeland’, which is covered by the 
Rotterdam Cancer Registry. A linkage of incidence and mortality between the municipal civil 
registries of ‘Zeeland’ and the Rotterdam Cancer Registry is performed on a regular basis. Men 
within the cohort were consecutively diagnosed with prostate cancer between January 1, 
1989 and December 31, 1997. Access to health care services is similar to that in the Rotterdam 
area, whereas PSA-determination was not commonly performed as a screening test.
Baseline characteristics
In cases with prostate cancer diagnosed within the intervention arm of the screening trial 
(n=822), and in those within the clinically diagnosed cohort (n=947), age-at-diagnosis (<55-
65 years, 66-70 years, 71-75 years, and ≥76 years), date-of-diagnosis, and histological differ-
entiation grade according to the World Health Organization (WHO) classification (well-, mod-
erately-, poorly differentiated) were obtained.104 Cases within both cohorts were categorized 
according to tumor extent: I. Localized disease (cT1 or cT2), II. Regional disease (cT3 or cT4, 
N1), and III. Distant disease (M1).
Initial treatment modalities (i.e., radical prostatectomy, radiation therapy, androgen depri-
vation therapy, watchful waiting) were derived from the database of ERSPC, and the Rotter-
dam Cancer Registry, respectively (table 5.1).
Overall survival
In both cohorts, the time of death irrespective of cause was obtained through a linkage to 
the municipal civil registries. In the clinically diagnosed cohort, active follow-up of all patients 
was performed through linkage with the 16 municipal population registries in the province 
of Zeeland. Each municipal registry provided the Rotterdam Cancer Registry a database with 
deaths for a given period. Dates of end of follow-up varied from May 23, 2001 to December 1, 
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2002. In case a patient did not die before the end of follow-up, survival time was calculated 
from the date of diagnosis to the end of follow-up for his municipal registry. No data on the 
cause of death was available, as these are susceptible to privacy regulations. Moreover, as the 
validity and comparability of the cause of death in screening cohorts is questionable using 
death certificates, overall survival was taken as the final outcome measure.105
For all cases within the two study cohorts, duration of survival was defined as the date of 
prostate cancer diagnosis to the date of death, or to the time of last follow-up if the patient 
was still alive. It is evident that the survival in the screen-detected cases is positively biased 
by lead-time.
Statistical analysis
The Chi-square (χ2) and the Mann-Whitney U test were used to assess the relationship between 
categorical and continuous variables, respectively, within the intervention arm of the screen-
ing trial and the clinically diagnosed cohort. P<.05 was considered statistically significant. 
Observed and expected survival rates were estimated with Stata freeware subroutine ‘strs’, 
which is related to the ‘surv2’ program. These survival rates were then used to draw survival 
curves for both cohorts, for men aged 55-75 at diagnosis in both cohorts, and for men aged 
55-75 at diagnosis in both cohorts with and without metastatic disease. The expected survival 
rate is the survival rate in a group of people in the general population, who are similar to the 
patients with respect to all of the possible factors affecting survival at the beginning of the 
period, except for the disease under study.106
RESULTS
Baseline characteristics
The characteristics of the 822 men diagnosed with prostate cancer in the intervention arm 
of the screening trial are presented in table 5.1. The median age-at-diagnosis was 67 years 
(range, 55-78). A description of the 947 men in the clinically diagnosed cohort is given in table 
5.1. The median age-at-diagnosis was 75 years (range, 47-95).
Overall survival
The median observation period for patients in the intervention arm was 8.1 years (range, 0.2-
11.6), and this was 4.8 years (range, 0.1-13.4) for men in the non-screened cohort. During 
follow-up, 182 men (22.1% of total) in the screening trial died, whereas this figure was 542 
(57.2% of total) for those diagnosed with prostate cancer in the clinically diagnosed cohort. 
The median age-at-death was 74 years (range, 59-85), and 81 years (range, 51-95), respectively 
(P<.001). The five-and-ten year survival was higher in the screened cohort than in the non-
screened cohort (88.8% versus 52.4%, and 68.4% versus 29.6%, respectively; P<.001) ( table 
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5.2). Differences in survival remained for all age-, stage-, and grade subgroups, except for 
metastatic disease-at-diagnosis.
Overall survival in both cohorts as a function of time after diagnosis, and expected survival 
rates are depicted in figure 5.1. Figures 5.2-5.4 show the same data for men aged 55-75 years, 
and for those without and with distant metastasis, respectively.
Table 5.1 Baseline characteristics at diagnosis, and primary treatment modalities. A comparison between men diagnosed with prostate cancer 
within the intervention arm of a randomized controlled screening trial for prostate cancer (randomization between December 1993 and May 
1997), and those clinically diagnosed with prostate cancer within a non-randomized cohort (prostate cancer diagnosis between January 1989 
and December 1997).
Clinically diagnosed cohort
N (% of Total)
Screen-detected cohort
N (% of Total)
P-value *
Age (years)    Median (range) 75 (47-95) 67 (55-78) <.001
<55- 65 151 (16.0) 305 (37.0)
<.001
66- 70 166 (17.5) 260 (31.6)
71- 75 193 (20.4) 244 (29.7)
≥76 437 (46.1) 13 (1.6)
Disease extent
Localized (cT1-cT2) 549 (62.2) 618 (83.1)
<.001Regional (cT3-cT4, N1) 131 (14.9) 120 (16.1)
Metastasized (M1) 202 (22.9) 6 (0.8)
Not known or not performed 65 78
Histological differentiation grade **
Well 293 (32.8) 551 (67.2)
<.001Moderately 350 (39.2) 216 (26.3)
Poorly 249 (27.9) 53 (6.5)
Undetermined/unknown 55 2
Initial treatment
Radical prostatectomy 105 (11.1) 298 (36.3)
<.001
Radiotherapy 211 (22.3) 384 (46.7)
Watchful waiting 89 (9.4) 124 (15.1)
Androgen deprivation therapy *** 439 (46.4) 16 (1.9)
Other or no treatment **** 103 (10.9) 0 (0.0)
Total 947 822
*  The Chi-square (χ2) test was used for categorical variables and the Mann-Whitney U test was used for continuous variables; undetermined/
unknown cases were not included in the analysis
** WHO classification system [16]
*** Bilateral orchiectomy or LHRH-analogues
**** E.g. chemotherapy, transurethral resection of prostate
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DISCUSSION
The current study provides comparisons of the distribution of prognostic factors and outcomes 
of two cohorts of prostate cancer patients from two well-defined neighboring geographical 
areas who were exposed to different intensities of prostate cancer screening. The interven-
tion arm of the ERSPC is known to have a 95% screening coverage, while at the end of 2004, 
approximately 30% of men in the control arm had their PSA-level measured at least once.107 
This control arm reflects the intensity of screening in the general population, although men 
enrolled in a screening trial are expected to be more prone to have their PSA tested. The 
overall survival in a cohort offered systematic PSA-based screening for prostate cancer, and 
that was subsequently diagnosed with prostate cancer, was longer than the overall survival 
in a cohort not previously subjected to systematic screening. Five and ten years after diagno-
sis, the cumulative overall survival differed by 36.4% and 38.8%, respectively (figure 5.1). As 
the contemporary analysis is non-randomized, the outcomes are likely to be influenced by 
several other factors than screening itself: (1) differences in overdiagnosis, (2) differences in 
age-at-diagnosis, (3) differences in stage-and-grade at diagnosis, (4) the intensity and efficacy 
of treatment modalities, (5) screening biases.
Table 5.2 Five and ten year survival. A comparison between men diagnosed with prostate cancer within the intervention arm of a randomized 
controlled screening trial for prostate cancer (randomization between December 1993 and May 1997)(n = 822), and those diagnosed with 
prostate cancer clinically within a non-randomized cohort (prostate cancer diagnosis between January 1989 and December 1997) (n = 947).
5-year survival
(number of men deceased)
10-year survival
(number of men deceased)
P-value*
Age (Years)
Clinically 
diagnosed
Screen 
detected
Clinically 
diagnosed
Screen 
detected
<55- 65 72.5 (41) 92.3 (23) 54.7 (50) 80.4 (45) <.001
66- 70 68.7 (52) 90.2 (25) 51.2 (65) 67.8 (57) <.001
71- 75 58.7 (78) 82.8 (41) 29.2 (100) 52.3 (74) <.001
≥76 36.4 (274) 92.3 (1) 12.4 (321) 62.9 (4) .003
Disease extent
Localized (cT1-cT2) 66.2 (182) 90.2 (59) 38.3 (245) 70.1 (121) <.001
Regional (cT3-cT4, N1) 45.6(70) 81.6 (22) 18.8 (80) 52.1 (42) <.001
Metastasized (M1) 22.3 (156) 33.3 (4) 9.8 (169) 33.3 (4) .92
Histological differentiation grade **
Well 73.2 (77) 91.4 (46) 45.7 (112) 76.4 (87) <.001
Moderately 52.0 (166) 86.4 (29) 27.6 (210) 62.1 (65) <.001
Poorly 34.4 (163) 73.3 (14) 14.2 (185) 36.4 (27) <.001
Overall 52.4 (445) 88.8 (90) 29.6 (538) 68.4 (180) <.001
* The logrank-test for trend
** WHO classification system
Overall survival compared in settings of different screening intensities
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Overdiagnosis
It is well known that screening efforts lead to the detection and treatment of cancers that 
have no impact on health or longevity, even in the absence of treatment.37,108 This detection of 
cancers that would not have surfaced clinically in the absence of screening is called overdiag-
nosis. The degree of overdiagnosis through screening can in part be estimated by changes 
in the incidence and mortality rates within the population. For instance, between 1989 and 
2003, the age-standardized incidence rates of prostate cancer increased by 48.4% in the Neth-
erlands (reaching 93 cases per 100,000), and by 13.6% in the United States (reaching 165 cases 
per 100,000).32,73 The age-standardized mortality rates remained relatively constant in this 
time period. Accordingly, the incidence-to-mortality ratio in the United States increased from 
115 to 34 per 100,000 (ratio, 3.4:1) in 1985 to 174 to 30 per 100.000 (ratio, 5.8:1) in 2006.33
In a computer model, Draisma et al. calculated that the rate of overdiagnosis equaled 48% 
(range, 44-55%) in men aged 55-67 years screened systematically with a 4-year interval.37 
In the intervention arm of the ERSPC, only one in every 30.3 men diagnosed with prostate 
cancer is likely to succumb of his disease during follow-up, and for every 6.4 deaths, one is 
due to prostate cancer (data not shown). In screening settings, therefore, the vast majority 
of men diagnosed with prostate cancer is not likely to die from its disease. Our data further 
indicate that overdiagnosis was considerable as the observed survival rates in the screened 
cohort mirror expected survival rates in the general population for all age-, stage- and grade 
subgroups (figures 5.1-5.3).
Age at diagnosis
In absence of screening, prostate cancer is mainly diagnosed at an older age. In the clinically 
diagnosed cohort, the median age-at-diagnosis was 75 years, with 33.5% of men having a 
prostate cancer diagnosis at or before the age of 70 years, and 26.9% after the age of 80 years. 
In a cohort of 223 patients managed conservatively, prostate cancer mortality was higher 
among those whose cancer was diagnosed at 70 years or younger than among those whose 
cancer was diagnosed at older ages.109 Older men have a higher rate of intercurrent illnesses 
and death. The proportion of men dying from prostate cancer at any given interval, and for 
any grade and stage of disease, is expected to be higher in the younger age group.110 Consid-
ering men aged 55-75 years only, overall survival for the cohort as a whole, and for those with 
non-metastatic disease was significantly higher in those subjected to screening than in those 
who were not (figure 2-3).
Stage and grade at diagnosis
Evidently, disease extent, and tumor grade at the time of diagnosis have a profound impact on 
outcome of men diagnosed with prostate cancer. Previous studies have indicated that declines 
in prostate cancer mortality may be attributed to a decrease in distant disease incidence and 
distant disease mortality.91,111 Data from the Surveillance, Epidemiology, and End Result (SEER) 
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Program indicate that overall survival rates for patients with distant disease were 80%, 49%, 
and 33% after 1-, 3-, and 5-years follow-up, respectively.96 As comparison, men with regional 
stage disease (cT3-cT4, N1) had 1-, 3-, and 5-year relative survival rates of 100%, 100%, and 
98%, respectively. A rapid reduction in prostate cancer deaths may therefore be explained 
by the detection and subsequent treatment of cancers in their localized or regional stage-of-
disease before they have metastasized. The finding that distant stage disease was a relative 
rare finding in the intervention arm of the screening trial compared to that in the clinically 
diagnosed cohort (i.e., 0.8% to 22.9% of diagnosed cases, respectively) is likely to explain at 
least in part the differences in overall survival.
Studies on the natural history of clinically localized prostate cancer in population-based 
cohorts indicate that men most likely to succumb of prostate cancer as early as 5 to 10 years 
after diagnosis were those with moderately or poorly differentiated tumors (i.e., Gleason 
scores 7 and 8-10, respectively; WHO 2 and 3, respectively).109,110 Those with well-differentiated 
tumors (i.e., Gleason scores 2-6; WHO 1) rarely died from the disease. Furthermore, SEER data 
indicate that relative survival rates of those with poorly differentiated prostate cancer were 
100%, 96%, and 87% after 1-, 3-, and 5-years of follow-up, i.e., evidently higher than those 
with distant stage disease. In a survival model, correcting for lead time and overdiagnosis 
rates by age, Parker et al. predicted that the absolute survival benefit of radical treatment 
for screen-detected prostate cancer was greatest in those with higher grade disease.112 Our 
data indicate that screening efforts provide for a window of curability as a large proportion of 
screen-detected cases have moderately-and poorly differentiated disease ( table 5.1).
Intensity and efficacy of treatment modalities
Improvements and refinements in techniques of radical treatment for localized disease such 
as radical prostatectomy and external beam radiation therapy may have influenced declining 
mortality rates.113,114 Men in the intervention arm of the screening trial were more likely to have 
curative radical prostatectomy or radiotherapy than their counterparts in the non-screened 
cohort ( table 5.1). This finding might at least partly have driven mortality rates down. Other 
explanations for the reported declines in mortality rates have been the early application of anti-
androgen therapy in advanced disease.115,116 The application of androgen-deprivation treatment 
in men in a relatively early phase of disease may have delayed disease progression to metastatic 
disease or death for several years, or until some of patients die of intercurrent illnesses.
Screening biases
Screening cohorts have increased survival rates compared to non-screened cohorts due to 
lead time (i.e., the time by which a screening test advances the diagnosis of disease) and 
length time (i.e., the detection of slowly growing, non-aggressive tumors).117 The magnitude 
of both lead and length time in prostate cancer screening trials is largely unknown, though 
it is estimated that lead time ranges between 3 and 12 years depending on age, tumor stage 
Overall survival compared in settings of different screening intensities
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and tumor grade.37,118 The effect of length time is expected to be limited as the number and 
aggressiveness of interval cancers is relatively low.103 In fact, with a 4-year screening interval, 
none of the detected interval cancers were poorly differentiated or metastatic. In many pa-
tients in the present cohort, the follow-up period may not have surpassed the survival time 
after a cancer diagnosis with added lead time. On the other hand, lead time of patients who 
present clinically with distant disease is probably shorter than those who present with local-
ized or regional disease, and most cases with aggressive disease beyond cure have probably 
surfaced (‘progressed’) on follow-up. By definition, these cases are at increased risk of dying 
from the disease.
Differences in the composition of, and risk factors in the male cohorts (e.g., smoking habits, 
presence of comorbidities and concomitant diseases) might have influenced endpoints apart 
from age-, stage-, and grade differences. For instance, men with synchronous malignant tu-
mors (except for basal cell carcinomas) were excluded from randomization in the screening 
trial, whereas these men were included in the survival analysis in the non-screened cohort. 
Also, participants of screening trials are probably more health aware, more likely to have 
a healthy lifestyle, to seek for medical care, and to comply to treatment (‘healthy attendee 
bias’).119 These two observations implicate that men in the intervention arm of the screening 
trial were healthier than men in the clinically diagnosed cohort, and probably even healthier 
than men in the general population (see also: figures 5.1-5.3). How and to what magnitude 
these selection biases affect the outcome of these two cohorts was not possible to assess. 
Only prospective, properly performed, randomized clinical trials will avoid most of these 
biases, and will give a final answer to the question whether screening for prostate cancer is 
beneficial, or not [38].
CONCLUSIONS
The overall survival rate in a contemporary series of men diagnosed with prostate cancer 
within a population-based screening trial was longer than that of men in a non-randomized 
cohort clinically diagnosed with prostate cancer in a geographical adjacent region. Differ-
ences in survival were observed for all ages, and for all stages and grades-of-disease, except 
for metastatic disease-at-diagnosis.
Differences in baseline characteristics (age-, stage-, and grade-of-disease) between cohorts 
may all explain differences in overall survival as screening achieves early diagnosis as well as 
a stage and grade shift. Furthermore, as observed survival rates in the screened population 
mirrored expected survival rates in the general population, the contribution of lead time 
and overdiagnosis of disease to final patient outcome is believed to be considerable. Data 
reported herein do not yet provide evidence of screening efficacy, as all possible biases may 
largely account for the observed differences in overall survival.
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ABSTRACT
Background
The use of PSA as a screening test has become increasingly prevalent in the general popula-
tion and therefore also in the control arm of the European Randomized study of Screening for 
Prostate Cancer (ERSPC). We present a feasibility study and impact simulation of a secondary 
analysis, which imitates a situation where all participants in the study are managed according 
to their random assignment.
Methods
The results of the Rotterdam section of the ERSPC were adjusted for contamination and non-
compliance according to Cuzick et al. (1997). Endpoints of this analysis were simulated reduc-
tions in prostate cancer mortality.
Results
Of the men allocated to the screen arm, 27.1% were non-compliant. In the control arm 30.7% 
had their PSA-level measured by a general practitioner (i.e. contamination). For a scenario in 
which the intention-to-screen analysis was assumed to give a decrease in the mortality in the 
men randomized to screening of 6.7%, the secondary analysis resulted in a decrease of 16.1% 
for those actually screened.
Conclusion
Although the definition of contamination as ‘PSA ever tested’ gives an indication of the pro-
portion of contamination, it will be important to differentiate the screening use of PSA from 
its diagnostic use. For the rest, adjustment for non-compliance and contamination was shown 
to be feasible in this prostate cancer screening trial. It can therefore be used to carry out a 
secondary analysis on the definitive outcome of the ERSPC and will provide accurate informa-
tion for those men who are in fact screened.
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INTRODUCTION
Prostate cancer is after lung cancer the most important cause of cancer-related death in Ameri-
can males.33 With the introduction of PSA in the late 1980s, a screening tool became available, 
which has proved to detect prostate cancers earlier in the course of the disease.24 Although 
the prostate cancer mortality in the US has decreased over the last decade, a differentiation 
between possible screening effects and other possible causes, such as more effective treat-
ments, has not been possible. Whether screening results in a lower prostate cancer mortality 
is therefore still unclear.
Four case-control studies evaluating the effect of screening have been published; only two 
found an effect on the endpoint under study.34-36,120 The most recent case-control study by 
Concato et al. did not show an effect of screening. Since case-control studies are inevitably 
biased, it is important to await the results of the two ongoing randomized controlled trials 
evaluating prostate cancer screening: (1) the Prostate, Lung, Colon and Ovarian (PLCO) cancer 
screening study and (2) the European Randomized study of Screening for Prostate Cancer 
(ERSPC).18
Ideally, in a randomized screening trial the use of screening should be limited to men in 
the screening arm. However, the freedom of choice cannot be denied to participants in either 
arm. Contamination is defined as the use of screening in the control arm. Another process that 
dilutes the effects of screening is non-compliance. Non-compliers are participants allocated to 
the screening arm of a trial, who do not undergo screening or parts of the screening process. 
Various methods were described to get a more realistic impression of the real effect screening 
has.121,122 The method described by Cuzick et al. offers a possibility to evaluate a randomized 
screening study by adjusting for non-compliance and contamination. Such a secondary analy-
sis imitates a situation in which all participants in the study are managed according to the 
random assignment and provides an unbiased estimate of the effect of screening in those 
prepared to accept it, as contrasted to the conventional intention-to-screen analysis which 
estimates the on a whole population offered screening.122
Although no population based prostate cancer screening programs exist in the countries 
participating in the ERSPC, the use of PSA as a screening tool has become increasingly preva-
lent, thereby leading to contamination in the control arm. The ERSPC was powered to detect 
a 25% difference in prostate cancer-specific mortality in the presence of a 20% contamination 
rate.78 The model of Cuzick et al. is likely to be helpful for the evaluation of the net effect of 
screening. It is unclear whether the Rotterdam center is capable of collecting the required 
data for such a secondary analysis. We therefore present a feasibility study and impact simula-
tion of adjustments for contamination and non-compliance applied to the Rotterdam section 
of the ERSPC.
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PATIENTS & METHODS
The ERSPC is a randomized controlled trial carried out in eight European countries and studies 
the effect of screening for prostate cancer in terms of prostate cancer specific mortality, qual-
ity of life and costs. In the Netherlands alone 42,376 men were randomized to the screening 
(n=21,210) or the control arm (n=21,166) from June 1993 through December 1999. The condi-
tions and algorithm of the ERSPC are described in greater detail elsewhere.21
Screening arm
From December 1993 through May 1997 all men with suspicious findings on digital rectal 
examination and/or trans-rectal ultrasound and all men with a PSA ≥ 4.0 ng/mL were invited 
for biopsy. After May 1997, digital rectal examination and trans-rectal ultrasound were omit-
ted as screening tests and the PSA-threshold value for biopsy was lowered to 3.0 ng/mL. All 
men in the screen group who were still eligible for screening after four years were reinvited for 
repeated screening. From June 1994 to March 1996 an early re-screen study was conducted to 
evaluate the value of a 1-year re-screening after a benign biopsy result.
Control arm
The 21,166 men in the control arm of the ERSPC were not invited for PSA testing and in case of 
symptoms received standard medical care, which meant that general practitioners (GPs) and 
local urologists provided the evaluation of symptoms and a diagnosis of prostate cancer. Men 
with prostate cancer in the control arm were identified through a linkage with the Compre-
hensive Cancer Registry.79 For this report, the cut-off date for diagnosed prostate cancers was 
January 1st 2005 in both the screen and the control arm.
Endpoint
The primary endpoint of the ERSPC is prostate cancer-specific mortality. This main endpoint 
of the study is subject to confidentiality at the level of the independent data monitoring com-
mittee, which carries out interim evaluations as indicated in the published evaluation plan.78 
For this report, we have therefore used simulated prostate cancer mortality rates as endpoints, 
which were varied in order to study the effect of contamination and non-compliance on pos-
sible different levels of prostate cancer mortality reduction.
Non-compliance
Non-compliance was defined as non-participation in the screening program after randomization 
for men allocated to the screening arm. In this study, all men who completed the first round of the 
screening program and subsequently followed the screening program’s protocol were labeled as 
compliers. Men who died, were diagnosed with an interval carcinoma or reached the age limit of 
the study protocol of our screening program (i.e. age ≥ 75), were not classified as non-compliers.
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Contamination
Contamination was defined as the use of PSA screening in the control arm of the study. PSA 
screening was defined as the measurement of at least one PSA level by the patient’s GP after 
randomization. Ideally one should only consider tests taken for the purpose of screening, i.e. 
in non-symptomatic men. The ability to ascertain this will be studied in a future report. Data 
on PSA tests performed in the period from randomization through January 1st 2005 were ob-
tained from the laboratory of the general practitioners (GP laboratory) in Rotterdam.
Model for adjustment of contamination and non-compliance
Cuzick et al. have described a procedure to adjust randomized controlled trials for contamina-
tion and non-compliance.122 The rationale is described elsewhere but can be summarized as 
follows: figure 6.1 illustrates that the proportion of non-compliers and associated endpoints 
in the screen arm are also accounted for in the control arm as ‘potential non-compliers’. The 
remaining participants are called ‘compliers’ (screening arm) and ‘potential compliers’ (control 
arm). Subsequently, the same is done for the contaminators in the control arm. The remaining 
cases fall in two groups (‘ambivalent’) in which the real effect of screening can be studied. A 
Taylor series expansion with a correction for the sampling of controls was used for calculation 
of the imaginary confidence intervals. The method for adjustment for non-compliance and 
contamination leads to wider confidence intervals due to a lower number of participants than 
in the intention-to-screen analysis. This is likely to be compensated by a gain in effect and is 
therefore expected to have little impact on power, but does affect the results.
Fig6.1 
non-compliers
n=5,738 (27.1%)
E=184 (3.2%)
'ambivalent'
n=8,959 (57.9%)
E=234 (2.6%)
'potential contaminators'
n=6,513 (42.1%)
E=176 (2.7%)
compliers
n=15,472 (72.9%)
E=410 (2.7%)
screening arm
n=21,210 (50.1%)
E=594 (2.8%)
'potential non-compliers'
n=5,726 (27.1%)
E=183 (3.2%)
'ambivalent'
n=8,941 (57.9%)
E=276 (3.1%)
contaminators
n=6,499 (42.1%)
E=175 (2.7%)
'potential compliers'
n=15,440 (72.9%)
E=452 (2.9%)
control arm
n=21,166 (49.9%)
E=635 (3.0%)
population
n=42,376
E=1,229
(2.9%)
Figure 6.1 Flowchart of the model, which adjusts for non-compliance and contamination; an example
N = number
E = Endpoint
The bold percentages are identical
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The lifetime risk of dying from prostate cancer in the US was 2,97% based on years 2000-
2002 in the SEER database. For this impact simulation, we assumed that the prostate cancer 
specific mortality of men in the control arm was 3.0% of the number of men randomized. We 
calculated the relative risks for three different scenarios: (1) screening for prostate cancer has 
no effect on the prostate cancer mortality (prostate cancer mortality is 3.0% in both the screen 
and the control arm), (2) the effect of screening on the mortality is small (prostate cancer 
mortality in the screen arm 2.8%, a reduction of 7%), and (3) the effect on the mortality is large 
(prostate cancer mortality in the screen arm 2.0%, a reduction of 33%).
RESULTS
From 1993 to 2005, the screening program in Rotterdam has detected 1,712 prostate cancers; 
134 cancers were diagnosed in between two screening rounds (i.e. interval cancers). During 
the same period, 521 cancers were diagnosed in men allocated to the control arm.
Non-compliance
Different types of non-compliance exist: some men refused to have their PSA drawn and 
some refused a biopsy indicated by screening. The latter can be a result of a medical contra-
indication as well. Both events of non-compliance occurred in multiple variations during the 
different screening rounds.
Table 6.1 shows that in round one 1,240 men (5.8%) refused a PSA test, in the early re-
screen round 332 (20.7%), in the second round 2,856 (15.4%), and in the partial third round 
(until January 1st 2005) 655 (5.5%), which adds up to 5,083 men (24.0%) who did not fully 
Table 6.1 Non-compliance in the screening arm of the Rotterdam section of the ERSPC
Round 1 Early re-screen Round 2 Round 3* Total
Eligible for screening 21,210 1604 18,504 11,982
No PSA-test
Interval carcinoma 7 109 18 134
Dead 25 716 222 963
Too old 24 2,348 929 3,301
Other 1,240 332 2,856 655 5,083
Biopsy indication
Done, no PC** 4,117 509 2,913 447 7,986
Done, PC 1,014 68 550 80 1,712
No, medication** 88 11 55 6 160***
Refuses after PSA** 327 30 175 21 553***
No biopsy indication** 14,424 668 9,389 2,074 26,555
* Incomplete; cut-off date 01-01-2005
** To next screen round
*** In total 655 men did not have a biopsy at least once, while a biopsy indication was present.
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comply with the screening program considering only the PSA determinations. 655 men (3.1%) 
did not fully comply with the screening program. They underwent the PSA test, had a biopsy 
indication but were not biopsied. The sum of these two (5,083 + 655 = 5,738; 27.1%) was the 
number of non-compliers used in the model.
Contaminators
The regional GP laboratory covers besides the municipality of Rotterdam 7 of the 12 neigh-
boring municipalities, or 16,455 (77.7%) out of 21,166 control men, from which the trial par-
ticipants were recruited. The group of GPs who are participating in the Rotterdam GP lab were 
not likely to be biased for demanding PSA tests. We therefore extrapolated the proportions 
to the control arm as a whole. The ability to ascertain this will be studied in a future report. 
The GP-laboratory covered 16,455 (77.7%) out of 21,166 men allocated to the control arm of 
the ERSPC. In those, 11,417 PSA-tests were performed in 5,004 men (30.4%) (mean 2.3 tests/
man; range 1-22). Table 6.2 shows the PSA values of all tests performed, per participant and 
per detected prostate cancer, together with the calculated positive predictive value (PPV). 
Considering the coverage of the GP laboratory after extrapolation 6.499 men (5,004 / 77.7%) 
were used as contaminators in the analysis, which is 30.7% of 21.166.
Table 6.2 PSA recordings in the control group population retrieved from the GP laboratory
PSA (ng/mL) Tests (%) Men* (%) Prostate cancers** 
(%)
PPV***
All values 11,417 5,004 (30.4%) 243 (1.5%) 4.9%
0-1.0 3,250 (28.5%) 1,566 (31.3%) 1 (0.4%) 0.1%
1.0-2.0 3,080 (27.0%) 1,428 (28.5%) 8 (3.3%) 0.6%
2.0-3.0 1,552 (13.6%) 667 (13.3%) 8 (3.3%) 1.2%
3.0-4.0 1,019 (8.9%) 386 (7.7%) 8 (3.3%) 2.1%
4.0-5.0 710 (6.2%) 252 (5.0%) 17 (7.0%) 6.7%
5.0-6.0 487 (4.3%) 148 (3.0%) 19 (7.8%) 12.8%
6.0-7.0 343 (3.0%) 132 (2.6%) 16 (6.6%) 12.1%
7.0-8.0 242 (2.1%) 107 (2.1%) 22 (9.1%) 20.6%
8.0-9.0 142 (1.2%) 43 (0.9%) 19 (7.8%) 44.2%
9.0-10.0 124 (1.1%) 45 (0.9%) 18 (7.4%) 40.0%
10.0-20.0 331 (2.9%) 134 (2.7%) 51 (21.0%) 38.1%
>=20.0 137 (1.2%) 96 (1.9%) 56 (23.0%) 58.3%
Mean; median 
(range)
3.8; 1.7 (0.1-1,764.8) 4.6; 1.5 (0.1-1,764.8) 38.0; 9.1 (0.8-1764.8)
The data account for 77.7% (16,455 / 21,166) of men who lived in the region of the GP-laboratory.
* In case more PSA tests were performed in one patient, the first test is used for calculations.
** In case more PSA tests were performed in one patient, the last test is used for calculations.
*** PPV=Positive predictive value; the number of diagnosed cancers divided by the number of men tested for PSA.
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Before 2005, 521 cancers were diagnosed in men allocated to the control arm of the ERSPC. 
Of those, 243 (46.6%) men had had their PSA tested by their GP; after extrapolation to the 
whole control group population 316 prostate cancers (60.7%) were considered to be diag-
nosed after a PSA recording by their GP. The mean delay between the first PSA recording and 
prostate cancer diagnosis, either by needle biopsy or TURP, was 19.8 months (median 8.5; 
range 0.13-87.9). A first PSA-recording within a half-year before prostate cancer diagnosis was 
present in 113 of the 243 men (46.5%). Figure 2 shows the time period from randomization to 
PSA test-date.
IMPACT SIMULATION
Three scenarios for the effect of prostate cancer screening were simulated using the contami-
nation and non-compliance rates described above (table 3).
1 2 3 4 5 6 7 8 9 10 11 12
Year since randomization
0
200
400
600
800
N
um
be
r o
f m
en
 w
ith
 a
 P
SA
 te
st
 
Fig 6,2
Figure 6.2 Timing of the first PSA-test after randomization of men in the control group of the Rotterdam section of the ERSPC
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The first scenario assumes that screening has no effect. The results of the intent-to-screen 
and the secondary analysis are comparable, although confidence intervals will be larger after 
correction. The second scenario assumes that screening has just a minor effect on the prostate 
cancer mortality.
Table 6.4 and figure 6.1 show that of men allocated to the screening arm 27.1% are non-
compliers and of these 3.2% have reached the endpoint. These proportions are used to 
calculate the number of ‘potential non-compliers’ (n=5,726) with the associated number of 
men who reached an endpoint (n=183) in the control arm. The remainder equals the group 
of ‘potential compliers’ (n=15,440) with 452 men (635-183) who reached the endpoint. Sub-
sequently, 6,499 men (42.1% of the ‘potential compliers’) of men allocated to the control arm 
of the study had a PSA test done (i.e. contaminators), with 175 men (2.7%) who reached the 
endpoint. These proportions have to be transferred to the screening side of figure 6.1. In this 
way 6,513 ‘potential contaminators’ are identified with 176 men who reached the endpoint. 
Table 6.3 Assumptions of endpoint proportions (endpoint/number of men) for men in three different scenarios. The results, with use of the 
proportions in the ‘total’ column are shown in table 4
Screen Control
Scenario for 
endpoints
Non-
compliers
Compliers Total Contaminators
Non-
contaminators
Total
1 3.0% 3.0% 3.0% 3.0% 3.0% 3.0%
2* 3.2% 2.7% 2.8% 2.7% 3.1% 3.0%
3 3.0% 1.6% 2.0% 2.0% 3.7% 3.0%
Scenario 1 No effect of screening
Scenario 2 Small effect of screening
Scenario 3 Large effect of screening
* Example used in fig. 1 and in the text
Table 6.4 Effect differences between the intention-to-screen analysis and the secondary analysis (i.e. after correction for non-compliance and 
contamination as illustrated in figure 1). The numerator is the number of men who reached the endpoint. The denominator in the proportions is 
the number of men randomized
Scenario Intention-to-screen Difference Secondary analysis Difference Point 
estimates 
(95%CI)
Absolute 
gain in 
effect
Screen Control Screen Control
1 3.0% 3.0% 0.0% 3.0% 3.0% 0.0% 0.0
(0.78-1.30)
0.0%
2 2.8% 3.0% 0.2% 2.6% 3.1% 0.5% 0.85
(0.65-1.11)
0.3%
3 2.0% 3.0% 1.0% 1.4% 3.7% 2.4% 0.33
(0.22-0.45)
1.4%
95% C.I. 95% confidence intervals
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The remaining ‘compliers’ and ‘potential compliers’ then equal the ‘ambivalent’ 8.959 men with 
234 endpoints reached (2.6%) in the screening arm and 8,941 men with 276 endpoints (3.1%) 
in the control arm. The intent-to-screen analysis gives a benefit in survival of 0.2%, which 
amounts to a reduction of 7%; after adjustment however, this effect was 0.5%, which amounts 
to a reduction of prostate cancer mortality in this constructed example of 16.7%. If screening 
has a larger effect on prostate cancer morality rates, as simulated in scenario 3, both, the 
intention-to-screen and the corrected analysis will indicate this significant difference.
DISCUSSION
The method for adjustment used in this paper has been applied to breast cancer screening 
trials before.123 This paper describes the first use of a screening related secondary analysis in a 
prostate cancer screening trial. The only randomized prostate cancer screening trial analyzed 
so far is the Quebec study.124,125 The way the data of this study were analyzed contrasts sharply 
with our methodology and plans. A secondary analysis allows to consider what the outcome 
is for those men who comply with all aspects of screening, it gives an answer to the question 
“what happens to me if I get screened”. The intention to screen analysis allows to judge what 
happens if a screening program is applied to the general population.
The Rotterdam centre has access to computerized data of PSA use in the area and the 
possibility of retrieving prostate cancer incidence data of men in the control arm of the study. 
Since data on contamination and non-compliance are reliably available for ERSPC Rotterdam, 
the method used in this report is feasible for this adjustment and can therefore be used in a 
secondary analysis. Within the Rotterdam section of the ERSPC, 72.9% of men allocated to the 
screen arm were fully screened in our screening program until January 1st 2005. Meanwhile, 
30.7% of men allocated to the control arm of the study had their PSA tested by their GP at 
least once. If a reduction in prostate cancer mortality by screening from 3.0% to 2.8% was 
assumed for the intention–to-screen analysis (scenario 2), adjustment for contamination and 
non-compliance led to a larger decrease of 0.5%. These figures translate into potential mortal-
ity reduction in the intention-to-screen and secondary analysis of 6.7% and 16.7%.
Non-compliance
Different moments and levels of non-compliance occurred: men can refuse to have their PSA 
drawn and it is possible that men subsequently refuse an indicated biopsy. The latter can be 
a result of a medical contra-indication as well. Both events of non-compliance can occur in 
multiple variations during the different screening rounds and therefore influence the clear 
rate of compliers in different ways. Compliers in this study are defined as those men who fully 
complied with the screening program. A secondary analysis in which men with different types 
of non-compliance are included as subgroups will be subject of future study.
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Contamination
In trials such as the ERSPC, PSA contamination, i.e. testing of asymptomatic men in the control 
arm of the trial for whatever reason must be closely monitored. The rate of contamination in 
the control arm may adversely affect the power of the trial. Beemsterboer et al. evaluated op-
portunistic PSA testing in the first 1.5 years of the ERSPC, Rotterdam section.126 They reported 
that after randomization, approximately 8% of the men in the control arm received 1 or more 
PSA tests each year. Otto et al. have also studied contamination in the Rotterdam section of 
the ERSPC.89 In the period evaluated, July 1st 1997 to May 31 2000, 20.2% of men in the control-
arm had at least one PSA-test done after randomization. We studied the same cohort, but with 
a different time frame, namely from randomization to January 1st 2005, during which 30.4% 
had their PSA tested by their GP. The use of PSA as a screening test has become more common 
during recent years, which explains the increase in the number of men tested.
Ciatto et al. reported on the PSA contamination in the different centers of the ERSPC.127 Low 
contamination rates were reported from the Netherlands (13.9%) and Spain (6.7%), whereas 
the frequency of opportunistic screening was higher in other centers, especially Italy (36.6%). 
However, these differences can at least in part be explained by the various methods (database 
linkage, self-administered questionnaires and interviews) by which the data were obtained.
The definition of contamination we have used in this paper is likely to overestimate the 
rate of contamination, because some of the PSA tests were done because they were medically 
indicated. On the other side, some men in the control arm are likely to be diagnosed as a result 
of screening use of PSA by medical specialists who do not use the GP laboratory. A limita-
tion of our study is that not all PSA tests performed outside the trial could be traced, since 
the regional GP laboratory does not cover all municipalities in which recruitment was carried 
out. We have no evidence of PSA testing carried out by physicians in the regional hospitals; 
however, in the Dutch healthcare system, patients are only referred to a specialist after referral 
by their GPs, implying that these men were most likely symptomatic and a PSA test ordered 
would rather be diagnostic than opportunistic testing. Another limitation of this study is that 
the time period between randomization and contamination was not taken into account. In 
order to obtain a more precise estimation of the reasons for the use of PSA, a differentiation 
between screening and diagnostic applications will be made. Furthermore, research into the 
results of PSA tests in terms of the proportion in which they lead to a prostatic biopsy indicated 
by a given test is important. The former can be achieved by sending questionnaires to the GPs 
of patients who had their PSA tested. The latter can be obtained by a link with the national 
pathology registration, which covers all reports of pathologists working in the Netherlands.
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CONCLUSIONS
Adjustment for non-compliance and contamination is an important undertaking when an in-
tervention such as PSA testing is also used in the control arm of a randomized screening trial. 
Since data on contamination and non-compliance are reliably available for ERSPC Rotterdam, 
the method used in this report is feasible for this adjustment and can therefore be used in a 
secondary analysis. This will be of importance especially if screening has just a minor effect on 
mortality from prostate cancer with the intention-to-screen analysis. Although the definition 
of ‘ever having had a PSA test’ gives an indication of the proportion of contamination, it will be 
important to differentiate the use of PSA for screening and diagnostic purposes and to correct 
for the time period after randomization at which the contamination occurred. These are our 
next steps in this research effort.
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ABSTRACT
Purpose
A family history of prostate cancer is an important risk factor for this disease. The clinical pre-
sentation and prognosis of familial disease remain uncertain. In this study these entities are 
evaluated in the first and second rounds of a screening program in The Netherlands.
Patients & Methods
Of all men randomized in the Rotterdam section of the ERSPC, 19,970 men were eligible for 
screening. Information regarding the family history was obtained by a self-administered ques-
tionnaire at baseline.
Results
In the prevalence screen the cancer detection rate in 1,364 men (7.1%) with a positive family 
history was 7.7% (106 cancers in 1,364 screened men with a positive family history) while the 
positive predictive value of the biopsies was 32.2% (154 cancers of 532 biopsies). In 12,803 
sporadic cases the detection rate was 4.7% and the positive predictive value was 23.6% (p 
0.0001 and 0.003, RR 1.63). No clinicopathological differences were found in the 1,559 men 
diagnosed in the first and second rounds. The overall biochemical-free survival rate after a 
mean follow-up of 56.8 months (range 0 to 129.9) was 76.8%, and was not significantly differ-
ent in familial and sporadic cases (p > 0.840). These findings were consistent for the specific 
treatment modalities as well.
Conclusions
Although screened men 55 to 75 years old with a father or a brother having prostate cancer 
themselves are at a substantially greater risk for the disease, the clinical presentation, treat-
ment modalities and prognosis by biochemical progression are not different compared to 
sporadic cases.
Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population
71
INTRODUCTION
prostate cancer is the most frequent cancer among men older than 50 years old in Europe 
and the United States, accounting for respectively 225,000 and 240,000 new cases each year.26 
Epidemiological studies have shown that prostate cancer tends to affect more members of 
the same family than can be explained by chance alone.128 Familial clustering of cancer was 
described almost a century ago, however it was not until the 1970s that genetic predisposi-
tion has been reported to have a role in the origin of cancer. Only in 1992 was the first study 
on the Mendelian inheritance of familial prostate cancer published. The susceptibility genes 
found so far explain only a fraction of the potentially inherited prostate cancer. Having a fam-
ily history of prostate cancer is nonetheless regarded as the greatest risk factor for develop-
ing the disease and the genetic predisposition is possibly the strongest among all common 
cancers.129 This indicates that the genetic basis of prostate cancer is more complex compared 
to cancer at other sites. Whether familial prostate cancer is clinically a different kind of dis-
ease than sporadic prostate cancer remains unclear. If there were a difference in prognosis 
between familial and sporadic prostate cancer, this would necessitate important clinical deci-
sion making. Two studies from the same American institution reported a poorer prognosis 
in men with familial prostate cancer,130,131 while other American and European studies have 
not been able to show a difference in clinical course between familial and sporadic prostate 
cancer.132-135 Little is known about PSA screening among men with a positive family history. 
We compared the risk of prostate cancer, the clinical and biological features at diagnosis and 
the prognosis of different treatment modalities for familial and sporadic prostate cancer in a 
screened population.
PATIENTS & METHODS
Data were collected from the screening arm of the Rotterdam section of the ERSPC. After 
giving written consent 21,210 of 42,376 men 55 to 74 years old were randomized into the 
screening arm from December 1993 through December 1999. A total of 19,970 men (94.2%) 
were actually screened. The participants were offered 3 screening tests of PSA measurement, 
digital rectal examination and TRUS. Biopsy indication was set at a PSA of 4.0 ng/mL or greater, 
or suspicious findings on digital rectal examination or TRUS. After November 1997 a PSA 3.0 
ng/mL or greater prompted a sextant biopsy. Men were eligible for second round screening, 
4 years later, if their age was younger than 75 years and if they were not diagnosed with 
prostate cancer in the prevalence screen. In the second screen round a PSA of 3.0 ng/mL or 
greater prompted a sextant biopsy. In case of a hypoechogenic lesion on TRUS a seventh, 
lesion directed biopsy, was taken. Clinical staging is done throughout the whole study ac-
cording to the 1992 UICC TNM classification. Prostate biopsy cores are labeled and processed 
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individually. Biopsy results were graded by 1 uropathologist (TvdK) using the Gleason score. 
Information on family history was obtained by a self-administered questionnaire at baseline. 
There were 5,648 men who answered the family history question with “probably not”. In these 
men 463 prostate cancers were found. All men who filled in “probably not” were excluded 
from this study. A positive family history was defined as having a father and/or 1 brother or 
more diagnosed with prostate cancer. None of the included men were first or second-degree 
relatives. We calculated the CDR and the RR in men with and without a positive family history. 
The PPV of the biopsies was calculated by dividing the number of prostate cancer found by 
the number of biopsies taken.
Follow-up data were obtained by reviewing patient charts every 6 months for the first 5 years 
following diagnosis and annually thereafter. Medical history, physical examination, dissemi-
nation studies and PSA tests were registered. Primary end point in this study was biochemical 
progression, which was defined as 2 consecutive PSA values of 0.2 ng/mL or higher after radi-
cal prostatectomy and 3 consecutive PSA increases (American Society for Therapeutic Radi-
ology and Oncology definition) after radiotherapy.80 Because no widely accepted definition 
for biochemical progression in watchful waiting exists, the American Society for Therapeutic 
Radiology and Oncology definition was arbitrarily used for follow-up of watchful waiters as 
well. Time of biochemical progression was backdated to the date between the first increase 
and the previous PSA test date. The criteria described by Collette et al were used for biochemi-
cal progression of men with metastasized disease receiving hormonal treatment (e.g. a 20% 
increase of the PSA over nadir, each to a value greater than 4.0 ng/mL).81 two sided p-values 
were calculated using the chi-square test for grouped variables. Kaplan-Meier projection was 
used for biochemical progression-free survival analysis. The curves were tested for significance 
(p 0.05) with the log rank test. All analyses were performed with the commercially available 
SPSS® software version 12.0. Treatment data were based on intention to treat basis.
RESULTS
Prevalence
In round 1 of the Rotterdam section of the ERSPC, 19,970 men were screened for prostate can-
cer and filled in the question regarding the family history. A total of 1,364 men (6.8%) reported 
that 1 or more affected first degree relatives had a positive family history. In 436 cases (32.0%) 
this involved a brother, in 867 cases (63.6%) their father and in 61 (4.5%) a father and a brother 
with prostate cancer. The age of onset of the affected relative or relatives was available in 685 
men (50.2%), of whom 50 (7.3%) relatives were 59 years or younger. Of all prevalence screened 
men with prostate cancer (1,014) 106 men reported a positive family history (10.5%). A total of 
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4,117 men underwent biopsy and 329 (8.0%) had a positive family history. Therefore, the CDR 
was 7.7% and the PPV of the biopsies was 32.2%.
A negative family history was reported by 12,803 men (64.1%). In men with a negative family 
history, 2,548 biopsies were performed (61.9%) resulting in 601 prostate cancer diagnoses in 
the prevalence screen. For this group the CDR was 4.7% and the PPV of the biopsy indication 
was 23.6% (table 7.1). Logistic regression analysis showed that family history is an independent 
predictor for being diagnosed with prostate cancer (odds ratio 1.35, 95% CI 1.06 to 1.73).136 
An additional 545 cancers were found by re-screening after 4 years. In the 2 screening rounds 
together 1,559 men with prostate cancer were diagnosed of 19,970 men screened (CDR 7.7%, 
RR 1.53). The age distribution was similar for both groups (data not shown).
Demographics
The respective median age at time of prostate cancer diagnosis for positive family history 
and negative family history was 66.2 (mean 66.5, range 55.4 to 75.6) and 66.8 (mean 66.2, 
range 55.0 to 75.6), with a median follow-up of 55.4 months (mean 56.8, range 0 to 129.9). 
As table 2 shows, the remaining baseline characteristics of the 2 groups were well balanced. 
The majority of the patients had a biopsy Gleason score of 3 + 3 or less (69.9). Only 6.5% had 
a biopsy Gleason score of 4 + 4 or greater. The clinical tumor extension was classified as T1C 
(46.1%), T2 (27.7%), T3 (9.8%), T4 (0.5%). Median PSA at time of diagnosis was 5.0 (mean 8.8, 
range 0.6 to 315.9 ng/mL).
Table 7.1
PFH1 NFH3 Total
N % N % N % P-value
Screened 1,364 6.8 12,803 64.1 19,970
Prevalence screen Biopsied 329 8.0 2,548 61.9 4,117
PC 106 10.5 601 59.3 1,014
PPV 32.2 23.6 24.6 0.003
CDR 7.7 4.7 5.1 <0.0001
RR 1.63
Round 2 PC 48 8.9 341 62.6 545
Total PC 154 9.9 942 60.4 1,559
CDR 11.3 7.4 7.8 <0.0001
RR 1.53
PFH = positive family history;
NFH = negative family history
PC = prostate cancer;
CDR = cancer detection rate;
PPV = Positive Predictive Value;
RR = Relative Risk.
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Table 7.2 Demographics and prognostic factors
PFH NFH
N % N % P-value
PC 154 942
Screen round 1 106 68.8 601 63.8 0.226
Follow up (months, median) 52.0 0-129.9 55.4 0-129.9
Age at diagnosis (years, median) 66.2 55.4-75.6 66.8 55.0-75.6
Clinical PSA group <4 49 31.8 325 34.5
4-10 81 52.6 449 47.7
>10 24 15.6 168 17.8 0.515
T stage T1C 58 39.2 434 46.9
T2 68 45.9 355 38.4
≥T3 22 14.9 136 14.7 0.106
missing 6 17
N-stage N1 1 0.6 10 1.1 0.634
M-stage M1 2 1.3 6 0.6 0.371
Biopsy Gleason sum =<3+3 109 70.8 657 69.7
7 33 21.4 226 24.0
>=4+4 12 7.8 59 6.3 0.649
PFH = positive family history
NFH = negative family history
PSA = prostate specific antigen
Table 7.3 Treatment modalities and survival
PFH NFH
Treatment N % Follow-up 
available
5 yr-BFS N % Follow-up 
available
5 yr-BFS P-value
RP 61 39.9 53 (86.9%) 89.8% 349 37.7 319 (91.4%) 86.8%
RT 71 46.4 62 (87.3%) 72.2% 403 43.6 351 (87.1%) 77.2%
WW 18 11.8 15 (83.3%) 38.7% 155 16.8 125 (80.6%) 67.1%
ET 3 2.0 3 (100%) 56.5% 18 1.9 18 (100%) 38.7%
missing 1 17
Total 154 133 (86.4%) 77.8% 942 813 (86.3%) 79.2% 0.487
RP = radical prostatectomy;
RT = radiotherapy;
WW = watchful waiting;
ET = endocrine treatment
5 yr-BFS = Five year biochemical free-survival
PFH = positive family history
NFH = negative family history
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Treatment modalities
The initial treatment modalities of positive vs. negative family history were 39.9% vs. 37.7% for 
radical prostatectomy, 46.4% vs. 43.6% for radiotherapy, 11.8% vs. 16.8% for watchful waiting 
and 2.0% vs. 1.9% for endocrine treatment. The numbers are shown in table 7.3. Between men 
with and without a family history, no differences with respect to median patient age, serum 
PSA level or biopsy rate were observed in the different groups of treatment.
Prognosis
Biochemical progression occurred in 166 men (10.6%) after a median follow-up time of 22.1 
month (mean 25.9, range 0 to 186.2). Of those men 22 (14.3%) had a positive family history. The 
time from treatment to biochemical progression was median 21.9 months (mean 25.8, range 
0,00 20,00 40,00 60,00 80,00 100,00 120,00 140,00
Time since diagnosis (months)
0,0
0,2
0,4
0,6
0,8
1,0
B
io
ch
em
ic
al
 p
ro
gr
es
si
on
 fr
ee
 s
ur
vi
va
l
NFH
PFH
NFH-censored
PFH-censored
Overall biochemical progression free-survival
 
 
 
Fig 7.1 
Figure 7.1 Kaplan-Meier projection of overall biochemical progression free-survival
Log-rank: P-value=0.840
Men at risk
0 20 40 60 80 100 120 140
PFH 133 110 69 34 17 8 0
NFH 813 660 459 263 134 49 7 0
Number of events
0 20 40 60 80 100 120 140
PFH 0 8 18 22 22 22 22
NFH 0 64 119 139 142 144 144 144
PFH Positive family history
NFH Negative family history
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0 to 129.9) in the PFH group. In the negative family history group were 144 men (15.3%) with 
biochemical progression, after median 23.6 months (mean 26.9, range 10.6 to 53.3). Overall 
5-year biochemical progression-free survival rates were 77.8% for positive family history and 
79.2% for negative family history (Kaplan-Meier curve in figure 7.1).
After radical prostatectomy, the 5-year biochemical progression-free survival rates were 89.8% 
for positive family history and 86.8% for negative family history (figure 7.2).
As shown in figure 7.3 the 5-year biochemical progression-free survival rates for radiotherapy 
were 72.2% for positive family history and 77.2% for negative family history. Table 7.3 shows 
the quantity of men with biochemical progression for each individual treatment modality dur-
ing total follow up. These differences were not significant.
0,00 20,00 40,00 60,00 80,00 100,00 120,00 140,00
Time since diagnosis (months)
0,0
0,2
0,4
0,6
0,8
1,0
B
io
ch
em
ic
al
 p
ro
gr
es
si
on
 fr
ee
 s
ur
vi
va
l fam
NFH
PFH
NFH-censored
PFH-censored
Radical Prostatectomy
Biochemical progression free-survival
 
Fig 7.2 Figure 7.2 Biochemical progression free-survival in radical prostatectomy patients
Log-rank: P-value=0.584
Men at risk
0 20 40 60 80 100 120 140
PFH 53 49 35 20 11 4 1 0
NFH 319 283 218 131 68 31 6 0
Number of events
0 20 40 60 80 100 120 140
PFH 0 1 5 5 5 5 5 5
NFH 0 11 30 36 38 39 39 39
PFH Positive family history
NFH Negative family history
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DISCUSSION
Prevalence
Our study provides further conformation that men with a father or a brother with prostate 
cancer themselves have a higher risk of developing prostate cancer (table 7.1). In the last 
50 years RRs ranging from 1.3 through 18 were described.137,138 The largest study on this 
topic reports on 1,922 men who were mainly diagnosed with prostate cancer before the PSA 
screening era.128 When a first-degree relative had a family history of prostate cancer, the RR of 
being diagnosed with prostate cancer themselves was 1.60 (95% CI 1.31 to 1.97). In our study 
the RR was 1.53, which is lower than in most other reports.136 However, most of those studies 
are case-control studies, which are subject to various kinds of bias. Therefore, the true RR is 
probably somewhat lower than in most studies. We only included men 55 through 75 years 
old. That means the RR we found might give an underestimation of the actual risk because 
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fig 7.3 Figure 7.3 Biochemical progression free-survival in radiotherapy patients
Log-rank: P-value=0.744
Men at risk
0 25 50 75 100 125
PFH 62 45 24 6 4 0
NFH 351 252 147 66 16 0
Number of events
0 25 50 75 100 125
PFH 0 6 10 12 12 12
NFH 0 38 60 62 63 63
PFH Positive family history
NFH Negative family history
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the influence of the family history is more explicit at a younger age, which is referred to as 
prostate cancer of early onset.139
The proportion of patients with a positive family history was 10.5% of all men diagnosed with 
prostate cancer in the prevalence screen. In the literature these percentages range from 11.1% 
through 18%.140,141 Our relatively small number of positive family histories may have been a 
result of the different selection criteria for familial prostate cancer we used. It may also have 
been underestimated because the “probably not” group contained some men with a positive 
family history. A second explanation for the higher proportion found in the literature could be 
that men who have patients with prostate cancer in their proximity, often being a father or a 
brother, are more aware of the disease and its screening possibilities.
Whether the use of a self-administered questionnaire at baseline is a reliable method of ac-
quiring data on family history is debatable. Family history was self-reported before screening 
started, and is believed to be fairly accurate and reliable, as has been shown by Zhu et al.142
Demographics
The clinical presentation of familial prostate cancer remains controversial. As this screen-
ing round was a prevalence screen, we should, like Gronberg et al, have been able to show 
differences in the tumor grade and frequencies of advanced disease between familial and 
sporadic cases.143 However, no such observations were made in our study, nor in other 
reports.130,132,134,135,140 Our findings of clinicopathological similarity (initial PSA, T stage and 
Gleason score) of both groups are consistent with those reports.
Although other studies have shown a significant lower age at diagnosis in men with a posi-
tive family history, we found no difference.133,144 Only 2 studies have reported findings similar 
to those in our study.132,137 Azzouzi et al postulated that this difference was due to selection 
bias, because only men treated with radical prostatectomy were described.132 The findings of 
Makinen et al and our findings are probably biased by selection of an age grouping which ex-
cludes men younger than 55 years.137 Among men with early onset prostate cancer, hereditary 
susceptibility is much more common, and may cause up to a third of cases diagnosed before 
age 60 years and almost half of those in men 55 years or younger.139 There are just a few stud-
ies that reported on familial prostate cancer in a screen setting. The report by Makinen et al 
describes the familial influence in the Finnish part of the ERSPC study. Their screen algorithm 
is quite similar to ours except for the PSA threshold value and the screen age, which is 55 to 
70 years. In Rotterdam men are screened until they are 75 years old. Makinen et al used a 
threshold value of 4.0 ng/mL as a biopsy indication,137 while ours was 4.0 ng/mL at the start of 
the study but changed to 3.0 ng/mL in November 1997. Since the authors showed that age at 
diagnosis did not statistically differ between a positive and a negative family history, a similar 
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age at diagnosis could well be a screen effect. Men having a close relative diagnosed with 
prostate cancer may also have a higher familial awareness of prostate cancer and, therefore, 
have a higher sense of urgency about getting screened. In this study men with positive and 
negative family history were screened in a similar way, thereby excluding the possible bias of 
familial awareness. The similarity in age at diagnosis is not due to a difference in age distribu-
tion in the recruited population, as this distribution was similar in participants irrespective of 
family history (data not shown). Although most men with early onset prostate cancer have 
been described as having a positive family history,139 the age distribution in our study was 
similar in both groups. It is possible that those younger men were not included in our study, 
because they had been diagnosed with prostate cancer before screening started. This would 
have caused us to overestimate the median age at diagnosis, which would also explain our 
relatively low proportion of men with a positive family history. In terms of treatment, if one 
considers the similar distribution of treatment modalities in both groups, knowledge of family 
history did not determine the choice of initial treatment.
Prognosis
In this study screen detected prostate cancer did not show a significant difference in overall 
biochemical progression-free survival between the positive and the negative family history 
group (figure 7.1). Therefore, we confirm the results of most reports on the follow-up of famil-
ial prostate cancer, except for those by Kupelian et al,4,5 which both show a worse prognosis 
for hereditary prostate cancer. We have no clear explanation for this difference other than 
the strictness of selection criteria used for familial and hereditary prostate cancer. This has 
been defined by Carter et al as the presence of prostate cancer in at least 3 first-degree rela-
tives, in 3 consecutive generations, or in 2 first-degree relatives with an age of onset less than 
55 years.144 Thus, hereditary prostate cancer is actually a subset of our population of familial 
prostate cancer, which was defined as the existence of a father and/or 1 brother or more with 
the disease. Contrasting the findings of Kupelian et al, Bova et al found that the prognosis of 
familial prostate cancer after radical prostatectomy is not different from that in men without 
a history of this disease.134 Patients receiving definitive radiation therapy for localized prostate 
cancer were described by Ray et al, who did not find a relationship between positive first-
degree family history of prostate cancer and biochemical progression-free survival rates.141 
Our data are uniform with these findings.
Although biochemical progression-free survival cannot be considered as a definitive end 
point for prostate cancer prognosis, it is supposed to be the best indicator for prostate cancer 
specific survival. Longer follow-up than ours of mean 56.9 months is mandatory for evaluation 
of (disease specific) mortality.
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CONCLUSIONS
In this evaluation of the first and second screen round of the ERSPC we have shown that men 
with a positive family history of prostate cancer are at a substantially greater risk of being 
diagnosed with the disease. However, the clinicopathological features of these patients age 
55 to 75 years old are not different and patients are treated in the same way as those with 
sporadic prostate cancer. Moreover, screen detected familial related prostate cancers have no 
significantly different prognosis, by the biochemical progression-free survival rates than those 
diagnosed in screened men without a family history of the disease. Whether overall mortality 
will be equal in both groups remains unclear until longer follow-up is available.
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ABSTRACT
Backgrounds
Screening for prostate cancer has not only led to a stage migration, but also to a higher in-
cidence of the disease. A decrease in mortality has occurred in several countries during the 
same time period. Risk stratification of screen-detected cancers at diagnosis has become more 
important for the anticipation and interpretation of changing incidence-mortality ratios.
Patients & Methods
From 1993 to 1998, 633 men were diagnosed with non-metastatic prostate cancer in the 
prevalence screen of the Rotterdam section of the European Randomized study of Screening 
for Prostate Cancer (ERSPC). The characteristics at diagnosis of men who developed metastatic 
disease were compared to men without evidence of metastases during follow-up.
Results
During the median follow-up of 7.5 years, 41 men developed metastatic disease. After 10 
years the metastasis-free survival rate was 89.6%, the overall survival 64.7%. In a Cox-model 
2logPSA, biopsy Gleason score and the number of biopsy cores with prostate cancer were 
independent predictors for the development of metastases; the latter only predicted metas-
tases that presented within 60 months of follow-up.
Conclusion
The metastasis-free survival of men with prostate cancer detected in our prevalence screening 
was very high. Whether this was related to the beneficial effects of screening or to overdiag-
nosis due to screening (or both) remains unclear. The prognostic factors known for clinically 
diagnosed disease also hold for screen-detected disease.
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INTRODUCTION
Prostate cancer is an important burden of health in the western world; it accounts for ap-
proximately 3% of all deaths in the US.33 Since prostate-specific antigen (PSA) became avail-
able in the late 1980s, it has not only been used for diagnostic and follow-up purposes but 
increasingly for screening practices as well. Age-adjusted incidence rates increased over the 
past several decades, with dramatic increases associated with the widespread use of prostate-
specific antigen (PSA) screening in the late 1980s and early 1990s, followed by a more recent 
fall in incidence. Age-adjusted mortality rates have recently paralleled incidence rates with 
an increase followed by a decrease in the early 1990s.32 However, whether this decrease in 
mortality is the result of screening efforts or of improvements in treatment modalities re-
mains a matter for debate. As a result of the increase in incidence and the decrease in mortal-
ity, the number of men diagnosed with prostate cancer per prostate cancer death (i.e. the 
incidence-mortality ratio) has increased accordingly. Between 1989 and 2002, for example, 
the incidence-mortality ratio increased by 61.5% in the US (reaching 6.3 diagnosed men per 
prostate cancer death),32 and has recently increased to 7.8.33 In the Netherlands it increased 
by 53.1% (reaching 3.0 diagnosed men per prostate cancer death in 2002).73 A mathemati-
cal model based on data from the Rotterdam section of the European Randomized study of 
Screening for Prostate Cancer (ERSPC) has shown that in a population-based screening pro-
gram with a four-year screen interval for men aged 55 to 75 years, 54% (95% CI: 51–59) of 
cases would not have been diagnosed in PSA test absence.37 By definition, these cancers are 
overdiagnosed, which tends to be followed by overtreatment, and the associated toxicity of 
the different prostate cancer treatment modalities.145,146
Due to this burden of overdiagnosis and its ethical and economical consequences, the 
need for risk stratification of prostate cancer patients has become increasingly important. In 
screening trials, it is still poorly understood which cancers deserve treatment and which do 
not. On the other extreme, it is important to identify those cancers which are at high risk 
for the development of prostate cancer metastases and prostate cancer death despite treat-
ment.147 In screening trials, a reduction in prostate cancer deaths may be obtained by the 
detection (and subsequent treatment) of poorly differentiated cancers in their localized or 
regional stage of disease before they have metastasized. On the other hand, some cases diag-
nosed with prostate cancer may still develop metastases despite screening efforts. If it were 
possible to identify these cases on the moment of diagnosis, a more intensified or aggressive 
therapeutic approach could be chosen.
This report contributes to the extreme side of the risk spectrum: the predictors of meta-
static disease. There are only limited survival data available of men with screen-detected 
prostate cancer. Therefore, we studied the prognostic factors related to the development of 
metastases in men with screen-detected non-metastatic prostate cancer at diagnosis.
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PATIENTS & METHODS
The European Randomized study of Screening for Prostate cancer (ERSPC) was designed to 
investigate the feasibility of screening for prostate cancer. The primary goal of the ERSPC is to 
show if a 25 % prostate cancer specific mortality reduction can be achieved by early detection 
at the 5% significance level with a power of 80%. Therefore, 267,994 men in eight European 
countries were randomized. From 1993 to 1999, in Rotterdam alone 42,376 men aged 55-74 
were randomized between the screening (n=21,210) and the control-arm (n=21,166) of the 
ERSPC. The details of the Rotterdam section of the ERSPC are described elsewhere.78 In short, 
men in the screen arm were offered a biopsy according to two subsequent protocols. The 
first one was applied from December 1993 to April 1997: in this protocol (protocol I) a biopsy 
was prompted by a suspicious digital rectal examination (DRE), transrectal ultrasound (TRUS) 
and/or a PSA ≥ 4.0 ng/mL. From May 1997, the protocol was changed and all men with a PSA 
≥ 3.0 ng/mL were offered a biopsy, regardless of the findings on DRE and TRUS (protocol II). 
A standardized, lateralized sextant biopsy was performed throughout the whole study.83 If a 
hypo-echogenic lesion was evident on TRUS, a seventh lesion directed biopsy was taken. All 
biopsy cores were processed individually, examined and scored according to Gleason by one 
uro-pathologist (T.H.v.d.K.).
Study group
All men diagnosed with non-metastatic prostate cancer during their first screening visit in the 
first four years of ERSPC screening (before January 1st 1998) were selected (N=633; CONSORT 
diagram figure 8.1). Nine men (1.4%) were excluded because they had metastatic disease at 
time of diagnosis. No comparisons with the control-group of the ERSPC were made, because 
of the close relationship of the used endpoint with the primary endpoint of the ERSPC (i.e. 
prostate cancer-mortality). Furthermore, the prognostic factors of the control arm of the study 
are incomplete, as data-acquisition is still ongoing.
Endpoint
The primary endpoint for this analysis was the occurrence of metastatic disease on follow-up. 
The secondary endpoint was overall survival.
Within ERSPC, an independent committee performs the review of deceased cases. Three 
reviewers (a surgeon, a urologist and a medical epidemiologist) separately judged the anony-
mized patient charts without knowledge of randomization arm. The methods described by De 
Koning et al. are used for judgment of metastatic disease as well.148 Additionally, all men with a 
PSA of 150 ng/mL or more at diagnosis or during follow-up were assumed to have metastatic 
disease.
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Statistics
Significant risk factors for time from diagnosis to prostate cancer metastases were examined 
using log-rank survivorship analysis and Cox proportional hazards regression. Separate uni-
variate (log rank test) and multivariate (Cox proportional hazards model) failure time analyses 
using metastatic disease as an endpoint were performed. A Cox proportional hazards model 
was used with P<.20 determining which variables should be entered into the model at each 
step. The proportional hazards assumption of the Cox model was tested through the graphical 
examination of the log-log survival plots for each of the variables in the model. These plots 
formed approximate parallel straight lines as required. All statistical analyses were performed 
using SPSS 12.0.1 (SPSS Inc., Chicago, IL), and P<.05 was considered statistically significant.
 
Fig 8.1 
ERSPC Rotterdam 
N=42,376 
Randomised before 1998 
N=27,658 (65.3%) 
Randomised after 1997 
N=14,718 (34.7%) 
Screening arm * 
N=13,947 (50.4%) 
Control arm 
N=13,711 (49.6%) 
Prostate cancer 
N=642 (4.6%) 
No prostate cancer 
N=13,069 (95.4%) 
M0 at diagnosis **
N=633 (98.6%) 
M1 at diagnosis 
N=9 (1.4%) 
M1 during follow-up 
N=41 (6.5%) 
M0 during follow-up 
N=592 (93.5%) 
Figure 8.1 CONSORT diagram
* 10.456 men (75.0%) were screened by protocol I and 3.491 (25.0%) by protocol II.
** 466 men (73.6%) were diagnosed by protocol I and 167 (26.4%) by protocol II.
Protocol I (December 1993-April 1997)
Biopsy prompted by:
1. Suspicious digital rectal examination (DRE)
2. Suspicious transrectal ultrasound (TRUS)
3. PSA >= 4.0 ng/mL
Protocol II (April 1997-January 1998)
Biopsy prompted by:
PSA >= 3.0 ng/mL
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RESULTS
From December 1993 to January 1998, 633 men were diagnosed with non-metastatic pros-
tate cancer in the Rotterdam section of the ERSPC. During the mean (SD) and median (range) 
follow-up times of 7.1 (2.2) and 7.5 years (0.2-12.0) 41 men (6.5%) were diagnosed with meta-
static disease. Table 8.1 shows the characteristics of men with prostate cancer who did and 
who did not develop metastatic disease on follow-up at baseline. The ten year metastatic-free 
survival was 89.6% (figure 8.2). The mean time period from diagnosis until metastatic disease 
was 62.4 months (median 58.7, range 13.7-110.3). After 10 years the overall survival was 64.7%. 
The time to metastases as a function of the significant prognostic factors Gleason score and 
initial PSA at diagnosis in the univariate analysis (log rank test) is graphically depicted in the 
Kaplan-Meier graphs of figure 8.3 and 8.4. The outcome of the different treatment modalities 
is shown in figure 8.5. PSA-level at diagnosis, biopsy Gleason score, clinical stage, the number 
of biopsy cores that were invaded with cancer and the applied treatment were significant 
predictors of metastatic disease in the univariate analysis (table 8.1).
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Fig 8.2 
Figure 8.2 Kaplan-Meier projection of overall-survival and metastatic free survival (N=633)
Men at risk
Year 0 2 4 6 8 10
Overall survival 633 612 574 485 255 36
% 100 97.3 93.6 85.9 78.4 64.7
Survival free of M+ 633 610 570 481 254 35
% 100 99.4 98.0 95.5 92.9 89.6
Log-rank test: P-value<0.001
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Table 8.1 Characteristics at baseline of 633 men with no evidence of metastasis at diagnosis
Men with 
metastatic 
disease during 
follow-up (M1)
Men without 
metastatic 
disease during 
follow-up (M0)
Total P-value
Patients No. (%) 41 (6.5) 592 (93.5) 633
Age (years)
Mean
(median; min-max)
67.3
(67.8 ; 56.4-75.0)
66.0
(66.7; 55.0-75.5)
66.1
(66.7; 55.0-75.5)
0.14 **
PSA (ng/ml)
Mean
(median; min-max)
17.9
(12.7; 2.7-62.9)
8.6
(5.6 ; 0.3-145.0)
9.2
(5.7; 0.3-145.0)
<0.001 **
≤3.0 (%) 1 (2.4) 89 (15.0) 90 (14.2)
<0.001 *
3.1-10.0 (%) 16 (39.0) 382 (64.5) 398 (62.9)
10.1-20.0 (%) 11 (26.8) 84 (14.2) 95 (15.0)
≥20.1 (%) 13 (31.7) 37 (6.3) 50 (7.9)
Clinical stage
T1C (%) 4 (9.8) 162 (27.4) 166 (26.2)
<0.001 *T2 (%) 15 (36.6) 302 (51.0) 317 (50.1)
T3/4 (%) 22 (53.7) 128 (21.6) 150 (23.7)
Biopsy Gleason
<7 (%) 10 (24.4) 396 (66.9) 406 (64.1)
<0.001 *7 (%) 16 (39.0) 156 (26.4) 172 (27.2)
>7 (%) 15 (36.6) 40 (6.8) 55 (8.7)
Number of cores 
invaded with 
prostate cancer
1-2 (%) 8 (19.5) 298 (50.3) 306 (48.3)
<0.001 *
3-4 (%) 11 (26.9) 203 (34.3) 214 (33.8)
5-6 (%) 14 (34.1) 76 (12.8) 90 (14.2)
7 (%) 8 (19.5) 15 (2.5) 23 (3.6)
Prostatic volume 
(cc)
Mean
(median; min-max)
41.6
(37.9; 20.4-92.5)
40.0
(35.1; 13.4-125.2)
40.1
(35.1; 13.4-
125.2)
0.26 **
Treatment
RP (%) 5 (12.2) 227 (38.3) 233 (36.8)
<0.001
RT (%) 35 (85.4) 299 (50.5) 334 (52.8)
WW (%) 0 (0.0) 59 (10.0) 59 (9.3)
ET (%) 1 (2.4) 7 (1.2) 7 (1.1)
Risk-group13
1 (%) 1 (2.4) 77 (13.0) 78 (12.3)
<0.0012 (%) 27 (65.9) 485 (81.9) 512 (80.9)
3 (%) 13 (31.7) 30 (5.1) 43 (6.8)
Follow-up (years)
Mean
(median; min-max)
5.2
(4.9; 1.1-9.2)
7.3
(7.6; 0.2-12.0)
7.1
(7.5; 0.2-12.0)
P-values were calculated for men with versus men without metastatic disease
* Chi-square test
** Mann Whitney U test
RP Radical prostatectomy
RT Radiotherapy
WW Watchful waiting
ET Endocrine therapy
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Two hundred thirty two men (36.3%) elected radical prostatectomy; 5 (2.2%) developed meta-
static disease. The 10-year metastasis-free survival was 97.7%. The mean time period from 
diagnosis to metastatic disease was 48.2 months (median 46.3; range 38.8-59.1). After 334 
radiotherapy treatments (52.8%), 35 men (10.5%) developed metastases; after a median time 
period of 62.6 months (mean 64.5; range 13.7-110.3).
Only one man was diagnosed with metastatic disease after hormonal treatment was ap-
plied. The nine men who had metastatic disease at diagnosis all received hormonal treatment; 
those were excluded from our analysis. In the watchful waiting group no one developed 
metastatic disease.
Regression models
In a multivariate model, the time to failure in radical prostatectomy patients is significantly re-
lated to the initial PSA level. Metastases occur earlier in time during the follow-up if the initial 
PSA is higher. A Cox proportional hazards model can describe this observation quantitatively 
(hazard ratio for 2log initial PSA = 3.2; 95% C.I. 1.4 – 7.4). In radiotherapy patients the group 
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Fig 8.3 
Figure 8.3 Kaplan-Meier projection of the metastatic-free survival by biopsy Gleason score groups (N=633).
Men at risk
Year 0 2 4 6 8 10
Gleason score < 7 406 393 372 310 162 17
Gleason score = 7 172 168 153 135 65 12
Gleason score > 7 55 50 42 30 18 5
Log-rank test: P-value<0.001
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with a Gleason score ≥ 8 and, jointly, a total number of biopsy cores positive for cancer of 6 or 
possible 7 clearly showed a different failure pattern when compared to the rest of the radio-
therapy patients. In the former group the metastases occurred between 23 and 51 months. In 
the remaining patients 2logPSA and a Gleason sum ≥ 8 predict the time to metastasis in a Cox 
proportional hazard model. A way to model both observations jointly is to assume that the 
predictive potential of the total number of biopsy cores with prostate cancer and the biopsy 
Gleason score strongly affects the time to metastasis during the first 60 months of the follow-
up. After that time period the predictive potential of the number of biopsy cores with prostate 
cancer decreases strongly and the initial PSA level and poorly differentiated tumors remain 
the only predictors. The hazard ratio for the time varying covariate condition described by 
[Gleason score ≥ 8 & number of biopsy cores with prostate cancer ≥ 6 and follow-up time less 
than 60 months] equaled 71 (18-288), the hazard ratios for 2log transformed initial PSA and 
Gleason score ≥ 8 equaled 1.6 (1.3 – 2.0) and 2.5 (1.1 – 5.7) respectively.
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Fig 8.4 
Figure 8.4 Kaplan-Meier projection of the metastatic-free survival by PSA groups.
Men at risk
Year 0 2 4 6 8 10
PSA ≤ 10.0 488 475 440 368 188 30
PSA 10.1-20.0 95 92 85 73 40 3
PSA > 20.0 50 44 42 34 17 1
Log-rank test: P-value<0.001
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DISCUSSION
Screening leads to the detection of a large number of prostate cancers. Most of these cancers 
are expected to have beneficial prognostic features compared to non-screened populations, 
with lower grades and lower stages of disease. Still, some men in the screened group will 
decease from the consequences of prostate cancer during follow-up. In the present study, 
41/633 (6.5%) of all diagnosed cases with prostate cancer developed metastatic disease dur-
ing the median follow-up period of 7.5 years. In the whole cohort of patients diagnosed with 
prostate cancer, the 10 year metastasis-free survival was 89.6%, which contrasted sharply with 
the overall survival of 64.7%. In the radical prostatectomy patients very few men developed 
metastases; the time to metastases was significantly related to the initial PSA level. In the ra-
diotherapy patients the 2log transformed PSA-level at diagnosis, the number of biopsy cores 
with prostate cancer and the biopsy Gleason score were identified as individual predictors 
for the development of metastases during the first sixty months of follow-up. Thereafter, the 
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Fig 8.5 
Figure 8.5 Kaplan-Meier projection of the metastatic-free survival of the different treatment modalities
Men at risk
Year 0 2 4 6 8 10
Hormonal treatment 7 7 7 5 1 0
Radical Prostatectomy 233 229 219 192 121 27
Radiotherapy 334 320 290 232 103 6
Watchful waiting 59 56 52 46 20 1
Log-rank test: P-value<0.001
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predictive value of the number of biopsy cores with prostate cancer decreased, while the 
Gleason score and the 2logPSA remained predictive for metastases.
Men detected in the prevalence screening round of the Rotterdam section of the ERSPC 
had a high metastasis-free survival. Two factors could explain this low rate of occurrence of 
prostate cancer metastases compared to pre-screened populations: (1) overdiagnosis and (2) 
downstaging and downgrading. The advent of screening has been the major reason for the 
increased incidence of prostate cancer over the last decades.33 The overdiagnosis which is 
caused by a systematic screening program like ours can only be expected to be larger.
In our study most patients developed metastases after radiotherapy. The characteristics at 
baseline indicate that more high risk patients were treated by radiotherapy. A retrospective 
analysis of radical prostatectomy versus radiotherapy, with a correction for the prognostic 
factors, has not been performed, because of its limited value in this non randomized setting. 
This study provides no proof of the effectiveness of the treatment modalities under study. 
In order to compare the oncological outcome of radical prostatectomy and radiotherapy in 
screen-detected disease, the results of randomized studies like the ProtecT study have to be 
awaited.149
Another reason for the poorer performance of men treated with radiotherapy is that most 
of the patients in current studies which have comparable oncological results as radical pros-
tatectomy series were irradiated with 72 Gray or more. During the past 5 years, there have 
been two major breakthroughs in the use of external-beam radiotherapy for early prostate 
cancer: dose escalation and the use of adjuvant hormone therapy. These new applications are 
based on evidence from prospective clinical trials with superior methods. A prospective ran-
domized trial, in which a conventional dose of 70 Gray was compared with a dose escalation 
to 78 Gray showed a significant survival benefit for intermediate and high risk patients.150 In 
our population, only 8.0% of men treated with external beam radiotherapy received 72 Gray 
or more; the remainder received less. The majority of men with metastatic disease have been 
irradiated with 66 or 68 Gray.
It is interesting to note that the subgroup of patients with metastases after 60 months 
of follow-up is absent in the radical prostatectomy group of patients. This may reflect that 
patients with favorable prognostic factors were preferably treated by radical prostatectomy. 
Although the follow-up period was similar for radical prostatectomy and radiotherapy, the 
time to diagnosis of metastases was different. After radical prostatectomy, metastases de-
veloped after a maximum duration of 59.1 months. This contrasts with the last event after 
radiotherapy, which occurred 110.3 months after diagnosis. The multivariate analysis clearly 
showed that radiotherapy patients with a Gleason score ≥ 8 and, jointly, a total number of 
biopsy cores of 6 or 7 with cancer, had a different failure pattern when compared to the rest 
of the radiotherapy patients. In the former group the metastases occurred between 23 and 51 
months. Remarkably, however, 5 patients with the same condition did not develop metastases 
so far (median follow-up time of these patients, 95 months; range 23-121).
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The majority of men who developed metastases were treated with curative intent, namely 
radiotherapy or radical prostatectomy alone. In these cases the curative treatment was clearly 
not sufficient to prevent the disease from developing metastases. Another explanation could 
be that these men already had tumor spread outside of the prostate at diagnosis. Therefore, 
these men would likely have been candidates for adjuvant treatment or should have been 
enrolled in early aggressive treatment trials. In men who developed metastatic disease in our 
series despite surgery or external beam radiotherapy alone, clearly the treatment applied was 
not aggressive enough.
CONCLUSION
Metastatic prostate cancer is relatively rare in men with screen-detected prostate cancer. It is 
not known to what extent this results from dilution by overdiagnosed cancers, and to what 
extent to treatment or screening. The individual risk factors for the development of metasta-
ses include 2logPSA, the biopsy Gleason score and the number of biopsy cores with prostate 
cancer. The latter loses its predictive value 60 months after diagnosis in our study. These data 
can serve as useful guidelines for the identification of patients who are in need of aggressive 
treatment. Furthermore, these prognostic factors predict with reasonable accuracy in which 
men the development of metastatic disease is less likely and which can therefore be consid-
ered for local treatments and for active surveillance strategies.
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ABSTRACT
Objectives
The stage and grade shift of diagnosed prostate cancer has led to a diminished prognostic 
power of the Gleason score system. We investigated the predictive value of the amount of 
high-grade cancer (Gleason growth patterns 4/5) in the biopsy for prostate-specific antigen 
(PSA) and clinical relapse after radical prostatectomy.
Patients & Methods
PSA-tested participants (N = 281) of the European Randomized Study of Screening for Pros-
tate Cancer (ERSPC) who underwent radical prostatectomy were analyzed. Besides clinical 
features, and serum-PSA, histopathologic features as determined in the diagnostic biopsy and 
matching radical prostatectomy specimen were related to patient outcome.
Results
At a median follow-up of 7 yr, 39 (13.9%), 24 (8.5%), and 12 (4.3%) patients had PSA ≥0.1 ng/
mL, PSA ≥1.0 ng/mL, and clinical relapse after radical prostatectomy, respectively. Using Cox 
proportional hazards, PSA level (p = 0.002), length of tumor (p = 0.040), and length of high-
grade cancer (p = 0.006) in the biopsy, but not Gleason score, were independent prognostic 
factors for biochemical relapse (PSA ≥0.1 ng/mL) when assessed as continuous variables. In 
radical prostatectomies, the proportion of high-grade cancer (p < 0.001) was most predictive 
of relapse (PSA ≥0.1 ng/mL). For PSA ≥1.0 ng/mL and clinical relapse, the amount of high-
grade cancer, both in the biopsy specimen (p = 0.016 and p = 0.004, respectively) and radical 
prostatectomy specimen (p = 0.002 and p = 0.005, respectively), but not Gleason score, was 
an independent predictor.
Conclusions
In biopsy and radical prostatectomy specimens of surgically treated prostate cancer, the 
amount of high-grade cancer is superior to the Gleason grading system in predicting patient 
outcome. We propose that, in addition to the Gleason score, the amount of Gleason growth 
patterns 4/5 in the biopsy (whether absolute length or proportion) should be mentioned in 
the pathology report.
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INTRODUCTION
The histologic differentiation grade is the strongest prognosticator of prostate cancer. Dif-
ferent histologic grading systems for prostate cancer have been developed historically, and 
the Gleason grading system and for prostate cancer is now being used most widely.84,151 This 
system is preferred over other grading systems such as those of the World Health Organiza-
tion (WHO), and the MD Anderson Cancer Center (Houston, TX) grading system because it 
accounts for the remarkable heterogeneity of prostate cancer by identifying five different 
growth patterns from 1 (most differentiated) to 5 (least differentiated).104,152 By adding the 
most dominant growth pattern (the primary Gleason pattern) to the next most dominant 
growth pattern (the secondary Gleason pattern) a 9-tiered total score of ascending aggres-
siveness from 2 to 10 is obtained.
A weakness in the Gleason grading system is that growth patterns that do not constitute the 
primary or secondary patterns (i.e., the tertiary growth patterns) are not reflected in the total 
score.153 To deal with this issue, the International Society of Urological Pathology (ISUP) group 
recommended that in presence of three different growth patterns on the needle biopsy, both 
the primary pattern and the highest grade should be recorded.154 It is hypothesized by some 
that the biologic behavior of a tumor is directly related to the presence and amount of poorly 
differentiated components within the tumour.155,156 For this reason, it was advised to mention 
the presence of even small foci of high-grade cancer in the pathology report.157,158 Stamey 
and colleagues have even argued that we should move away from the Gleason scoring sys-
tem and simply estimate the percentage of high-grade cancer in the radical prostatectomy 
specimen.155
In counseling patients with prostate cancer about their choice for local treatment alone, for 
combined modality treatment, or for active surveillance, an accurate risk assessment at the 
time of diagnosis is warranted. Therefore, provision of all clinically relevant prognostic infor-
mation is needed to guide clinical decision-making.159 This is one of the few studies that we 
know of that correlates the amount of high-grade cancer in the diagnostic biopsy, and in the 
radical prostatectomy specimen, with biochemical and clinical recurrence rates after radical 
prostatectomy.
PATIENTS & METHODS
Patients
The study group consisted of 281 consecutive men who underwent radical prostatectomy 
at the Erasmus Medical Center Rotterdam between June 1994 and December 1999. Mean 
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age was 64 yr (range: 55–73), and median prostate-specific antigen (PSA) level was 5.2 ng/
mL (range: 0.8–29.5 ng/mL). All men were participants in the screening arm of the European 
Randomized Study of Screening for Prostate Cancer (ERSPC).101 A biopsy was prompted when 
the PSA level was ≥3.0 ng/mL or when digital rectal examination (DRE) was suspicious for 
cancer at low PSA values (0.0–2.9 ng/mL). The biopsy procedure consisted of a systematic 
lateralized sextant biopsy.160 The decision to perform radical prostatectomy was made by the 
patient and his urologist with consideration of the patient’s age, comorbidities, biopsy tumor 
features, and personal preferences. All patients underwent pelvic lymph node dissection prior 
to radical prostatectomy, and none received hormonal treatment or transurethral resection 
for benign disease prior to operation.
Follow-up
Patients were followed with serial PSA measurements at 3-mo intervals for the first year after 
radical prostatectomy, semiannually for the second year, and yearly thereafter. Two definitions 
for PSA relapse were used. The first definition was two sequential detectable PSA levels ≥0.1 
ng/mL, and the second definition demanded that serum PSA had to reach a level of 1.0 ng/
mL at least. This latter definition was chosen to identify those who are believed to be at risk 
of clinical disease progression. Time to biochemical progression was defined as the time from 
radical prostatectomy to the time of PSA relapse, or until last follow-up, if the patient did not 
have a relapse. For those with PSA relapse after radical prostatectomy, DRE was performed to 
assess whether there was local disease progression. Local relapse was defined as recurrence of 
disease as proven by a positive result for cancer histology near the vesicourethral anastomosis. 
Metastatic disease was indicated by hotspots on bone scintigraphy or lesions suspicious for 
cancer on abdominal computed tomography. Time to clinical progression was defined as the 
time from radical prostatectomy to the time of first recording of clinical recurrence or to date 
of last follow-up if the subject did not have a relapse. No patient received adjuvant hormonal 
or radiation therapy, until disease progression occurred.
Pathologic evaluation
All sextant diagnostic biopsy cores were labeled and processed separately. The biopsy cores 
were inked at their capsular ends, fixed in 10% buffered formalin, embedded in paraffin, 
freshly cut into 4-μm tissue sections, and mounted on glass slides. Haematoxylin and eosin 
slides of three subsequent levels of the biopsy cores were histologically examined, the length 
(in millimeters) of each separate core was measured, and a total Gleason score of the biopsy 
sextant was assigned by a specialized genitourinary pathologist (TvdK). The number of cores 
positive for cancer was assessed. Each biopsy core was schematically divided into 10 parts, 
and presence of low-grade (Gleason growth patterns 1–3) and high-grade (Gleason growth 
pattern 4/5) cancer was determined. Using the length of the biopsy cores, the length of tumor 
(in millimeters) could be assessed for each biopsy core and for the biopsy sextant, as was the 
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length (in millimeters) of high-grade cancer. Subsequently, biopsy tumor involvement (the 
percentage of the biopsy specimen involved with cancer) was determined, as was high-grade 
tumor involvement (the percentage of the cancer that had high-grade components).
Radical prostatectomy specimens were fixed, embedded, and processed according to well-
established protocols.161,162 A global prostatectomy Gleason score was determined, and the 
tumor was staged according to the TNM 1997. The proportion of the tumor consisting of high-
grade cancer was evaluated on an incremental scale from 0% to 100%. All tumor areas were 
traced and outlined on the slides, and subsequent morphometric analysis was performed 
to determine tumor volume.163 Presence of tumor cells at the inked margin of resection was 
considered a positive surgical margin.
Statistical analysis
Statistical analysis was performed using the statistical package for the social sciences (SPSS 
12.0; SPSS, Chicago, IL). Spearman rank correlations were used to determine the correlation 
between clinical and histopathologic variables as assessed in the biopsy specimen and those 
in the radical prostatectomy specimen. Cox proportional regression analysis was used to as-
sess the relationship between preoperative or postoperative variables and PSA relapse (≥0.1 
ng/mL, ≥1.0 ng/mL) or clinical relapse after radical prostatectomy. Preoperative variables were 
used as continuous variables in the models except for biopsy Gleason score and clinical tumor 
stage (table 9.2 and table 9.3). Subsequently, analyses were also performed when Gleason 
score 7 cancers were divided into 3+4 and 4+3 subcategories. Postoperative variables such 
as percentage of high-grade cancer and tumor volume were used as continuous variables; 
others were used as categorical variable (Gleason score) or dichotomized (extraprostatic ex-
tension, invasion into adjacent organs, surgical margins). For all Cox regression multivariable 
analyses the assumptions were tested and met. Kaplan-Meier curves were constructed to 
show the probability of remaining free of PSA relapse and clinical progression as a function of 
time after radical prostatectomy. The assumption that no predictive value existed for the vari-
able evaluated was rejected if p < 0.05. To identify independent prognostic factors, backward 
stepwise Cox regression analysis was performed by removing variables from the model that 
were not statistically significant at the univariate level, while controlling for other variables. 
Forward stepwise elimination was performed to verify that the same parameters remained of 
prognostic significance in the final models.
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RESULTS
Patients
Median follow-up for the cohort of 281 patients was 81 mo (range: 5–120 mo); follow-up 
started on the day of radical prostatectomy and concluded on 1 July 2005, or the date of 
Table 9.1 The distribution of clinical and histopathological features as determined in the biopsy specimen of 281 participants who underwent 
radical prostatectomy. Spearman Rank Correlations for pairs of variables.
Preoperative
variables
N (% of total) †
Median 
(range) ‡
Postoperative variables
pT RP 
Gleason 
score
Gleason 
grade 
4/5, %
Surgical 
Margins, 
Yes/No
Tumor 
volume, 
mL
Age, years
64 (55 – 73) .114 .306 * .177 .095 .125
Clinical tumor stage
T1c 112 (39.9) .194 .147 .174 .123 .192
T2a-c 165 (58.7)
T3a 4 (1.4)
Serum PSA (ng/mL)
5.2 (0.8 – 29.5) .253 * .112 .196 .141 .458 *
Number of positive for tumor biopsy cores
1 101 (35.9) .283 * .182 .282 * .249 * .537 *
2 82 (29.2)
3 49 (17.4)
4-6 49 (17.4)
Biopsy Gleason score
2-6 203 (72.2) .284 * .443 * .462 * .095 .296 *
7 66 (23.5)
8-10 12 (4.3)
Length of tumor (mm)
7.2 (0.4 – 51.0) .320 * .273 * .365 * .298 * .613 *
Length of high-grade cancer (mm)
0.0 (0.0 – 42.0) .306 * .450 * .534 * .09 .336 *
Proportion of high-grade cancer (%)
0.0 (0.0 – 100.0) .290 * .451 * .528 * .076 .300 *
Total 281
PSA Prostate-specific antigen
RP Radical Prostatectomy
pT Pathological Tumor Stage
* Correlation is statistically significant at the P <.001 level (2-tailed)
† N (%) for categorical variables
‡ Median (range) for continuous variables
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death. PSA relapse (≥0.1 ng/mL) occurred in 39 (13.9%) patients after a median follow-up of 
21.0 mo (range: 1–97 mo). PSA relapse with subsequent rise of the PSA value above the 1.0 ng/
mL threshold occurred in 24 (8.5%) cases, and 12 (50.0%) progressed clinically. Local disease 
progression and distant metastatic disease were found in 7 (2.5%) and 8 (2.8%) patients. All 
patients with clinical progression had PSA levels ≥1.0 ng/mL after treatment.
Preoperative features
In table 9.1 the distribution of preoperative variables is listed along with correlation with 
postoperative pathologic variables. For those with no high-grade cancer in the biopsy, 80.5% 
had ≤5% high-grade cancer in the prostate. For those with larger amounts (≥3 mm) of poorly 
differentiated components in the biopsy, 88.4% had substantial amounts (≥5%) of high-grade 
cancer in the prostate.
Cox proportional hazards models for PSA relapse and clinical recurrence of disease are shown 
in table 9.2 and table 9.3, respectively. Preoperative PSA level (p = 0.002), length of tumor 
(p = 0.040), and length of high-grade cancer (p = 0.006) in the biopsy were independent 
Table 9.2 Cox Proportional Hazards Model for PSA-relapse after radical prostatectomy using clinical and histopathological variables as assessed 
in the biopsy specimen.
Preoperative
Variables
PSA-Progression (≥0.1 ng/mL) after radical prostatectomy
Univariate analysis Multivariate analysis
HR P-Value HR P-Value
Number of positive for tumor 
biopsy cores 1.439 .001 ns
Biopsy Gleason score
2-6 Baseline †
7 2.943 .001 ns
8-10 2.886 .045 ns
Length of tumor (mm) 1.055 <.001 1.012 .04
Length of high-grade
cancer (mm)
1.079 <.001 1.033 .006
Clinical tumor stage
T1c Baseline ‡
T2a-c 1.813 .095 ns
T3a 1.883 .532 ns
PSA-level (ng/mL) 1.117 <.001 1.120 .002
PSA Prostate-specific antigen
HR Hazard ratio
† For biopsy Gleason score 7 and 8-10 combined, compared to baseline: HR= 3.617 (P< .001)
‡ For clinical tumor stage T2a-c and T3a combined, compared to baseline: HR= 1.950 (P = .069)
ns Not statistically significant
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Table 9.3 Cox Proportional Hazards Model for clinical progression of disease after radical prostatectomy using clinical and histopathological 
variables as assessed in the biopsy specimen.
Preoperative
Variables
Clinical Progression after radical prostatectomy
Univariate analysis Multivariate analysis
HR P-Value HR P-Value
Number of positive for tumor 
biopsy cores 1.513 .025 ns
Biopsy Gleason score
2-6 Baseline †
7 2.809 .076 ns
8-10 1.984 .512 ns
Length of tumor (mm) 1.037 .098 ns
Length of high-grade
cancer (mm)
1.074 .004 1.074 .004
Clinical tumor stage
T1c Baseline ‡
T2a-c 3.315 .122 ns
T3a 1.000 1.00 ns
PSA-level (ng/mL) 1.144 .021 ns
PSA Prostate-specific antigen
HR Hazard ratio
† For biopsy Gleason score 7 and 8-10 combined, compared to baseline: HR= 3.177 (P= .050)
‡ For clinical tumor stage T2a-c and T3a combined, compared to baseline: HR= 3.043 (P = .151)
ns Not statistically significant
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prognostic factors for PSA relapse ≥0.1 ng/mL. Length of high-grade cancer was the single 
independent prognostic factor for PSA relapse ≥1.0 ng/mL (p = 0.016) and clinical recurrence 
of disease (p = 0.004). Biopsy Gleason score was rejected in the final equations in the presence 
of high-grade components.
figure 1 shows PSA failure rates for 0, >0–3, ≥3–10 and ≥10 mm high-grade cancer in the bi-
opsy. An increase of cumulative failure probability is shown with a rise of Gleason grades 4/5. 
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Fig 9.2b 
Figure 9.2 Kaplan-Meier curve of the probability of a.) biochemical (PSA ≥0.1 ng/mL) and b.) clinical disease recurrence (local relapse at the 
vesico-urethral anastomosis site, distant metastasis) after radical prostatectomy as a function of absolute length (in mm) of high-grade cancer in 
the diagnostic biopsy specimen
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The probability of biochemical and clinical relapse after radical prostatectomy as a function of 
length (in millimeters) of high-grade cancer is depicted in figure 9.2A and B, respectively.
Subsequently, we performed Cox multiple regression analysis with the same variables, but 
now with biopsy tumor involvement, and proportion (instead of absolute length in millime-
ters) of high-grade cancer. PSA level (p = 0.032), biopsy tumor involvement (p = 0.002), and 
proportion of high-grade cancer (p = 0.001) in the biopsy were independent predictors of PSA 
relapse ≥0.1 ng/mL.
When biopsy Gleason score 7 cancers were subcategorized into 3+4 and 4+3 cancers and ana-
lyzed further for prognostic significance, the amount of high-grade cancer (whether length 
or percentage) was the most important predictor of relapse, whereas the Gleason grading 
system was rejected in presence of high-grade components (figure 9.3).
Table 9.4 The distribution of histopathological features as determined in the radical prostatectomy specimen of 281 participants who 
underwent radical prostatectomy. Association with PSA-relapse and clinical recurrence of disease after radical prostatectomy.
Postoperative
Variables
Progression after radical prostatectomy
PSA (≥0.1 ng/mL)
N (% of total) †
Median (range) ‡
PSA (≥1.0 ng/mL)
N (% of total) †
Median (range) ‡
Clinical Progression
N (% of total) †
Median (range) ‡
Pathological stage*
pT
2
18/211 (8.5) 9/211 (4.3) 3/211 (1.4)
pT
3a
10/49 (20.4) 4/49 (8.2) 1/49 (2.0)
pT
3b-4
11/21 (52.4) 11/21 (52.4) 8/21 (38.1)
RP Gleason score
2-6 9/165 (5.5) 5/165 (3.0) 0/165 (0.0)
7 25/109 (22.9) 15/109 (13.8) 9/109 (8.3)
8-10 5/7 (71.4) 4/7 (57.1) 3/7 (42.9)
High-grade tumor 
involvement (%) 25 (0 – 100) 50 (0 – 100) 62.5 (25 – 100)
Surgical Margin Status
Negative 17/215 (7.9) 10/215 (4.7) 8/215 (3.7)
Positive 22/66 (33.3) 14/66 (21.2) 4/66 (6.1)
Tumor Volume (mL) 1.32 (0.01 – 13.48) 1.42 (0.46 – 13.48) 1.63 (0.46 – 4.60)
Total 39/281 (13.9) 24/281 (8.5) 12/281 (4.3)
PSA Prostate-specific antigen
* TNM 1997
RP Radical prostatectomy
† N (%) for dichotomized or categorical variables
‡ Median (range) for continuous variables
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Postoperative features
table 9.4 and table 9.5 show that only the proportion of high-grade cancer (p < 0.001), pT3b-
pT4 (p = 0.013) and surgical margin status (p = 0.001) remained in the equation models after 
multiple Cox regression analysis. Gleason score was rejected in the presence of high-grade 
components. For PSA ≥1.0 ng/mL as a criterion of PSA relapse, and clinical relapse, pT3b-pT4 
(p < 0.001, both analyses) and percentage of high-grade cancer (p = 0.002 and p = 0.005, 
respectively) were independent prognosticators.
DISCUSSION
Radical prostatectomy has become a common procedure in patients diagnosed with early 
prostate cancer, and the intervention is reported to reduce disease-specific mortality, overall 
mortality, and the risks of metastasis and local progression.113 Whether the surgical procedure 
itself is of benefit for individual patients depends on a constellation of variables such as pa-
tient age, serum PSA level, tumor extent, histologic grade of disease, and the remaining life 
Table 9.5 Cox Regression Analysis for PSA-relapse after radical prostatectomy using histopathological variables as assessed in the radical 
prostatectomy specimen.
Postoperative
variables
PSA-Progression (≥0.1 ng/mL) after radical prostatectomy
Univariate analysis Multivariate analysis
HR P-Value HR P-Value
Extraprostatic 
extension
(pT3a)* 1.529 .249 ns
Invasion of adjacent 
organs (pT3b – pT4)* 6.852 < .001 2.766 .013
RP Gleason score
2-6 Baseline
7 2.942 .001 ns
8-10 9.937 < .001 ns
High-grade tumor 
involvement (%) 1.029 < .001 1.023 <.001
Positive surgical 
margins 4.619 <. 001 3.169 .001
Tumor Volume (mL) 1.401 <. 001 ns
PSA Prostate-specific antigen
RP Radical prostatectomy
HR Hazard ratio
* TNM 1997
ns not statistically significant
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expectancy of the patient diagnosed with cancer. In prostate cancer screening programs, no 
reliable set of prognostic parameters exists today that accurately distinguishes patients with 
nonaggressive disease from those with fatal disease beyond cure. Such tools are required 
because it is considered that a substantial proportion of screen-detected prostate cancers 
have been overdiagnosed, whereas others might not have been detected (and treated) early 
enough.37 In the counseling of patients who are to benefit from radical treatment, or who have 
a substantial risk of (early) disease recurrence after definite treatment, a careful individual risk 
assessment at the time of diagnosis is mandatory.
In the PSA era, established prognostic factors as clinical tumor stage, biopsy Gleason score, 
and PSA level are losing clinical utility because the vast majority of cases with newly detected 
prostate cancer have clinically localized disease and have cancers of intermediate grade, that 
is, biopsy Gleason scores 6 and 7.164 Low-grade tumors (Gleason scores 2–5), and high-grade 
tumors (Gleason scores 8–10) become a relatively rare finding. It was further reported that on 
repeated screening, even the serum PSA test loses its predictive power for both the detection 
of prostate cancer and the identification of adverse prognostic tumor features and patient 
outcome.165,166 Therefore, more sensitive tools for stratification of patients into prognostic 
risk groups are needed. For now, no molecular markers exist that give validated prognos-
tic information superior to conventional histopathologic features, so more scrutiny on the 
prognostic value of well-established histopathologic variables is warranted. Prior studies have 
attempted to establish whether the subclassification of Gleason score 7 cancers (3+4 versus 
4+3) as determined in the radical prostatectomy specimen provides further information 
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Fig 9.3 
Figure 9.3 Kaplan-Meier curve of the probability of biochemical (PSA ≥0.1 ng/mL) relapse after radical prostatectomy as a function of biopsy 
Gleason score (2-6, 3+4, 4+3, 8-10)
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about patient outcome.167-174 Besides the finding that the rates of disease-free survival after 
radical prostatectomy for patients with Gleason scores 7 appear to be intermediate between 
patients with Gleason score ≤6 and ≥8, the distinct and heterogeneous behavior of tumors 
within the Gleason score 7 group itself is striking.167 This can, in part, be explained by the 
observation that a single Gleason score 7 varies in its percentage of Gleason grades 4/5 from 
5% to 95% without altering the total score. Even small amounts of high-grade cancer in the 
radical prostatectomy may, according to some authors, alter the biologic aggressiveness of 
disease as reflected by an increased biochemical recurrence rate after radical prostatectomy 
compared to those without high-grade components.173 Therefore, it seems plausible that a 
categorization of tumors according to their amount of high-grade cancer is prognostically 
more important than a sub-classification of Gleason score 7 cancers into just two categories. 
A few studies confirmed this view by showing independent prognostic value for the propor-
tion of Gleason growth patterns 4/5 in the radical prostatectomy specimen for biochemical 
recurrence.155,156,174
For the pathologist this may sometimes be difficult to perform because pattern 4 seems to 
evolve from pattern 3. On the other hand, Gleason grading is microscopically a low-power 
exercise, and criteria for grade 4/5 are well-established.157 Furthermore, according to most 
authors a very limited amount (<5%) of high-grade cancer in the radical prostatectomy speci-
men does not seem to have a major impact on prognosis (own data).155,156 The same seems to 
hold true for the presence of a minor amount of high-grade cancer in needle biopsies (our 
data, not shown). This should allow a relatively consistent estimation of the percentage of 
high-grade cancer in both needle biopsies and prostatectomy specimens.
Following radical prostatectomy, the proportion of high-grade cancer was an independent 
predictor of outcome for PSA ≥0.1 ng/mL, PSA ≥1.0 ng/mL as a criterion of PSA relapse, and 
clinical progression of disease. Our data indicate that the percentage of high-grade cancer in 
the radical prostatectomy was superior to the original Gleason score in predicting outcome 
of patients who underwent radical prostatectomy. These findings are in line with those of 
others.155,156,174
Our data further indicate that the amount of Gleason growth patterns 4/5 in the diagnostic 
biopsy (whether absolute length or proportion) is an important predictor of adverse prognos-
tic factors in the radical prostatectomy specimen ( table 9.1). In absence of high-grade cancer 
in the biopsy, >80% had minor (≤5%) amounts of high-grade cancer in the prostatectomy 
specimen. In those with larger amounts (≥3 mm) of poorly differentiated components in the 
biopsy, almost 90% had substantial and prognostically important amounts of high-grade can-
cer in the surgically treated prostate. Thus, a good correlation was found between the amount 
of high-grade cancer in the biopsy and that within the corresponding radical prostatectomy 
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specimen. The amount of high-grade cancer in the biopsy proved to be an independent and 
stronger prognostic factor for outcome (PSA ≥0.1 ng/mL, PSA ≥1.0 ng/mL, clinical relapse) 
after radical prostatectomy than Gleason score.
Several caveats may limit the interpretation of our data. First, it should be acknowledged that 
PSA relapse after radical local treatment is a questionable surrogate and a not proven end 
point for clinical relapse and disease-specific mortality. Only a fraction of asymptomatic men 
with PSA relapse will experience local or distant disease progression or death from prostate 
cancer. Pound et al., who reported on a relatively adverse prognostic cohort as reflected by 
a 45.6% organ-confinement rate after radical prostatectomy, showed that the 3-, 5-, and 7-yr 
metastasis-free rates after radical prostatectomy with subsequent PSA relapse were 78%, 
63%, and 52%, respectively, without additional therapeutic intervention.88 Caution should be 
kept in generalizing our results because the number of men reaching a clinically relevant end 
point is limited.
Second, the follow-up period may still be too short for those with PSA relapse to progress 
clinically. Johansson et al. reported that in a cohort of initially untreated men with localized 
prostate cancer, tumor progression developed even after 15 yr of follow-up.109 Pound et al. 
reported that the median time to metastatic progression in those with a rising PSA level after 
radical prostatectomy was 8 yr, longer than our median follow-up of 7 yr.88 The number of cas-
es progressing clinically might thus further increase with continued follow-up. On the other 
hand, it is likely that the majority of cases with PSA relapse have already been identified in our 
study, because it is recognized that >80%–90% of patients undergoing radical prostatectomy 
will have a relapse within 5 yr after surgery.88,175
Third, patient selection and participation bias may be introduced in our study due to the 
observation that all men included were candidates for radical prostatectomy. These men 
are younger, healthier, and have longer life expectancy compared to those who underwent 
external-beam radiotherapy. The figures reported herein do only apply for those who eventu-
ally consider radical prostatectomy, the preferred treatment modality for prostate cancer.
And fourth, arbitrary cut-off levels for the amount of high-grade cancer in the biopsy were 
used in our analyses. There are no generally accepted breakpoints for grouping subjects ac-
cording to the amount of high-grade cancer in the biopsy, as there are for Gleason score and 
PSA level. Also, there are no recommendations to use either the absolute or relative amount 
of high-grade cancer in the biopsies. An attempt was made to obtain clinically practical 
definitions.
Should we replace the Gleason score with the amount of high-grade prostate cancer?
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CONCLUSIONS
In the present study, the amount of high-grade cancer in the diagnostic biopsy proved to be 
an independent and stronger prognostic factor for relapse (PSA ≥0.1 ng/mL, PSA ≥1.0 ng/mL, 
clinical relapse) after radical prostatectomy than Gleason score. Therefore, we propose that, 
in addition to the Gleason score, the amount of Gleason growth patterns 4/5 in the biopsy 
(whether absolute length or proportion) should be mentioned in the pathology report.
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ABSTRACT
Background
Screening for prostate cancer has resulted in an increased incidence-to-mortality ratio. Not 
all cancers deserve immediate treatment. It has therefore become more important to be 
able to identify those cases of screen-detected prostate cancer most likely to show indolent 
behavior.
Patients & Methods
The Kattan-nomogram for the prediction of indolent prostate cancer has been validated and 
re-calibrated for use in a screening setting. The recalibrated nomogram was used to calculate 
the number of men who were predicted to have indolent cancer in a screen-detected co-
hort from the European Randomized study of Screening for Prostate Cancer (ERSPC), section 
Rotterdam.
Results
Of 1,629 cancers detected in two subsequent screening rounds 825 were suitable for nomo-
gram use. The remainder was very unlikely to have indolent cancer. A total of 485 men (485 
/ 825=59%) were predicted to have indolent cancer, which is 30% (485 / 1,629) of all screen-
detected cases. Cancers found at repeated screening after four years had a higher probability 
of indolent cancer than cases from the prevalence screening (44% vs. 23%; P<.001).
Conclusion
The current nomogram can identify substantial groups of screen-detected cancers which are 
likely indolent and can therefore be considered for active surveillance.
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INTRODUCTION
Screening diagnoses prostate cancers earlier in their natural course. Moreover, screening leads 
to the detection of prostate cancers that would not have surfaced clinically in the absence 
of screening (i.e. overdiagnosis).37 This has resulted in an increased incidence.33 However, a 
considerable proportion of the detected cancers will not lead to death. In order to counsel 
between immediate treatment and active surveillance with the possibility for deferred cura-
tive treatment, it is important to risk-stratify patients at the time of diagnosis. Recently, dif-
ferent nomograms for the risk assessment of prostate cancer have been described.12,176-178 The 
nomogram of Kattan et al. predicts the probability of indolent prostate cancer in a clinical 
setting.12 It has been validated and re-calibrated for use in a screening setting by Steyerberg 
et al in a subgroup of men diagnosed with prostate cancer in the ERSPC.108 We applied the 
latter nomogram to men diagnosed in the screening program of the European Randomized 
study of Screening for Prostate Cancer (ERSPC) section Rotterdam in order to estimate the 
proportion of indolent cancers.101
PATIENTS & METHODS
The Rotterdam section of the ERSPC has randomized 42,376 men and a PSA-based screening 
program with a four-year interval was offered to men allocated to the screening arm (figure 
10.1).101 Lateralized sextant systematic biopsies were obtained. The nomogram was applied 
to men identified with screen-detected prostate cancer comprising the following features: 
1) clinical stage T1c or T2 disease, 2) PSA 20 ng/mL or less, 3) primary and secondary Gleason 
grade 3 or less, 4) positive cores 50% or less, 5) total cancer in biopsy cores 20 mm or less 
and 6) benign tissue in all cores 40 mm or more. The range of predictor variables of detected 
cancers appear in table 10.1. Men who do not match the stated criteria are very likely to have 
more advanced cancers, which are therefore very unlikely to be indolent. Indolent cancer 
was defined by a total tumor volume less than 0.5 cc, confined to the prostate (no focal or 
established extra-capsular extension) and with no Gleason pattern 4 or 5.179,180 The number of 
men with indolent disease was estimated by the sum of the probabilities for indolent cancer 
(i.e. cumulative probability). The exact formula to calculate the probability of indolent cancer 
is given under table 10.2
RESULTS
Of 1,629 cancers detected in two subsequent screening rounds 825 (51%) were suitable for 
nomogram use according to the given criteria. A total of 485 of the 825 men suitable for 
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application of the nomogram (485 / 825 = 59%) were predicted to have indolent disease. 
If one assumes that none of the cases excluded for nomogram use were indolent (N=804), 
an estimated 30% (485 / 1,629) of all screen-detected men were predicted to have indolent 
disease. In the prevalence screen 455 men (42%; 455 / 1,078) were eligible for nomogram use 
and an estimated 243 (53%; 243 / 455) were predicted indolent, which is 23% of 1,078 cancers 
detected in the first screening round. In the repeat-screen after four years, 550 cancers were 
detected, 370 (67%; 370 / 550) were eligible for nomogram use and 242 (65%; 242/370) were 
classified as predicted indolent; 44% of all 550 cancers detected by repeated screening.
Many men eligible for nomogram use underwent radical prostatectomy (N=336; 41%), 
including the 278 used for the re-calibration of the Kattan nomogram. The remainder elected 
radiation therapy (N=274; 33%), watchful waiting (207; 25%) or hormonal treatment (N=4; 
1%); the initial treatment modality was unknown in 4 men (1%).
Although the number of indolent cancers can be estimated by taking the sum of the 
probabilities for indolent cancer (i.e. the cumulative probability), it is at present impossible to 
individually identify these patients. Therefore, a cut-off point for the probability of indolent 
Table 10.1 Predictive variables of all men detected with prostate cancer in the prevalence screening (i.e. round 1) and the repeat screening after 
four years (i.e. round 2) in ERSPC Rotterdam
Screen round 1 Screen round 2 Total P-value
Prostate cancer Number 1,079 550 1,629
PSA (ng/mL)
Median (25-75p) 5.7 (3.9-9.3) 3.9 (3.1-5.4) 4.8 (3.5-7.7) <.001*
<= 20 ng/mL (%) 992 (92) 541 (98) 1533 (94) <.001**
Prostate vol. (cc) Median (25-75p) 37.2 (29.3-49.1) 38.2 (30.1-49.6) 37.6 (29.5-49.3) .34*
Clinical stage
T1c (%) 398 (37) 344 (63) 742 (46)
<.001**
T2 (%) 534 (50) 198 (36) 732 (45)
Biopsy Gleason 
grade
Primary <=3 (%) 988 (92) 521 (95) 1,509 (93) .02**
Secondary <=3 (%) 711 (66) 449 (82) 1,160 (71) <.001**
% Pos cores
Median (25-75p) 40.0 (22.5-57.1) 33.3 (16.7-50.0) 33.3 (16.7-50.0) <.001*
<= 50% (%) 752 (70) 476 (87) 1228 (75) <.001**
Mm PC
Median (25-75p) 7.6 (3.3-18.4) 3.4 (1.4-7.9) 5.8 (2.5-14.4) <.001*
<= 20 mm (%) 835 (77) 511 (93) 1346 (83) <.001**
Mm non PC
Median (25-75p) 55.8 (44.8-66.0) 68.4 (61.2-75.2) 60.8 (49.2-70.3) <.001*
>= 40 mm (%) 900 (83) 531 (97) 1431 (88) <.001**
*  Mann-Whitney U test
**  Chi square test
PC  Prostate cancer
25-75p  25th and 75th percentile
PSA  Prostate-specific antigen
Prostate vol. (cc) The prostate volume was determined using 5mm-step-section planimetry
% Pos cores Proportion of biopsy cores involved with prostate cancer
mm PC  Total millimetres of cancer tissue in all biopsy cores
mm non PC Total millimetres of benign tissue in all biopsy cores
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cancer is required for clinical decision making on further therapy. This cut-off value depends 
on the level of acceptable primary undertreatment of potentially aggressive cases resulting 
from delay of active treatment in those men who are misclassified. Table 10.2 shows numbers 
of men with increasing cut-off points for the probability of indolent prostate cancer (>30% 
to >90%). We note that 27% (N=432) of all cancers and 45% (N=247) of cancers diagnosed in 
round two would be classified as indolent with a cut-off of 60%. Using that cut-off, 31% of the 
current cohort chose for watchful waiting and 33% for radical prostatectomy.
DISCUSSION
Overdiagnosis (and overtreatment) are defined as the diagnosis (and treatment) of cancers 
which would never surface during the lifetime of their carrier (and would therefore be treated 
unnecessarily). Obviously, both parameters are co-determined by disease related factors and 
by the natural life expectancy of a given patient. A tumor classified as non-indolent whose 
carrier dies of intercurrent disease was also overdiagnosed.37 Men with indolent disease 
are often subjected to overtreatment due to the difficulty and uncertainty of being able to 
predict the presence of indolent prostate cancer. These men are unnecessarily subjected to 
the burden of treatment and to potential complications with no impact on the survival of 
the disease. With more solid information active surveillance strategies can be advised more 
strongly, making use of reasonable cut-offs for the probability of indolent prostate cancer. 
Table 10.2 Cumulative probabilities of predicted indolent prostate cancer of men detected with prostate cancer in the prevalence screen (i.e. 
round 1) and the repeat screen after four years (i.e. round 2)
Screen round 1
Number (%)
Screen round 2
Number (%)
Total
Number (%)
Prostate cancer 1,079 550 1,629
Indolent** 243 (23) * 242 (44) * 485 (30)
Probability
for
indolent
prostate cancer
> 30% 380 (35) * 350 (64) * 730 (45)
> 40% 316 (29) * 320 (58) * 636 (39)
> 50% 256 (24) * 294 (54) * 550 (34)
> 60% 185 (17) * 247 (45) * 432 (27)
> 70% 124 (12) * 181 (33) * 305 (19)
> 80% 65 (6) * 92 (17) * 157 (10)
> 90% 16 (2) 12 (2) 28 (2)
Numbers are the sum of the predicted probabilities of indolent cancer as calculated with the recalibrated Kattan nomogram.
The exact formula to calculate the probability of indolent cancer is:
P(indolent) = 1 / (1+exp(-[-4.196 + 0.25 * score])], where score = -5*(ln(PSA)-3) [in ng/ml] + 0.1*(US volume-20) [in cc] + 4*Gleason22 [0 if 
false, 1 if true] + 1*Gleason23 [0 if false, 1 if true] -3*(ln(mm cancerous tissue)-3) + 0.1*(mm non-cancerous tissue-40)
* Mann-Whitney Test: P-value <.001 for difference in P(ind) between round 1 and 2.
** Calculated in 455 (round 1), 370 (round 2) and 825 (total) men suitable for nomogram use.
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Evidence accumulates that wrongly selected men and men with dedifferentiating tumors will 
surface through active surveillance using PSA kinetics and repeated biopsies.181-185
We assumed that no indolent prostate cancers were present in men not suitable for nomo-
gram use. Although this has led to an underestimation, it is highly unlikely that men who do 
not match the eligibility criteria have indolent cancer (i.e. those with clinical stage T3 or higher 
disease, PSA over 20 ng/mL, primary and secondary Gleason grade 4 or higher, positive cores 
over 50%, total cancer in biopsy cores over 20 mm, or benign tissue in all cores less than 40 
mm). Nevertheless, if the underestimated 30% of predicted indolent cancers in the first two 
screen rounds of the ERSPC would be extrapolated to a heavily screened population such as 
the U.S., where 234,460 men are annually diagnosed with prostate cancer 69,869 would have 
predicted indolent disease.33 Those men could avoid immediate treatment and may avoid 
treatment at all.
Although the absence of poor prognostic factors suggests that these tumors are unlikely 
to influence longevity,110 the application of active surveillance for predicted indolent cases 
has not conclusively been shown to be safe in avoiding disease progression and prostate 
cancer death while on observation.186 It is therefore not definitively known whether these 
really are the cancers which can be left untreated and observed. Moreover, tumors which 
have a high probability to be indolent could appear to be important prostate cancers due to 
biopsy undersampling and dedifferentiation.187 However, given the minimal improvement in 
cancer-specific survival when comparing surgical treatment to no treatment among men with 
cancers not detected by screening,113 it seems unlikely that active surveillance of low-risk, 
screen-detected cancers will place patients at an undue risk of an adverse outcome.
Clinical validation of the endpoint ‘indolent prostate cancer probability’ with use of out-
come data of untreated men is mandatory. Furthermore, the present nomogram requires 
further validation and updating for use in men excluded in the previous analyses and for men 
diagnosed by more extensive biopsy sampling.12
With the screening regimen used in this study (ERSPC Rotterdam) the proportion of over-
diagnosed cases is estimated to be 54% of all diagnosed cancers.37 It is unknown which pro-
portion is classified as overdiagnosed because of intercurrent mortality. On this background, 
the suggested capability of diagnosing indolent disease in 30% of all screen-detected cases 
seems to be an important step.
CONCLUSION
The current nomogram for screen-detected prostate cancer can assist in identifying sub-
stantial groups of prostate cancers which are likely indolent and can be considered for active 
surveillance.
PART IV
ACTIVE SURVEILLANCE AS A WAY OUT OF 
THE OVERDIAGNOSIS DILEMMA
Chapter 11
Management and survival of screen-detected prostate cancer patients who might 
have been suitable for active surveillance
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ABSTRACT
Background
Screening practices for prostate cancer have resulted in an increasing incidence of prostate 
cancers. Our knowledge about which prostate cancers are life threatening and which are not 
is limited. It is for ethical, medical and economical reasons important to define which patients 
can be managed by active surveillance.
Patients & Methods
From 1993 through 1999, men from the Rotterdam section of the European Randomized 
study of Screening for Prostate Cancer (ERSPC) were screened by two strict protocols, which 
were based on PSA, digital rectal examination and transrectal ultrasound. For this study, men 
with criteria that reflect current active surveillance studies were selected: men with a biopsy 
Gleason score <=3+3 in 2 cores or less, with a PSA density lower than 0.2 and a maximum 
PSA-level of 15 ng/mL. Clinical stage had to be T1C or T2.
Results
Of the 1,014 prostate cancers detected in the prevalence screen, 293 men (28.9%) matched 
the criteria for active surveillance. Their mean age was 65.7 years and the mean PSA-level 
was 4.8 ng/mL. Radical prostatectomy was elected by 136 men (46.4%), radiotherapy by 91 
(31.1%) and watchful waiting by 64 (21.8%). The mean follow-up was 80.8 months. The 8-year 
prostate cancer-specific survival was 99.2%, while the overall survival was 85.4%. Nineteen 
men on watchful waiting changed to definitive treatment during follow-up.
Conclusion
Only three men died of prostate cancer, none on watchful waiting. Our observations provide 
preliminary validation of the arbitrary selection criteria for active surveillance.
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INTRODUCTION
Screening has caused a marked increase in prostate cancer incidence, while it is unclear 
whether the stage and grade shift which has been caused by prostate-specific antigen (PSA)-
based screening reduces the prostate cancer mortality.188 For the US, it is estimated that more 
than 230,000 men will be diagnosed with, and 30,000 will die of prostate cancer in 2005. If 
the current trend towards using lower PSA-thresholds to determine the need for biopsy and 
towards taking more cores per biopsy continues, the prostate cancer incidence will continue 
to rise.27 Most of the cancers diagnosed at low PSA-values have good risk, low-grade tumors, 
which would not have been diagnosed in the absence of screening (i.e. overdiagnosis).189 
Although men with these cancers are likely to die as a result of other causes, the majority of 
them are currently treated.
The side-effects of prostate cancer treatment are substantial.145,190 Therefore, the present 
challenge should be to identify those cancers which need treatment and which do not. Ac-
tive surveillance entails a strategy by which selected men are managed expectantly with the 
intention to apply potentially curative treatment if signs of progression occur. By means of 
the PSA-kinetics, digital rectal examinations (DRE) and repeat biopsies, this goal should be 
achievable. Expectancy is maintained until the patient dies of other causes, until he receives 
definitive treatment or until he requests treatment. Active surveillance is still subject to stud-
ies. The inclusion criteria of such studies are, besides patient wish, based on the PSA-level, in 
combination with prostatic size, the DRE and the pathological features of the biopsy.191 This 
report describes the outcome and management of all men diagnosed with prostate cancer 
within the prevalence screen of the European Randomized study of Screening for Prostate 
Cancer (ERSPC), section Rotterdam who matched criteria typically designed for an active 
surveillance program.
PATIENTS & METHODS
The ERSPC was designed to study the feasibility of population based screening for prostate 
cancer. Therefore, 183,000 men were randomized in eight European countries starting in 
1993.78 In the Netherlands alone, 42,376 men were randomized to the screen (n=21,210) or 
the control arm (n=21,166) from June 1993 through December 1999. From start until May 
1997 men were offered a lateral sextant biopsy if either the PSA level was ≥4.0 ng/mL, the DRE 
and/or the TRUS was suspect for carcinoma. From 1997, only a PSA≥3.0 ng/mL prompted a 
lateral sextant biopsy. PSA levels were determined in all patients at diagnosis with the Beck-
man-Coulter Hybritech Tandem E Assay (Hybritech Incorporated, San Diego, CA), which was 
replaced after January 2000 by the automated version (Beckman-Access; Beckman-Coulter 
Inc., Fullerton CA).
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Definition
Watchful waiting entails a strategy for all men who are managed expectantly, whereas ac-
tive surveillance focuses on those men in whom therapy is delayed until the tumor becomes 
progressive and curative treatment can be offered. Men on watchful waiting who are not on 
active surveillance are mainly those who are too sick or too old for treatment. They receive 
endocrine treatment if indicated as in the SPG4 trial.113
Study population
The criteria we considered acceptable for enrolment in an active surveillance protocol were: 
(1) a biopsy Gleason score <=3+3, (2) a maximum of two cores invaded with prostate cancer, 
(3) clinical stage T1C or T2, (4) a PSA-density (PSA D) smaller than 0.2 ng/mL/cc and (5) a PSA-
level below 15 ng/mL. The criteria we considered appropriate for active surveillance strategies 
were defined according to the literature; furthermore are they based on analysis of the data 
ERSPC has generated so far.110,191,192 Those men who were diagnosed in the prevalence screen 
of the ERSPC and who fulfilled the criteria were selected as our study population.
Endpoints
The primary endpoint of this study was prostate cancer-specific mortality. Within ERSPC, an 
independent committee performs the review of all deceased prostate cancer patients with 
three reviewers (a surgeon, a urologist and a medical epidemiologist) who separately judge 
the anonymized patient charts.148 The review of men diagnosed in the first round of screen-
ing was complete until January 1st 2005. The secondary endpoints of this study were overall 
mortality, metastatic disease and biochemical progression. Biochemical progression in radical 
prostatectomy patients was considered to be present when PSA was >0.1 ng/mL and rising. 
For men treated with radiotherapy the ASTRO definition was used.80 The date of progression 
was set at the median of the date of the first PSA rise and the previous PSA record date. For 
active surveillance PSA progression does not serve as an endpoint but as a trigger point to 
treatment. Therefore no biochemical progression rates were calculated. The only man who 
received hormonal treatment had a stable PSA and thus showed no progression with any of 
the definitions of biochemical progression for hormonal treatment.
Follow-up
Patients were seen at 3-month intervals within 1 year after therapy initiation; thereafter, twice 
yearly controls were performed at our institution and surrounding hospitals. At each visit, a 
serum PSA level was obtained, and a DRE was performed. PSA values that were obtained by 
other assays (in surrounding regional hospitals) were corrected for known differences with the 
Hybritech assay using the regression method of Passing and Bablok, as described by Yurdakul 
et al.193 The median follow-up was 79.4 months (mean 80.8; range 6.8-129.8) and was equal in 
the treatment arms.
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Pathologic processing
Systematic, lateralized sextant biopsies were obtained during longitudinal and cross-sectional 
ultrasonographic scanning of the prostate.83 A seventh, lesion directed biopsy was taken in 
case of a hypo-echogenic lesion. Prostate biopsy cores were labeled and processed individu-
ally. One pathologist (TvdK) reviewed all biopsies and classified carcinoma, prostatic intraepi-
thelial neoplasia, and lesions that were suspicious for malignancy.
Slides from radical prostatectomy specimens were retrieved from the archives of the pa-
thology laboratories of our institution and surrounding hospitals of the Rotterdam region. 
There was a single protocol for total embedding of the prostate in use in all pathology 
laboratories, allowing accurate measurements of tumor volume, grading, and staging.194 In 
short, after fixation, radical prostatectomy specimens were inked and serially sectioned at 
4-mm intervals, and they were embedded totally in paraffin blocks. After a pathology review, 
pathologic disease stage, and Gleason score were determined.84 Tumor volume was measured 
by morphometry, as described previously.195 For tumor staging of radical prostatectomy speci-
mens, the 1992 TNM classification system for prostate carcinoma was used.196
Statistics
For statistical analysis the commercially available software SPSS was used (version 12.0.1; 
SPSS, Inc., Chicago, IL). P-values < 0.05 were considered significant. The survival analyses for 
biochemical progression, metastatic disease, disease specific and overall survival were calcu-
lated by the Kaplan-Meier method.
RESULTS
From 1993 through 1999 21,210 men were randomized to the screen arm of the Rotterdam 
section of the ERSPC. During the first round of screening 19,970 men were actually screened 
and 1,014 were diagnosed with prostate cancer. Our study group consisted of the 293 men 
(28.9%) who met the criteria we defined as currently representative for active surveillance. 
At baseline, the study population had a mean age of 65.7 years (range 55.0-75.3) and a mean 
PSA-level of 4.8 ng/mL (0.3-15.0). In 186 patients (63.5%) the DRE was not suspicious for car-
cinoma (stage T1C).
Radical prostatectomy was elected by 136 men (46.4%), radiotherapy by 91 men (31.3%) 
and 64 men (21.9%) were managed by watchful waiting. One man received hormonal treat-
ment and in another patient no treatment was initiated, because he deceased very shortly 
after the prostate cancer diagnosis. The baseline characteristics are shown in table 11.1.
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Radical prostatectomy
Table 11.2 shows that the median volume of tumors found in 117 radical prostatectomy speci-
mens was 0.24 mL. (mean 0.49; range 0.001-4.71); in 34 prostates (29.1%) the tumor volume 
was more than 0.50 mL. In five prostates (3.9%) capsular perforation was present, vascular 
infiltration was present in 2 and seminal vesicle infiltration in 1 prostate. Undersampling in 
Gleason score (i.e. undergrading) was present in 23 men (17.6%), of whom two (1.5%) had a 
Gleason score of the radical prostatectomy specimen higher than 7 (5+4=9 and 5+3=8).
Radiotherapy
Radiotherapy was elected by 91 men: external beam radiotherapy by 88 and brachytherapy 
by 3. The radiotherapy dosage varied from 64 Gray (one man), 66 Gray (41 men), 68 Gray (38 
men) to 78 Gray (5 men). In three men, the dosage could not be retrieved. Brachytherapy 
was applied as monotherapy in one out of the three men, the other two received additional 
external beam radiotherapy, with dosages 45 and 68 Gray.
Table 11.1 Characteristics at baseline for all 293 patients with tumors which met the criteria for active surveillance
RP RT WW Total P-value
Number 136 (46.4%) 91 (31.1%) 64 (21.8%) 293 (RP vs. WW)
Age Mean ± sd 62.9 ± 4.1 67.9 ± 4.7 68.4 ± 4.5 65.7 ± 5.1
<0.001*
(<0.001***)
PSA (ng/
mL)
Mean ± sd 4.9 ± 2.5 5.2 ± 2.3 4.1 ± 1.5 4.8 ± 2.2
0.01* (0.05***)
0-5 80 (58.8%) 49 (53.8%) 47 (73.4%) 178 (60.8%)
5-10 53 (39.0%) 38 (41.8%) 17 (26.6%) 108 (36.9%)
10-15 3 (2.2%) 4 (4.4%) 0 (0.0%) 7 (2.4%)
PSA 
density
Mean ± sd 0.11 ± 0.04 0.11 ± 0.04 0.10 ± 0.04 0.11 ± 0.04 0.37* (0.16***)
Biopsy 
cores with 
PC
1 76 (55.9%) 43 (47.3%) 49 (76.6%) 169 (57.7%)
<0.001** (0.01**)
2 60 (44.1%) 48 (52.7%) 15 (23.4%) 124 (42.3%)
Clinical 
stage
T1C 83 (61.0%) 52 (57.1%) 50 (78.1%) 186 (63.5%)
0.020** (0.02**)
T2 53 (38.9%) 39 (42.9%) 14 (21.9%) 107 (36.5%)
RP Radical Prostatectomy
RT Radiotherapy
WW Watchful Waiting
PSA Prostate-Specific Antigen
PC Prostate Cancer
The p-values in the last column are the results of the statistical tests for the null-hypothesis that all three groups are part of the same population and 
thus not different. The P-values between brackets result from the statistical test of the null hypothesis that the RP and the WW group are not different 
from each other.
* Kruskal-Wallis test
** Chi-square test
*** Mann-Whitney U test
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Watchful Waiting
Of 64 men initially managed on a watchful waiting policy, 19 (29.7%) received deferred treat-
ment after a median of 40.1 months (mean 38.9; range 9.1-78.6). Deferred radical prostatec-
tomy was performed in 2 men; both had organ-confined disease. Radiotherapy was provided 
in 13 men; two of them received high dose rate brachytherapy. The remainder received solely 
external beam radiotherapy (one patient 66 Gray, one patient 72 Gray, the remainder 68 Gray, 
all in portions of 2 Gray). Four men received hormonal treatment. The major reason for de-
ferred treatment was an increasing PSA-level.
Outcome
During a mean follow-up of 80.8 months, three men died from prostate cancer (1 radical 
prostatectomy, 2 radiotherapy) and 40 men died from intercurrent disease (table 3). After 
8-years, the prostate cancer-specific survival was 99.2% and the overall-survival was 85.4% 
(figure 11.1). The baseline characteristics of men who died from prostate cancer or developed 
metastases are stated in table 4.
Metastatic disease developed in 2 men who elected radical prostatectomy and in 2 radio-
therapy patients; three of those died as a result of prostate cancer. The fourth man was still 
at risk at December 1st 2005. His last PSA-level was 555 ng/mL, but he was active and feeling 
well.
Table 11.2 Pathological features of radical prostatectomy specimens for the 136 patients who were treated with immediate radical 
prostatectomy
n.a.
Tumour volume (ml)
Median (range) 0.24 (0.001-4.71)
18
<0.2 51 (43.2%)
0.2-0.5 33 (28.0%)
0.5-1.0 20 (16.9%)
1.0-2.0 8 (6.8%)
>2.0 6 (5.1%)
Pathological stage
pT0 1 (0.8%)
5
pT2 122 (93.1%)
pT3 4 (3.1%)
pT4 4 (3.1%)
Gleason score
<= 6 (3+3) 108 (82.4%)
57 21 (16.0%)
8-10 2 (1.5%)
Capsular perforation 5 (3.9%) 7
Vascular invasion 2 (1.5%) 0
Seminal vesicle invasion 1 (0.7%) 0
n.a. not available
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Table 11.3 Outcome for all 293 patients with tumors which met the criteria for active surveillance
RP RT WW Total
No. 136 91 64 293
PSA progression 13 (9.6%) 16 (17.6%) - 29 (9.9%)
Metastatic disease 2 (1.5%) 2 (2.2%) 0 (0.0%) 4 (1.4%)
Death 14 (10.3%) 19 (20.9%) 9 (14.1%) 43 (14.7%)
5-year survival* 94.8% 90.0% 91.1% 93.2%
8-year survival* 91.3% 79.2% 85.3% 85.4%
prostate cancer death 1 (0.7%) 2 (2.2%) 0 (0.0%) 3 (1.0%)
5-year PCS survival** 99.2% 100% 100% 99.6%
8-year PCS survival** 99.2% 98.6% 100% 99.2%
RP Radical Prostatectomy
RT Radiotherapy
WW Watchful Waiting
PSA Prostate-Specific Antigen
PCS Prostate cancer specific
* = P-value 0.08 (log-rank test for trend)
** = P-value 0.26 (log-rank test for trend)
Table 11.4 Characteristics of men who developed metastatic disease
Patient 1 Patient 2 Patient 3 Patient 4
Treatment RP RP RT RT
Characteristics
At baseline
Clinical stage T2A T2A T1C T2A
Cores prostate cancer 2 2 2 2
PSA (ng/mL) 6.4 6.5 4.4 7.6
PSA D (ng/mL/cc) 0.16 0.14 0.06 0.15
Planimetric volume 40.9 46.2 67.9 49.6
Age at diagnosis 68.8 69.8 73.4 74.1
RP specimen
Tumour volume (ml) 1.63 1.11
Gleason score 5+4=9 4+3=7
Vascular infiltration yes no
Pathological stage pT4a pT4a
Follow-up
Time to BP (months) 4.8 6.6 87.5 21.3
Time to M+ (months) 38.9 49.8 109.1 57.2
Time to death (months) 53.2 - 110.1 63.2
RP Radical Prostatectomy
RT Radiotherapy
PSA Prostate-Specific Antigen
BP Biochemical Progression
M+ Metastatic disease
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Biochemical progression was present in 13 radical prostatectomy patients (9.6%) and 16 
radiotherapy patients (17.6%). The 8-year biochemical progression free survival was 89.8% in 
radical prostatectomy, 71.7% in radiotherapy, and 100% in those who received active treat-
ment after surveillance (log-rank test for trend: P-value=0.12).
With a mean follow-up of 82.4 months (mean 80.4; range 23.8-119.9), of 64 men initially 
managed with watchful waiting, none developed metastatic disease or died from prostate 
cancer. Without having received definitive treatment for their prostate cancer, 8 men (17.8%) 
died of other causes.
DISCUSSION
This study describes the treatment and follow-up of screen detected prostate cancer patients 
with baseline characteristics currently regarded suitable for active surveillance. Men were 
treated by radical prostatectomy, radiotherapy or watchful waiting. The high disease specific 
survival (99.2% after 8 years) is in sharp contrast with the overall survival of 85.4%. The results 
of all treatment modalities applied to candidates for active surveillance in this study also 
 
 
 
Fig 11.1 
 
Figure 11.1 Kaplan-Meier graph of the overall and disease specific mortality.
PC-specific survival
Overall survival
Men at risk
Time (years) 0 2 4 6 8 10
Men at risk 293 286 279 190 81 4
PC-spec (%) 100 100 100 99.2 99.2 95.6
Overall (%) 100 97.6 95.2 90.8 85.4 57.9
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contrasts with the five year biochemical progression-free survival rates of 75.0% in radical 
prostatectomy patients, 77.5% for radiotherapy patients and 58.3% for patients with hormonal 
treatment.189 The follow-up of the watchful waiters showed that the natural course of 
these selected cancers is favorable. In addition, the radical prostatectomy specimens showed 
disease characteristics of men who matched the active surveillance criteria as well. Although 
the prognostic factors of the radical prostatectomy group were significantly less favorable 
than those in the watchful waiting group, this probably only results in an overestimation of 
these factors in the watchful waiting group. As a result, the real pathological features at the 
time of diagnosis of men in the watchful waiting group are likely to be more favorable than 
suggested.
The cohort we described consists of men aged 55-74 who took part in the prevalence 
screen. They were screened for the first time and represent a large group of men in the gen-
eral population. Within ERSPC Rotterdam, men are re-screened after 4 years. Re-screening has 
been described to result in an ongoing downstaging of tumours.197 Therefore, the proportion 
of men who are suitable for active surveillance will only increase when men have had a PSA 
recording earlier in their life. An important part of these men diagnosed with prostate cancer 
would not have developed symptoms of their prostate cancer in the absence of screening (i.e. 
overdiagnosis). It is evident that overdiagnosis is an important issue in current screening prac-
tices, although it is difficult to estimate its amount, which is, among other factors, dependent 
on the intensity of screening. Draisma et al. described the results of a computer estimation 
which used the ERSPC Rotterdam data.37 They came to an overdiagnosis rate of 27%-56% for 
men who were screened once and were in the age range of 55 to 75. Until new biomarkers 
become available, PSA will be used as a screen test; the future results of screening studies in 
Europe and the US are destined to influence the intensity of PSA-testing more than the ques-
tion whether the test should be used for screening purposes at all.18 The current challenge lies 
therefore in selecting those cancers which do not need treatment, or at least not at the time 
they are diagnosed. Thereby, the overtreatment as a result of overdiagnosis is minimized and 
the treatment related toxicity can be avoided.145,190
The objective of active surveillance policies should be to include those men in whom it 
seems safe to defer treatment; during the period of surveillance those men with more aggres-
sive, significant disease should be filtered out and offered definitive treatment. Deferred treat-
ment should not be considered a failure of active surveillance as a management strategy. The 
expectation is that most men will die as a result of intercurrent disease without being treated 
during their lifetimes. In our cohort 14.1% of men initially managed on a watchful waiting 
policy have already died as a result of other causes, while no metastatic disease developed. 
The prostate cancer-to-intercurrent death ratio in this study was 3/41=7.0%, meaning that for 
every man who dies of prostate cancer, more than 13 men decease with prostate cancer, but 
from other causes. The overall life expectancy for Dutch men aged 65.5 is 15.4 years, thereby 
reaching an age of 80.9 years.198 The mean age for men from our study group who were alive 
Management and survival of screen detected prostate cancer patients who might have been suitable for active surveillance
127
at January 1st 2005 was 72.3 years (range 61.3-83.5); for the watchful waiters the mean age 
was 75.3 years (range 65.0-83.6). According to Pound et al. the median survival time from 
the development of metastatic disease after radical prostatectomy to death from prostate 
cancer was slightly less than 5 years.88 Since all men who were initially managed on a watchful 
waiting policy were free from metastatic disease, it is unlikely that many men will die from 
prostate cancer.
One of the main challenges for active surveillance is in recognition of the suitable patients. 
PSA should certainly play a role in patient selection, but the possibility to differentiate more 
aggressive cancers is lost in the lower PSA ranges. Furthermore, the biological variation of 
PSA in and between patients is large. The same holds for the value of the DRE, which has a 
poor positive predictive value, especially in the lower PSA ranges.102 The third pillar of patient 
selection is in the pathological features of the biopsy specimen. Currently, more research is 
invested in adequate sampling of the prostate. The value of a uniform application of sextant 
biopsies in all prostates has been debated.199 In order to find cancers with a certain volume and 
to estimate their actual grading in prostates of different sizes with a certain level of certainty, 
the number of biopsies should be individualized.200 Unfortunately, few studies exist which 
investigated the prognostic value of the tumor volume on the outcome.201 The undersampling 
rate is likely to increase with increasing prostatic size, although one study reported the op-
posite.202 The radical prostatectomy specimens of men who matched our active surveillance 
criteria on beforehand illustrate the undersampling of prostates in our study: 6.1% of men 
were shown to have a pathological stage that was higher than the expected pT2, and 17.5% 
had a Gleason score of more than the expected 3+3=6. Both men in whom a radical pros-
tatectomy was performed and subsequently developed metastases had a prostatic volume 
higher than the median volume of prostates included in our study group. Retrospectively, it 
was evident that these men were undersampled and more biopsy cores should have been 
taken in order to allow a proper estimation of the tumor volume and the grade. The biopsy 
table which was proposed by Vashi et al. is likely to be a good scheme for estimating the num-
ber of biopsy cores needed in relation to prostatic size.203 Extensive sampling of the prostate 
has been shown to estimate tumor volume with reasonable precision.187 On the other hand, 
more extensive sampling of the prostate will result in a higher incidence of prostate cancer. 
Many of the additionally found cancers will be insignificant and will increase the proportion 
of overdiagnosis.
CONCLUSION
Among those men fulfilling our eligibility criteria for active surveillance, the natural course 
of the disease could be investigated in 64 patients. After a mean follow-up of 80.8 months, 
already 14.1% of men initially managed with watchful waiting have died as a result of other 
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causes; contrasted to the development of zero metastases. Our eligibility criteria could be 
validated in 136 men who underwent radical prostatectomy. Although further follow-up will 
be necessary, this study shows that prostate cancer patients who match the selection criteria 
applied in this study might be safely managed by active surveillance. However, undersam-
pling is still a problem. Therefore, appropriate prostate sampling, with respect to the prostatic 
size, at the time of diagnosis and during follow-up is essential.
Chapter 12
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ABSTRACT
Objective
To study active surveillance as a management option for the important number of prostate 
cancer patients that would not have been diagnosed in the absence of screening.
Patients & Methods
We analyzed baseline characteristics and outcome parameters of all men on active surveillance 
who were screen-detected in the Rotterdam section of the European Randomized study of 
Screening for Prostate Cancer (ERSPC). Recruitment and surveillance of men were not guided 
by a protocol, but dependent on individual decisions of patients and their physicians.
Results
Active surveillance was applied in 278 men detected by screening from 1993 to 2006. At diag-
nosis, their median age was 69.8 years (25-75p; 66.1-72.8); median PSA 3.6 ng/mL (25-75p; 3.1-
4.8) and the clinical stage was T1c in 220 (79.1%) and T2 in 58 (20.9%). During the follow-up of 
median 3.4 years, a total of 103 men (44.2%) had a PSA doubling time which was negative (i.e. 
half-life) or longer than 10 years. Men detected at re-screening were significantly more likely 
to be on active surveillance and they had more beneficial characteristics. Deferred treatment 
was elected in 82 cases (29.0%). Overall survival was 89.0% after eight years; the cause-specific 
survival was 100.0%.
Conclusion
This report shows a beneficial outcome, although preliminary, of screen-detected men man-
aged on active surveillance. Men were more likely to be on active surveillance if the disease 
was detected at repeated screening. It furthermore shows that an important proportion of 
men have prolonged PSA doubling times, although the value of this parameter has not been 
established in untreated men.
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INTRODUCTION
Prostate cancer is an important cause of death in males. It is after lung cancer the second most 
important cause of cancer-related death in American males.33 With the introduction of prostate-
specific antigen (PSA) in the late 1980s a screening tool became available which has proved to 
detect prostate cancers earlier in the course of the disease.24 One of the downsides of screening 
is a frequent diagnosis of low-risk cancers which would not have been detected during the 
man’s lifetime in the absence of screening (i.e. overdiagnosis). As screening becomes globally 
more prevalent, the side-effects such as overdiagnosis will increase as well. It can be calculated 
that if all U.S. men with PSA levels ≥ 2.5 ng/mL would be biopsied 775,000 cancers would be 
diagnosed, which is 542,910 more than the estimated 232,090 cases to be diagnosed in 2005 in 
the United States and 25.6 times more than the 30,350 men expected to die of the disease.30 A 
large proportion of these men will have insignificant cancers. Although men with these cancers 
are likely to die as a result of other causes, the majority of them are currently treated.204
Active surveillance focuses on men for whom therapy is delayed until the tumor becomes 
progressive and curative treatment can be offered. It is distinct from watchful waiting as 
described in currently used guidelines in that the former has a curative intent.28 Although 
several studies have examined the role of watchful waiting prior to the widespread use of 
PSA,109,110,205 the natural course of screen-detected prostate cancer is less well known.206,207 
Screen-detected prostate cancer is different from clinically diagnosed cancer. This is among 
other factors caused by lead- and length-time sampling bias.
Arguments to elect active surveillance include quality of life issues, costs associated with 
treatment and ethical aspects. Little is known about the quality of life regarding active surveil-
lance strategies. The Sprostate cancerG-4 study has shown that the assignment of patients to 
watchful waiting or radical prostatectomy entails different risks of erectile dysfunction, urinary 
leakage, and urinary obstruction, but that on average, the choice has little if any influence on 
well-being or the subjective quality of life after a mean follow-up of four years.61 Another 
argument is the costs of treatment. Although no literature is available, it seems obvious that 
active surveillance is less expensive than immediate treatment. The most important argument 
for active surveillance is probably an ethical argument: Our profession needs to decide what it 
considers is an acceptable number of patients that need to be treated to prevent one prostate 
cancer death.208 If any, the number of life-years gained will be small, because of the fact that 
prostate cancer is a disease of older age. The potential benefit should be contrasted to the 
side-effects of all applied treatments.145,146
To investigate the natural course of prostate cancers detected by screening, this report 
describes the baseline characteristics, PSA kinetics, deferred treatment and outcome of all 
men diagnosed with prostate cancer within the first, second and partial third screen rounds of 
the European Randomized study of Screening for Prostate Cancer (ERSPC), section Rotterdam 
who were initially managed with active surveillance.
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PATIENTS & METHODS
The ERSPC was designed to study the feasibility of population-based screening for prostate 
cancer and its effect on prostate cancer mortality. Therefore, by the end of 2002, 183,000 men 
were randomized in eight European countries starting in 1993.78 In the Netherlands alone, 
42,376 men were randomized to the screen (n=21,210) or the control arm (n=21,166) from 
June 1993 through December 1999. Men in the screening arm were enrolled in a screening 
program with a four-year interval. From start until May 1997 men were offered a lateral sextant 
biopsy if either the PSA level was ≥ 4.0 ng/mL, the digital rectal examination (DRE) and/or the 
transrectal ultrasound (TRUS) was suspect for carcinoma. From 1997, only a PSA ≥ 3.0 ng/
mL prompted a lateral sextant biopsy and DRE and TRUS were omitted as screening tests. A 
seventh, lesion directed biopsy core was taken in case of a hypo-echogenic lesion.
Study population
This observational study describes a cohort of men on active surveillance who were detected 
within the screening program of the Rotterdam section of ERSPC. All men retrospectively met 
the following criteria:
1. Clinical stage T1c or T2 disease
2. PSA at diagnosis 15 ng/mL or less
3. Biopsy Gleason score less than 8
The cut-off date for this analysis was January 1st 2006. By then, the first and second round 
of the Rotterdam section of the ERSPC were completed; the third round will be finished in 
December 2007. The choice of initiating and continuation of an active surveillance policy was 
patient desire and/or physician advice. These criteria resulted in a study group of 278 men 
initially managed by active surveillance.
Endpoints
The primary endpoint of this analysis was prostate cancer mortality. Within ERSPC, an inde-
pendent committee performs the review of all deceased prostate cancer patients with three 
reviewers (a surgeon, a urologist and a medical epidemiologist) who separately judge the 
anonymized patient charts.148 The secondary endpoints of this study were overall mortality 
and change of therapy. For active surveillance practices PSA progression does not serve as an 
endpoint but may serve as a trigger point to treatment.
Follow-up
Because follow-up regimens varied among local practices, data for this study were collected 
from semi-annual patient chart reviews for the first 5 years and annually thereafter. Charts 
were assessed for medical history, physical examination (DRE), dissemination studies and PSA 
tests.
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Statistics
To calculate PSA doubling time (PSADT) the base 2 logarithm of the PSA value was calculated 
using the formula, 2log(PSA) - 10log(PSA)/10log(2), and plotted against time since diagnosis 
(date of PSA measurement to date of diagnosis). The linear regression line through these 
points estimates the PSA slope. The doubling time can be calculated as the reciprocal value 
of a positive slope, while a negative or decreasing slope represents PSA half-life. PSA slopes 
were only calculated in patients with 3 or more PSA values acquired prior to a possible therapy 
change. For statistical analysis the commercially available software SPSS was used (version 
12.0.1; SPSS, Inc., Chicago, IL). P-values < 0.05 were considered significant. The survival analy-
ses for disease specific and overall survival and for deferred treatment-free survival were cal-
culated by the Kaplan-Meier method.
 
 
 
Fig 12.1 
Figure 12.1 CONSORT-diagram of men screened for prostate cancer in the first three screening rounds of the Dutch branch of the ERSPC
PC Prostate cancer
AS Active surveillance
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RESULTS
Baseline characteristics
From 1993 through 1999 21,210 men were randomized to the screen arm of the Rotterdam 
section of the ERSPC. During the first screen round 1,078 men were diagnosed with prostate 
cancer (figure 12.1). Of those, 106 men (9.8%) elected active surveillance. In the second screen 
round 550 prostate cancers were detected and 134 (24.4%) of those elected active surveil-
lance. In the incomplete third round 144 prostate cancers were diagnosed and 38 (26.4%) 
elected active surveillance. Of the 1,772 cancers detected in the first, second and third round 
278 men (15.7%) elected active surveillance. At diagnosis, the study population had a median 
age of 69.8 years and a median PSA-level of 3.6 ng/mL. In 220 men (79.1%) the clinical stage 
was T1c; clinical stage T2 was present in 58 (20.9%). The initial PSA level for men diagnosed 
with prostate cancer at repeated screening was significantly lower. The other baseline charac-
teristics, which are shown in table 12.1 were not significantly different. The median follow-up 
time was 3.4 years; 6.0 years for round 1 men, 3.2 years for round 2 and 1.2 years for those 
detected in round 3.
Table 12.1 Characteristics at diagnosis of men on active surveillance in three subsequent screen rounds
R I R II R III*** Total P-value
PC Number 1,078 550 144 1,772
AS Number (%) 106 (9.8) 134 (24.4) 38 (26.4) 278 (15.7) <0.001*
Age (years)
Median
(25-75p)
69.4
(65.7-72.4)
69.9
(65.9-73.1)
70.5
(67.3-73.3)
69.8
(66.1-72.8)
0.45**
PSA (ng/mL)
Median
(25-75p)
4.2
(3.3-5.5)
3.4
(2.6-4.4)
3.8
(3.3-5.6)
3.6
(3.1-4.8)
<0.001*0-5 72 (67.9) 119 (88.8) 27 (71.1) 218 (78.4)
5-10 28 (26.4) 15 (11.2) 11 (28.9) 54 (19.4)
>10 6 (5.7) 0 (0.0) 0 (0.0) 6 (2.2)
Clinical stage
T1C 83 (78.3) 113 (84.3) 24 (63.2) 220 (79.1)
0.21*
T2 19 (17.9) 21 (15.6) 14 (36.8) 58 (20.9)
Biopsy Gleason
≤6 98 (92.5) 127 (94.1) 37 (97.4) 262 (94.2)
0.50*
7 8 (7.5) 7 (5.2) 1 (2.6) 17 (5.8)
Cores with PC 
(number)
1-2 (%) 91 (85.8) 111 (82.8) 34 (89.5) 236 (84.9)
0.82*3-4 (%) 14 (13.2) 20 (14.9) 3 (7.9) 37 (13.3)
5-7 (%) 1 (0.9) 3 (2.2) 1 (2.6) 5 (1.8)
* Chi-square test
** Kruskal Wallis test
*** Round 3 will be complete in December 2007
PC Prostate cancer
AS Active surveillance
25-75p 25th and 75th percentile
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Deferred treatment
Of 278 men initially managed on an active surveillance policy, 82 (29.0%) received deferred 
treatment after a median of 2.5 years (25-75p; 1.3-5.0, table 12.2). Deferred radical prostate-
ctomy was performed in 13 men (15.9%). Radiotherapy was administered in 56 men (68.3%). 
The remainder (n=13; 15.9%) received hormonal treatment. The five year deferred treatment-
free survival was 70.8% (figure 12.2). After deferred radical prostatectomy 1 man had capsular 
penetration (pT3A) and 4 had positive margins ( table 12.3).
Table 12.2 Follow-up characteristics of men detected in three subsequent screening rounds who were managed on active surveillance
R I R II R III Total P-value
Active surveillance No. 106 134 38 278
Follow-up (years)
Median (25-75p) 6.0 (3.4-7.9) 3.2 (2.1-4.5) 1.2 (1.2; 
0.0-3.3)
3.4 (1.8-
6.0)
<0.001**
PSA DT
0-2 yrs 2 (2.2) 11 (9.2) 4 (17.4) 17 (7.3)
0.02*
2-4 yrs 9 (10.0) 20 (16.7) 3 (13.0) 32 (13.7)
4-6 yrs 23 (25.6) 20 (16.7) 2 (8.7) 45 (19.3)
6-8 yrs 14 (15.6) 8 (6.7) 1 (4.3) 23 (9.9)
8-10 yrs 6 (6.7) 7 (5.8) 0 (0.0) 13 (5.6)
>10 yrs 22 (24.4) 21 (17.5) 7 (30.4) 50 (21.5)
Negative 14 (15.6) 33 (27.5) 6 (26.1) 53 (22.7)
N/a 16 14 15 45
Treatment change
RP 8 (7.5) 4 (3.0) 1 (2.6) 13 (4.9)
0.05*
RT 27 (25.5) 25 (18.7) 4 (10.5) 56 (20.1)
HT 9 (8.5) 4 (3.0) 0 (0.0) 13 (4.9)
Total 44 (41.5) 33 (24.6) 5 (13.2) 82 (29.0)
Time to treatment 
(months)
Median (25-75p) 3.9 (1.6-6.4) 2.0 (1.2-4.0) 1.2 (0.7-2.0) 2.5 (1.3-
5.0)
0.03**
Mortality
All causes 18 (17.0) 8 (6.0) 0 (0.0) 29 (10.2) 0.001*
PC 0 0 0 0 (0.0)
Overall survival1 5-yr 87.2 91.9 89.0 0.45***
PC-survival1 5-yr 100.0 100.0 100.0 100.0
* Chi-square Test
** Kruskal Wallis Test
*** Log-rank Test for trend
AS Active surveillance
PSA DT PSA doubling time
Yrs Years
RP Radical prostatectomy
RT Radiotherapy
HT Hormonal treatment
PC Prostate cancer
N/a Not available; less than three PSA values.
1 Kaplan-Meier
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Fig 12.2 
Figure 12.2 Kaplan-Meier projection of deferred treatment free survival (N=263)
Follow-up (yrs) 0 2 4 6 8 10
Men at risk 263 200 122 71 26 3
Deferred 
treatment
0 34 51 67 77 82
DTFS (%) 100 86 78 66 53 31
DTFS  Deferred treatment-free survival
Table 12.3 Pathological characteristics of men with deferred radical prostatectomy
PSA at diagnosis (ng/mL) Median (25-75p) 4.2 (3.1-5.9)
Clinical stage cT1C 10
cT2A 3
Biopsy Gleason score <7 12
>=7 1
PSA before surgery Median (25-75p) 6.6 (5.0-7.4)
Pathological stage pT2A 1
pT2C 9
pT3A 1
N1 0
Gleason score <7 9
=7 2
Margin status Positive 4
25-75p 25th and 75th percentile
According to the 1992 TNM system
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PSA doubling time
Table 12.4 shows that the initial PSA-level and the PSA doubling time, while not a prede-
termined reason for changing to deferred treatment, had a significant relationship with that 
decision, in contrast to the last PSA level before treatment. A total of 1,799 PSA tests were 
performed, with a median of 4 tests per patient (25-75p; 2-7 tests). The PSA doubling time was 
calculated for 234 men with 3 or more PSA tests. A PSA doubling time longer than 10 years or 
negative (i.e. PSA half-life) was noted in 21.4% and 22.6%.
Table 12.4 Prognostic factors for freedom of deferred treatment and death
5-yr DTFS (%) Log-rank
iPSA
<=5.0 75.2
0.03
>5.0 57.9
Last PSA
<= 10.0 72.1
0.92
> 10.0 68.8
PSA DT
<3 yrs 35.6
<0.0001
3-5 yrs 47.6
5-10 yrs 86.7
>10 yrs 96.2
Negative 91.2
iPSA  Initial PSA
5-yr DTFS 5-year deferred treatment free survival
PSA DT  PSA doubling time
Outcome
Twenty six men (9.4%) died during follow-up; none from prostate cancer. After 8 years, the 
prostate cancer-specific survival was 100.0% and the overall-survival was 84.0% (table 12.2). 
Forty three men (15.5%) were still at risk after 8 years; 26 (60.5%) of those had not received any 
treatment for their prostate cancer.
DISCUSSION
Of men diagnosed at the prevalence (i.e. first) screening of the ERSPC screening program, 
10.2% were safely managed by active surveillance: during the median follow-up of 6 years 
18.1% deceased; all of intercurrent diseases. Men diagnosed at repeated screening had more 
beneficial characteristics and were more likely to elect active surveillance. The latter either is 
the result of an ongoing stage and grade shift, but is likely to be influenced by a time trend as 
well. Active surveillance has become a more popular management option for prostate cancer 
in the Netherlands. Men on active surveillance had PSA doubling times longer than 10 years 
Chapter 12
138
or negative in 43.7% of cases. Although this suggests insignificant cancer, the value of PSA 
kinetics in evaluating untreated screen-detected prostate cancer patients is still unclear.
It is currently difficult to risk-stratify men well enough and with acceptable confidence in-
tervals, although better and more individual predictors for outcome are being developed. This 
study shows that men with Gleason score 7 might well be good candidates to systematically 
keep their cancers under surveillance until they decease from other causes. Vis et al. showed in 
a radical prostatectomy series that the proportion of high-grade Gleason pattern in a biopsy 
was superior to the currently used Gleason score.209 Another step towards a more personal-
ized risk prediction of potentially indolent prostate cancer is the development and use of 
nomograms.12,210 The window of opportunity for active surveillance strategies is unknown, 
but based on incidence-to-mortality ratios it is likely to be larger than the number of men in-
cluded in watchful waiting and active surveillance cohorts published so far.109,110,181,186 Tumors 
which have a high probability to be indolent could appear to be important prostate cancers 
due to biopsy undersampling and dedifferentiation.187 However, given the minimal improve-
ment in cancer-specific survival when comparing surgical treatment to no treatment among 
men with cancers not detected by screening,113 it seems unlikely that active surveillance of 
low-risk, screen-detected cancers will place patients at undue risk of an adverse outcome.113 
Two studies could not find adverse effects of prolonged delays on the outcome after radical 
prostatectomy for men enrolled in their active surveillance programs.182,211 The current cohort 
differs from that in the Scandinavian study in both the recruited population and the intent of 
expectancy. The research challenge for the years to come lies in optimizing risk prediction.
It is difficult to identify the reasons why patients and/or doctors elect deferred radical treat-
ment. Anxiety in patients seems to be an important factor in the decision to change to active 
treatment.61 It would be a big advance if variables predicting anxiety in patients could be 
identified in order to risk stratify patients. Offering men a support program could be of help.67 
Rapid rising PSA values are only assumed to predict metastases and eventually death from 
prostate cancer. The predictive value of PSA doubling time as a predictor for prostate cancer 
death is mainly based on radical prostatectomy series and there is no direct evidence to sup-
port this relationship in the natural course of screen-detected prostate cancer.212 McLaren et 
al. showed that on multivariate analysis PSA doubling time strongly correlated with clinical 
progression (P < 0.001), stage progression (P = 0.01), and time to treatment (P < 0.001).213 
To further establish these correlations an evaluation of PSA kinetics on a proper endpoint is 
important. Due to the absence of possible endpoints in our cohort, it is for the present not 
possible to further evaluate the predictive value of PSA doubling time. Even after seven years, 
our cohort includes almost a quarter of men with doubling times under five years who show 
no signs of progression. In the cohort of Carter et al. the median PSA doubling time (DT) 
was 2.5 years for those who underwent therapy; those remaining on watchful waiting had a 
median DT of 25.8 years.181
Active surveillance for prostate cancers detected in three subsequent screening rounds
139
Klotz et al. reported that in a cohort of 299 patients 65% remained free of treatment at 8 
years, which is more than the 52.0% in our study.186 During a follow-up of 3.8 years Carter et al. 
had ninety-eight patients who remained on watchful waiting; 215 proceeded to treatment.181 
A total of 57.3% and 73.2% chose treatment within the first 2 and 4 years, respectively. In our 
cohort 29% elected deferred treatment with a lower 4-year deferred treatment rate of 22%.
One should note that men detected by screening in our screening program have a calcu-
lated lead-time of 11.2 years (range 10.8-12.1).37 This means that men are diagnosed a mean 
11.2 years before the cancer would be diagnosed clinically. An important proportion of these 
men is therefore eligible for active surveillance. We have to await the follow-up periods of 
15 years and beyond to draw more definitive conclusions. Current active surveillance pro-
grams, including the Rotterdam program use standard repeat biopsies and more intensive 
biopsy sampling. All treatment decisions in the contemporary series were based on initial 
sextant biopsy sampling according to the ERSPC protocol and no standard repeat biopsies 
were scheduled. There is evidence that detection rates increase with the number of cores.214 
More importantly, obtaining more cores results in more adequate sampling and allows for 
increased risk stratification.215 Furthermore it should be noted that a predetermined protocol 
for the enrolment and follow-up of men in an active surveillance strategy was not used; the 
outcomes described in this study are based on an observational study. Currently, a prospective 
study to asses the value of a fixed active surveillance program has been initiated in Rotterdam 
(i.e. PRIAS). Although these measures were not implemented at the time of follow-up of this 
cohort, the oncological control was still optimal. This outcome taken together with current 
incidence-to-mortality ratios might support the view that entry criteria for active surveillance 
strategies could be wider than currently practiced.
CONCLUSION
Active surveillance plays an important role in the management of men with screen-detected 
prostate cancer detected within our screening program. Men detected at repeated screening 
are more likely to be on active surveillance. The cause-specific survival of our cohort was 100% 
at 5 years. Although the exact value of PSA doubling time as a predictor of prostate cancer 
death needs to be established for untreated, screen-detected men, an important proportion 
of men have prolonged PSA doubling times or even PSA half-lives, which are generally re-
garded as indicative for insignificant disease. Active surveillance seems to offer an important 
opportunity for the current overtreatment that results from screening.

PART V
GENERAL DISCUSSION
Chapter 13
Discussion
Chapter 14
Epilogue

Chapter 13
Discussion

Discussion
145
TOWARDS A CLINICAL POLICY FOR ACTIVE SURVEILLANCE
Natural course of screen-detected prostate cancer
The current knowledge of the natural history of prostate cancer is mainly based on clinically 
detected cases.109,110,205 The available studies show histological grade to be the most important 
prognostic variable. In 1994 Chodak et al. concluded from a pooled analysis of 828 case re-
cords from six nonrandomized studies, that the strategy of initial conservative management 
and delayed hormone therapy is a reasonable choice for some men with grade 1 or 2 clinically 
localized prostate cancer, particularly for those who have an average life expectancy of 10 
years or less.205 Factors that had a significant effect on disease-specific survival were grade 3 
tumors (risk ratio, 10.04), residence in Israel (risk ratio, 2.48) or New York (risk ratio, 0.37), and 
age under 61 years (risk ratio, 0.32). Ten years after diagnosis, disease-specific survival was 
87 percent for men with grade 1 or 2 tumors and 34 percent for those with grade 3 tumors; 
metastasis-free survival among men who had not died of other causes was 81 percent for 
grade 1, 58 percent for grade 2, and 26 percent for grade 3 disease. These findings were not 
affected by the inclusion of men who had early-stage cancer, were older, had worse-than-
average health, or underwent delayed radiation therapy or radical prostatectomy.
Johansson et al. have studied a cohort of 223 conservatively managed men who had organ 
confined disease at diagnosis.109 If progression occurred, orchiectomy or exogenous estrogens 
were offered. After a median follow-up of 21 years 91 percent of patients had died; prostate 
cancer was the cause of death in 16 percent, while 40 percent had progression of disease. 
Again, poorly differentiated disease was the worst prognostic factor.
Data published by Albertsen et al. describe the survival of men with organ confined prostate 
cancer who were managed conservatively.110 The 20-year prostate cancer specific mortality 
for men with a Gleason score smaller than 6 varies from 4 percent to 15 percent, according to 
age at diagnosis. Overall mortality is then determined by comorbidity. The majority of these 
men are currently treated with invasive procedures, which might not be needed.49 Although 
the cause-specific mortality is 20 percent to 30 percent in men with Gleason score 6 tumors, 
in men with Gleason score 7 disease already 40-75 percent decease as a result of prostate 
cancer. Moreover are these men less likely to die from other causes. The population described 
by Albertsen et al. was diagnosed before PSA was introduced. Therefore, 60 percent of men 
were diagnosed by transurethral resection of the prostate (TURP). Categories T1a and T1b may 
have a different outcome which is not specified. As mentioned before, screening diagnoses 
prostate cancers earlier in their course, thus at younger age, and as a result the survival of men 
is likely to be longer.37,44,46
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There is a lack of evidence concerning the differences in outcome between expectancy and 
treatment with curative intent for localized prostate cancer. From the Surveillance Epidemiol-
ogy and End Results (SEER) database, several population-based studies towards the effect of 
treatment of clinically localized prostate cancer on the overall and disease-specific survival 
have been performed.216,217 Lu-Yao and Yao published the data on 10-year survival of a cohort 
of 59,876 men.216 The study showed that by the intention-to-treat approach, 10-year prostate-
cancer-specific survival for grade 1 cancer was 94% (95% CI 91-95) after prostatectomy, 90% 
(87-92) after radiotherapy, and 93% (91-94) after conservative management. The correspond-
ing survival figures in grade 2 cancers were 87% (85-89), 76% (72-79), and 77% (74-80); those 
in grade 3 cancer were 67% (62-71), 53% (47-58), and 45% (40-51). The authors did not test 
for significance of the differences formed and concluded that it was impossible to adjust for 
all confounding factors.216 Therefore, the authors did not attempt to draw definite conclusions 
about treatment efficacies. In fact, they conclude that randomized controlled trials are needed 
to provide definitive information about the relative efficacy of prostate cancer treatments. 
However, Wong et al. performed a comparable study using the same SEER database to study 
the value of radical treatment compared to observation in older men with prostate cancer.217 
Although the impact of biases on the performed analyses has not changed over almost a 
decade, these authors conclude that observation is associated with a lower chance of overall 
survival than radical treatment. In both studies, observation implies that men are managed 
expectantly and offered hormonal treatment once progression occurs.
Only one study has randomized men between watchful waiting and radical prostatectomy. 
This study from the Scandinavian Prostate Cancer Group number 4 (Sprostate cancerG-4) 
showed that operated men had a slightly better survival after 8 years of follow-up.113,218 The 
difference between the two groups in the cumulative incidence of death from prostate cancer 
increased over time, from 2 percentage points (95 percent confidence interval, –0.6 to 4.7) 
after five years of follow-up to 5.3 percentage points (95 percent confidence interval, –0.3 to 
11.0) after 10 years, in favor of radical prostatectomy. The relative risk among men assigned 
to radical prostatectomy, as compared with those assigned to watchful waiting, was 0.56 (95 
percent confidence interval, 0.36 to 0.88). Twenty patients had to be operated to save one 
death from prostate cancer. However, it was shown that men under 65 had larger effect dif-
ferences. Although a longer follow-up would be very valuable, it is important to make two 
remarks with regard to the extrapolation of these data for judging the value of active surveil-
lance. Firstly, watchful waiting should be clearly differentiated from active surveillance. While 
men were offered hormonal treatment in case of progression in the Sprostate cancerG4 study, 
men in active surveillance strategies discussed in this thesis should be fit for and must receive 
curative treatment in case of (suspected) progression. Currently ongoing studies have to show 
how important this difference in approach is.186 The second important argument against the 
use of the Scandinavian trial as evidence for the application of radical treatment instead of 
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active surveillance is the baseline risk of men randomized. Participants were clinically diag-
nosed men who had a PSA at diagnosis of more than 10 ng/mL in 44 percent, a biopsy Gleason 
score higher than 6 in 39 percent and a clinical stage T3 or T4 tumor in 14 percent of cases. 
This is a relatively high-risk group of patients of which most would not be included in one of 
the present active surveillance studies. Even with these men included and not accounting for 
lead-time in currently detected cancers, only a small, but possibly significant effect difference 
of surgery might be shown. For all these reasons, a revaluation of the costs and benefits of 
immediate active treatment in the era of widespread screening is necessary: the number of 
patients needed to be treated is high, and the lead time to the onset of symptoms and treat-
ment may be long in those undergoing monitoring, but the removal of small tumors may 
facilitate surgery and result in fewer side effects. There are no randomized controlled trials 
which compare radiotherapy with watchful waiting.
Early detection by PSA advances prostate cancer diagnosis in time (i.e. lead time).44 For men 
aged 55–67 years lead time amounts to 12.3 years in a screening setting.37 This lead-time is 
expected to be shorter for aggressive cancers and longer or even indefinite for indolent ones. 
Long-term outcome data on the natural course of screen-detected disease are not available, 
but will be provided by ongoing studies, such as the START trial, the ProtecT study and from 
PRIAS. The latter originates from Rotterdam and is in fact a spin-off from the ERSPC. More 
information about these initiatives can be found in the future perspectives section.
Deferred treatment
Outcome data for men on active surveillance are rare, but Klotz et al. have reported on their 
cohort of 299 men with a mean follow-up of 8 years.186 Although only three men died from 
prostate cancer, the high proportion of advanced disease at the time of a deferred radical 
prostatectomy has been mentioned as a point of concern. However, these results are con-
trasted by the report of Warlick et al. from the Johns Hopkins group.182 Their active surveil-
lance program includes annual repeat biopsies and relies less on PSA kinetics for follow-up. 
The authors have compared outcomes of 38 patients with small, lower-grade prostate cancer 
in their expectant management program who underwent delayed surgical intervention at 
a median of 26.5 months (95 percent confidence interval (CI): 17 to 32 months; range: 12.0-
73.0 months) after diagnosis with 150 similar patients who underwent immediate surgical 
intervention at a median of 3.0 months (95 percent CI: 2 to 4 months; range: 1.0-9.0 months) 
after diagnosis. After adjusting for age and prostate-specific antigen (PSA) density, the risks 
of non-curable cancer associated with delayed and immediate intervention did not differ 
significantly (relative risk=1.08, 95 percent CI = 0.55 to 2.12). Age, PSA, and PSA density were 
all significantly associated with the risk of non-curable cancer. They therefore concluded that 
delayed prostate cancer surgery for patients with small, lower-grade prostate cancers does 
not appear to compromise curability.
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Also, Khatami et al. have conducted a case-control study to investigate the chance of radical 
cure after a delay in treatment because of active surveillance.211 Tumor volume did not dif-
fer significantly between cases and controls: 1.35 vs. 1.05 cm (3), respectively. The frequency 
of extracapsular growth, Gleason score and time to progression after radical prostatectomy 
within a mean follow-up period of 2 years were also similar between the two groups. It was 
concluded that in selected patients with very early prostate cancer it seems that close surveil-
lance followed by prostatectomy when signs of progression appear is a low-risk option.
The impact of a delay in treatment was addressed in a small retrospective study in the Rotter-
dam region as well, comparing men with immediate curative treatment to age matched men 
initially managed with watchful waiting followed by deferred curative treatment.219 Of 261 men 
managed on watchful waiting, 27 (10.3 percent) received deferred treatment with curative 
intent, six with radical prostatectomy and 21 with radiotherapy. Most tumors had a Gleason 
score of 3+3=6 (77 percent). Median time of follow-up was comparable to the controls, and 
between 3 and 5 years for both treatment modalities. The outcome of the comparison with 
age-matched controls directly treated with curative intent was that biochemical progression 
rates were equal in both groups. This small retrospective study supports the hypothesis that 
deferring treatment in patients with selected, favorable prostate cancer characteristics does 
not influence the time of biochemical progression.
In order to cope with the large numbers of men currently (over)diagnosed with prostate 
cancer, it is an important research goal to risk stratify men whose prostate cancer is detected 
by screening and to subsequently offer them active surveillance. Therefore, efforts towards a 
standard clinical approach have to be made. Early detection causes a significant stage shift to-
wards more locally confined and less aggressive cancers.46 The long lead-time, stage reduction 
and natural history data cited above indicate that for properly selected cases there is a long 
‘time-window’ during which active observation must be safe without losing the opportunity 
for cure. This is supported by evidence from nomograms, prognostic tables, and by the only 
available randomized study of observation against radical prostatectomy.12,113,192,220,221
Biopsy technique
Prostate cancer is generally diagnosed by an ultrasound (TRUS) guided prostatic biopsy. The 
current literature has not reached agreement about the optimal number of cores which should 
be taken. This not only holds for the detection of prostate cancers, but also for the reliability 
of risk-stratification based on pathological parameters, such as the amount of invaded tissue 
and the Gleason score. The majority of the publications on this subject indicate that a higher 
number of cores per biopsy results in the detection of more cancers.83,199,203,222,223 There is only 
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one study which was not able to show a significant difference in cancer detection between 6 
and 12 cores per biopsy.224
Undersampling is defined as the effect that the pathology based on tissue obtained by biopsy 
underestimates the tumor in grade, stage and/or size. The amount of undersampling can 
be lowered by increasing the number of biopsy cores. More intensive sampling (i.e. taking 
more biopsy cores) results not only in more, but also detects many cancers which are likely 
indolent and should not have been detected at all.187 For sampling and for detection reasons, 
the number of biopsy cores has been increased in the last decade. A sextant biopsy used to 
be common in the nineties, when the ERSPC was initiated. Although the current number of 
biopsy cores varies widely by geographical region, sextant biopsies are now regarded on the 
lower end of the ‘ideal’ number of cores to be obtained. An extreme consequences of the 
desire for improved cancer detection and adequate sampling are saturation biopsies, which 
can include up to 54 cores.187
The size of the prostate also influences the probability of finding a tumor. Therefore, the size of 
the prostatic gland should be considered in determining the number of cores to be obtained. 
Vashi et al. have constructed a mathematical model to calculate the amount of cores needed 
to diagnose a tumor of certain size with 90 percent certainty.203 For example: to diagnose 
a tumor with a volume of 1 cc in a prostate of 20 grams with a probability of 90 percent, a 
sextant biopsy would be sufficient, while 15 cores are needed to diagnose the same tumor in 
a prostate of 50 grams. With the increase of the size of the prostate, the detection rate of both 
the standard and the lateralized sextant biopsy decreases significantly. Eskicorapci show the 
additional value of 10 over 8 cores per biopsy in prostates larger than 35 grams.225 Remarkably, 
findings at repeat biopsy correlated well with the presence of insignificant disease in a study 
by Stephenson et al.226 It is realized that biopsy grading is associated with undergrading in 20 
to 30 percent due to the nature of the sampling procedure.176,227-230 This, however, might be 
compensated for in the strategy for monitoring. On the other side, more extensive sampling 
of the prostate will result in a higher incidence of prostate cancer; many of the additionally 
found cancers will be insignificant and will increase the proportion of overdiagnosis.187
Patient selection
Criteria for selecting patients for active surveillance have not been established. Ideally, pa-
tients should be selected who either will not show disease progression during their lifetime 
or, if they show progression, will still be eligible for curative management with a high chance 
of success. Patients selected for active surveillance should be fit for surgery or radiotherapy 
if needed.
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Regarding tumor stage, various authors have chosen locally confined, non-palpable and just 
palpable disease (T2a on digital rectal examination DRE) as entry criterion for their studies.59,60 
Carter et al. have shown in clinical series that with a pre-treatment PSA level greater than 5.0 
ng/mL, 30 percent of 317 clinically detected cancers were non-curable (pT3). In the experi-
ence of the Rotterdam section of the ERSPC, a PSA of 8-10 ng/mL relates to 25 percent of pT3-4 
cases. The absolute role of serum PSA levels may be limited in patient selection, because of 
prostate volume, the biological variation of PSA within and between patients is large, and 
because there is a poor correlation with tumor grade. Just like DRE. PSA density and free/total 
ratio need to be studied for their adjuvant value.
In the study of Postma et al. the clinical follow-up of men with minimal cancers was studied 
in a group of participants from the general population of the Rotterdam region.147,197 This 
study described the incidence and follow-up of patients with clinical focal (minimal) prostate 
carcinoma in 2 screening rounds with an interval of 4 years. Focal carcinoma was defined as 
≤3.0 mm involvement by tumor in 1 biopsy core on sextant biopsy, lacking Gleason pattern 
4 or 5. The proportion of patients with focal prostate carcinoma increased significantly from 
16 percent in the first screening round to 29 percent in the second screening round. In those 
treated with radical prostatectomy (108 out of 355), the median tumor volume was 0.16 mL. 
A PSA density cut-off level of ≤0.1 ng/mL/cmP3P at the time of diagnosis predicted a minimal 
(<0.5 mL), organ-confined tumor in 94 percent of patients. The authors concluded that a 
considerable number of men with screen detected cancers have minimal disease. A low PSA, 
prostate volume, the number of positive cores, the grading, and the cancer length of prostate 
biopsies can predict minimal cancers with a high accuracy.
The prognostic value of the biopsy Gleason score has been shown to be the most important 
independent prognostic factor in multivariate analyses. It is therefore incorporated in all avail-
able nomograms.175,192,228,231-233 A man with clinical stage T1 or T2 disease, a PSA-level of 10 ng/
mL or less and a biopsy Gleason score 6 or less has a 98 percent chance not to die from pros-
tate cancer in the next five years, according to the nomogram of d’Amico et al.228 Although 
the Gleason score is currently the gold-standard for the grading of prostate cancer, the study 
by Vis et al, which is part of this thesis, found a superior predictive value of the proportion or 
length of high grade Gleason patterns in the biopsy.209 Cheng et al. studied the same variable 
in radical prostatectomy specimens and corroborate with our findings.156 However, Freedland 
et al. reported that the proportion of cancerous tissue and not the proportion of 4 and 5 tissue 
was most predictive of biochemical failure or adverse pathology.234 More research into the 
feasibility of using the length of high grade cancer in the biopsy instead of the Gleason score 
is ongoing at our institution.
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It is undisputed that men with a family history of prostate cancer have a higher risk to be 
diagnosed with this disease. The relative risk was 1.63 in our analysis based on men allocated 
to the screen-arm of the ERSPC. An effect of family history on the biochemical outcome could 
not be found. It was therefore concluded that although screened men 55 to 75 years old with 
a father or a brother having prostate cancer are at a substantially greater risk to be diagnosed 
with prostate cancer, the clinical presentation and prognosis by biochemical progression are 
not different compared to sporadic cases. The results of this analysis were contrasted by a 
more recent study of Kupelian et al.131 The authors claim it to be the first study that demon-
strates the presence of a family history of prostate cancer to correlate with treatment outcome 
in a large unselected series of patients. Their findings suggest that familial prostate cancer 
may have a more aggressive course than non-familial prostate cancer, and that clinical and/
or pathologic parameters may not adequately predict this course. Thompson et al. studied 
the results from the Prostate Cancer Prevention Trial (PCPT) and found that a positive fam-
ily history was associated with an increased risk for prostate cancer, but not for high-grade 
disease. It remains to be seen what the follow-up of this group of men reveals. Siddiqui et al 
reported that except for preoperative prostate specific antigen, clinico-pathological features 
and long-term oncological outcomes are equivalent after radical prostatectomy in patients 
with familial, hereditary and sporadic prostate cancer.235 Recent reports confirm our findings 
of equal aggressiveness of men with familial and sporadic prostate cancer detected in the PSA 
era.235,236 Family history is therefore solely a risk factor for a higher incidence of prostate cancer, 
but not for a higher risk of diagnosed cancers.
Follow-up
A fundamental question in prostate cancer research is whether screening with PSA just de-
tects more tumors with favorable characteristics or if dedifferentiation is actually prevented by 
early detection and subsequent treatment. The latter option implies that tumors dedifferenti-
ate in the preclinical screen-detectable phase. Although epidemiological evidence shows that 
dedifferentiation as a major mechanism of progression in prostate cancer, this key question 
is still heavily investigated.45 Tumors dedifferentiate during the screen-detectable phase and 
consequently screening with PSA and early treatment can prevent further dedifferentiation. 
Various retrospective and prospective studies have addressed the evaluation of prognostic 
factors at entry relative to disease progression. The factors evaluated are 1) PSA and related 
derivatives like PSA-doubling time (PSA density), the ratio between free and total serum PSA 
(FT-ratio), and prostate size corrected PSA (PSA density), and 2) biopsy related information 
like biopsy grade, cancer length, and the number of positive biopsies. Comorbidity and age 
influence overall survival, but are not correlated to disease progression.237-239 In two studies 
the initial PSA and PSA doubling time obtained during the follow-up correlated significantly 
with clinical progression.59,213,226 In another study PSA density and F/T-ratio correlated well 
with disease progression, while the absolute annual PSA increase did not.60,240 Zietman et 
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al. found that age was the most important determinant for remaining free from therapeutic 
intervention.240
In the studies published on watchful waiting,59,60,213,226,240 most authors feel that patients 
should be followed at 3–6-monthly intervals, and 3-monthly during the first 1–2 years. A 
3-monthly interval during the initial period of follow-up will provide many PSA values, which 
gives the opportunity to consider biological variation and to calculate the PSA density. All 
authors used DRE during the follow-up visits in order to detect progression. A repeat biopsy of 
6-12 cores, either 6-monthly, yearly or 18-monthly, or on indication, was used to detect grade 
progression.59,60,226,240
Parameters for initiating treatment have been shown to be arbitrary, and are often governed 
by uncertainties and the patient’s psychological stress. The candidate criteria identifying 
those cases that tend to progress to a potentially incurable stage, are clinical stage (by DRE), 
PSA-increase (expressed in PSA density), grade progression (by repeat biopsy), and increase 
of tumor volume (as indicated by the number of positive repeat biopsies, or the tumor length 
in cores). In order to assess PSA changes over time adequately, many observations over a 
period of ≥ 2 years are necessary to take account of the biological variation of serum PSA 
when calculating PSA velocity and doubling times.241 Several groups have addressed the best 
way of determining PSA increases and there seems to be a growing consensus that PSA-DT is 
the most suitable variable.
All considerations of PSA-change over time are based on the assumption that PSA levels 
correlate with tumor mass, as has been found in some reports,242,243 but questioned lately.244 
Although there is a weak correlation between tumor mass and the absolute level of pretreat-
ment PSA, PSA changes as expressed in PSA density appear to correlate significantly with 
clinical progression,241,245 especially in early stages when no endocrine manipulations have 
been made. PSA doubling time is defined as the time PSA needs to double its start-value. To 
preserve a difference in men who for example have a PSA of 2 and 10, the 2logPSA should be 
used. The PSA doubling time can subsequently be calculated by 1/slope. The slope denotes 
the slope through all 2log PSA values.
The use of PSA doubling time as a decision tool is based on the observation that preoperative 
PSA levels are significantly correlated with the tumor volume in radical prostatectomy speci-
mens.243 It is furthermore based on the knowledge that PSA values have an exponential course 
in individual non-treated patients.242 The PSA doubling time should therefore be a straight 
line in a log-plot.183 It is intuitively correct that the PSA doubling time is a good indicator for 
tumor growth, and this assumption is supported by studies which show that PSA doubling 
time is a strong predictor for the risk of metastases and death due to prostate cancer after 
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radical prostatectomy or radiotherapy.246,247 McLaren et al. have shown that the PSA doubling 
time was the strongest predictor of clinical progression in conservatively treated men.213 Klotz 
described that in his active surveillance cohort the metastases free survival was 99 percent 
after 8 years. Initially, a PSA doubling time of less than two years led to curative treatment.183 
Khatami et al. have a significant relationship between the PSA doubling time and the bio-
chemical control in men who received a deferred prostatectomy.
If a given prostate cancer is indeed clinically insignificant, the doubling time will be more 
alike that of men without prostate cancer.248 Prostate cancer with a PSA doubling time < 3 
years is thought to have a poor prognosis. The 3 to 10 years range is unclear and needs further 
study. To minimize the chance of local progression, it is therefore advisable to perform a re-
peat biopsy during this time. A PSA doubling time longer than ten years suggests an indolent 
prostate cancer and therefore there is no need for a repeat biopsy. Clinical progression in 
locally confined disease with no in crease of PSA seems to be extremely rare. The PSA density 
during watchful waiting is extremely variable due to the presence of benign hyperplasia, and 
ranges between less than 2 years to over 50 years.249 When less than 4 years, disease progres-
sion by T-stage was reported in 27 percent of men on watchful waiting.226 A strong correla-
tion between PSA doubling time and clinical progression was also observed in the study of 
McLaren in which men on watchful waiting were stratified according to PSA density.213 Those 
with no PSA doubling time progression also did not show clinical progression, while all men 
with a PSA doubling time of less than 1.5 years progressed within one year. The utility of PSA 
doubling time needs to be established further.
The DRE has a high interobserver variability.59 In the different active surveillance studies, dif-
ferent thresholds for the clinical stage are used.59,60,250 The correlation between progression 
measured by DRE and that by PSA density is low.226
In conclusion, patient selection, follow-up and trigger points for treatment are still under 
investigation. Significant recent progress has however been made which allows the set-up of 
large scale studies.
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FUTURE DIRECTIONS
Based on the presented data and on the literature review provided in the general discus-
sion of this thesis, a prospective, observational active surveillance study has been initiated. 
This research endeavor has been named Prostate cancer Research International on Active 
Surveillance (PRIAS) and its outlines are described in this chapter. There is an internationally 
growing interest in the study of the natural course of the disease and the management of men 
with low-risk prostate cancer by active surveillance. Investigators from the British Columbia 
Cancer Agency (BCCA) and the University hospital of Helsinki (HYKS) have shown interest to 
collaborate intensely by sharing a centralized database based on the protocol and web-tool 
constructed in Rotterdam.
The PRIAS-project will deliver:
•	 A	web-based	decision	tool	for	active	surveillance
•	 Evidence	based	guidelines	(protocol)	for	active	surveillance
•	 A	longitudinal	biomaterial	bank
•	 A	database	of	active	surveillance	participants
•	 A	calculator	for	risk	of	progression
•	 Insight	in	health	related	quality	of	life	(HRQoL)	effects	of	active	surveillance
•	 Risk	 factors	 for	 increased	anxiety	and	choice	of	deferred	active	therapy	for	reasons	unre-
lated to progression of prostate cancer
Internet-based monitoring and decision tool
The website www.prias-project.org has been created for this study. It includes an information 
portal as well as an internet-based web-tool to facilitate and support clinicians to include 
and manage their active surveillance patients. The web-tool connects to an individual patient 
data files, which is password protected, and can only be entered by the physician, and by the 
data monitor of the study for quality control. This instrument is user-friendly and requires 
minimal handling in order to improve patient inclusion and follow-up compliance. Individual 
patient data are related to the protocol that supports monitoring and treatment decisions at 
every date of entry of follow-up data. The web-tool indicates the parameters used for decision 
making for the continuation of a patient on active surveillance, or for a change towards active 
treatment. All data entered into the web-tool become available in a structured database and 
will therefore be available for research.
The PRIAS protocol is divided into three parts: the biopsy protocol, the inclusion criteria and 
the follow-up protocol.
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Biopsy protocol
Based on the available literature, we created a biopsy protocol which has already been intro-
duced at our institution. In men with prostates smaller than 40 mL eight cores are obtained, 
in prostates 40-60 mL ten cores and in men with a gland larger than 60 mL 12 cores are taken. 
The reported undergrading of 20-30% is also compensated by the strategy for monitoring: 
repeated biopsies are included for follow-up.176,227-230,251
Eligibility (entry criteria)
A maximum PSA-level of 10 ng/mL was chosen in combination with a PSA-density limit of 
0.2 ng/mL/mL in order to correct for the influence of benign prostatic hyperplasia (BPH) at 
increasing age and with repeated screening.
The definition of active surveillance implies that included men should be fit to receive cura-
tive treatment at any time during their disease. This implies that men should have an organ 
confined (clinical stage T1c or T2) prostate cancer at the time of inclusion.
Not only the proportion of cancer invasion in the biopsies, but also the number of cores invaded 
with prostate cancer can be of help in the decision which treatment should be applied.234,252-254 
The criteria of Epstein et al. use the proportion of prostate cancer in the biopsy as well; they 
found that men with a Gleason score ≤ 6, with two or less biopsies positive for prostate cancer 
with less than 50% invasion have a high probability (79%) to have a minimal focus of prostate 
cancer (≤ 0.5 mL).176,177 this requires that every core is analyzed separately by the pathologist.
Inclusion criteria for the PRIAS study are:
•	 Patient	should	be	fit	for	curative	treatment
•	 PSA-level	at	diagnosis	10	ng/mL	or	less
•	 PSA	density	(PSA	D)	less	than	0,2
•	 Clinical	stage	T1C	or	T2
•	 Adequate	biopsy	sampling
•	 One	or	2	biopsy	cores	invaded	with	prostate	cancer
•	 Gleason	score	3+3=6	(or	less)
•	 Participants	must	be	willing	to	attend	the	follow-up	visits
Exclusion-criteria:
•	 Patient	can	not	or	does	not	want	to	be	irradiated	or	operated
•	 A	previous	therapy	for	prostate	cancer
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Follow-up protocol
Taking all information into account alluded to earlier in the discussion of this thesis, recom-
mendations regarding a balanced policy for monitoring and treatment indications can be 
made.255
Frequency of visits
It is unnecessary to calculate the PSA DT with every new PSA recording. The biological varia-
tion in serum PSA necessitates that calculation of PSA DT is based on several measurements. 
For this reason annual evaluations are recommended. At the end of the first year, an evalu-
ation on biochemical, clinical and histological progression can be made. By the end of the 
second year, the evaluation is based on at least DRE and PSA DT.
The argument for choosing a 3-monthly visit-schedule in the first two years and a semi-annual 
schedule thereafter is to recognize and filter out the fast growing tumors, which are not cor-
responding with the definition of clinically irrelevant tumors. Those are likely the tumors that 
were undersampled at diagnosis. By means of repeat biopsy, four PSA measurements and 
two DREs in the first year during the follow-up, men who have aggressive cancers should be 
identified. They would then have a therapy delay of a year. Most reports in the literature do 
not show a negative effect for this delay.250,256-259
The proposed pattern for repeat biopsies is a one, four, seven, ten, fifteen and twenty years 
biopsy scheme. These moments are arbitrary, but do corroborate with the randomized con-
trolled study of radical prostatectomy versus active surveillance START study. The number of 
biopsy cores is again indicated by our biopsy protocol. Besides the standard biopsies, a repeat 
biopsy is necessary if the PSA doubling time is between three and ten years. No more than 
one biopsy per year should be obtained. Repeat biopsy after 12-18 months often shows no 
cancer at all,260 but when upgrading is present, this may be the result of having missed the 
less differentiated parts in earlier biopsies. Upgrading therefore should be regarded as an 
indication for active treatment.
Decision parameters
PSA-doubling times, histology by repeat prostate biopsy, and clinical stage assessed by DRE 
are considered to be criteria for follow-up and change towards active therapy. For identical 
reasons, changes in PSAD and FT-ratio were chosen as parameters that need further study 
within this protocol.
During the first two years, three-monthly PSA determinations are needed to reliably calculate 
the PSA doubling time with at least three (but better four) values. A cut-off level of 3 years was 
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chosen in line with the most extensive active surveillance study on clinical cases performed so 
far by Klotz in which the cancer-specific survival at 8 years was 99,3 %.186
It is realized that small alterations on DRE might be the result of previous biopsy procedures 
or interobserver variability.14
Any indication of the presence of a larger (but previously missed) tumor, or a growing or 
multifocal tumor by an increase in the number of positive biopsies cores will be taken as an 
indication to advise curative treatment. The same is true for any increase of the Gleason grade 
that might be the result of understaging or dedifferentiation over time. The small decreases 
of understaging that saturation biopsies (more than 20 core samples) might give at the time 
of study entry are not considered to be in balance with the increase of patient discomfort that 
results from such an extra procedure.187
Nomograms
It is likely that in the near future nomograms will be used for the selection and follow-up of ac-
tive surveillance participants instead of fixed criteria. The Kattan nomogram for the prediction 
of indolent prostate cancer has been updated and recalibrated with the use of our cohort of 
screen-detected patients in whom a radical prostatectomy was performed.12,220 Although the 
Steyerberg nomogram has not been validated on clinical endpoints yet, it is very well possible 
that a certain probability for indolent cancer will serve as a cut-off for the eligibility of active 
surveillance programs. For example, for a 70% or higher probability of indolent disease using 
the Steyerberg risk indicator could prompt patients and doctors to consider active surveil-
lance. With the help of nomograms a custom-made risk profile is available that can reassure 
men in their choice for active surveillance.
Quality of life
It is known from the scarcely available studies that anxiety in patients is an important reason 
for choosing deferred curative treatment. This study provides the possibility of investigating 
this issue further by adding a quality of life component.
Shortly after entering the active surveillance protocol, baseline HRQoL and potential determi-
nants of unfavorable HRQoL while being on active surveillance and of a shift to active treat-
ment without medical reasons will be assessed. Factors assessed as potential determinants of 
unfavorable HRQoL include:
•	 Demographic	characteristics	(e.g.	level	of	education)
•	 Personality	characteristics	 (we	will	use	Eysenck	Personality	Questionnaire	–	 revised	Short	
Form261);
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•	 Knowledge	of	localized	prostate	cancer	and	of	effectiveness	of	treatment	options	(approx.	
10 items based on Nijs, Essink-Bot et al.262);
•	 ‘Risk	perception’:	estimation	of	own	risk	of	disease	progression,	and	perceived	seriousness	
of this risk (3 items, based on Van Dooren et al263, and Kruijshaar et al264)
•	 Decisional	 conflict	 (with	 the	 adaptations	 to	 assess	 decisional	 conflict	 regarding	prostate	
cancer treatment choice as proposed by Steginga et al 2004 (uncertainty about prostate 
cancer; men’s satisfaction and confidence with their treatment decision)65,265
At baseline and during follow-up, HRQoL will be assessed by:
•	 prostate	cancer-specific	quality	of	life:	EPIC266
•	 Generic	HRQoL:	SF-12	267
•	 Mental	 health:	 STAI-state	 (6-item	 version)268, CES-D 269, Impact of Event scale270; prostate 
cancer-specific anxiety271
The measures for the last three variables are chosen to allow for comparison of the data with 
data from patients who were actively treated by radical prostatectomy (radical prostatectomy) 
or external beam radiotherapy.40,272,273 The measures also follow recent reviews such as Penson 
et al., and international studies such as Steginga and Roth.65,146,271
The HRQoL study will include biannual follow-up in the first two years and annual follow-up 
afterwards for the duration of the study. Follow-up assessments will include decisional conflict 
and HRQoL. Follow-up data will be collected irrespective of whether the patient elected active 
therapy or not (data collection following ‘intention to treat’ principle).
In addition to the regular (bi)annual HRQoL assessments, patients who are referred to active 
treatment will be interviewed by telephone to explore the feelings of the patient around the 
deferred treatment. In case of a choice for active treatment for other reasons than disease pro-
gression (as defined in the study protocol), the reasons for change of therapy are explored.
Analysis of HRQoL data will be directed at:
•	 Description	of	HRQoL	over	time	(repeated	measures	analysis	of	variance),	both	for	the	group	
as a whole and by subgroup (those still on active surveillance versus those with deferred 
active therapy).
•	 Comparison	with	HRQoL	data	of	patients	who	underwent	radical	prostatectomy	and	exter-
nal beam radiotherapy.272,273
•	 Analysis	of	associations	of	baseline	characteristics	(demographic	characteristics,	personal-
ity characteristics, knowledge, risk perception, decisional conflict) with unfavorable HRQoL 
scores at later time points, and with a shift to active treatment for non-medical reasons.
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A prognostic model to predict ‘referral to active treatment’
Potential practical applications of the results of these analyses include (a) the selection of 
patients for active surveillance: if groups can be identified who are at high risk of negative 
HRQoL effects of being on active surveillance, this information may be used in the interaction 
between doctor and patient when discussing treatment options for localized prostate cancer; 
and (b) the potential of offering psychosocial support to men on active surveillance who are 
at high risk of unfavorable HRQoL or for shifting to active treatment without medical reasons. 
Hence, the results of the HRQoL study will contribute to prevention of unfavorable HRQoL 
and/or ‘unnecessary’ active treatments of localized prostate cancer.
Psychosocial interventions with favorable effects on HRQoL among patients with localized 
prostate cancer are found in the literature, see e.g. Penedo et al., Steginga et al. and Dauben-
mier et al.67,274,275
Endpoints
The main endpoints for the PRIAS study are:
•	 Percentage	of	disease	progression	as	indicated	by	a	change	of	parameters
•	 Time	to	disease	progression
Secondary endpoints are:
•	 The	number	of	men	on	active	surveillance	as	a	proportion	of	the	total	number	of	prostate	
cancers detected in a region
•	 The	number	of	men	who	shift	from	active	surveillance	to	active	treatment
•	 Median	time	to	treatment
•	 Treatment	modality
•	 Outcome	of	treatment	(staging,	grading)
•	 Reason	for	treatment	alterations
•	 Quality	of	life,
•	 (Time	to)	overall	death
•	 (Time	to)	prostate	cancer	death
Other research initiatives
Prostate testing for cancer and Treatment (ProtecT)
The ProtecT study is an ongoing, multi-centre, randomized trial of treatments for localized 
prostate cancer in which asymptomatic men aged 50–69 years in nine parts of the UK (Bir-
mingham, Bristol, Cambridge, Cardiff, Edinburgh, Leeds, Leicester, Newcastle and Sheffield) 
are invited for prostate cancer testing. Men diagnosed with localized prostate cancer are asked 
to consent to a three-arm treatment trial of prostatectomy, radiotherapy or active monitoring 
(i.e. active surveillance). The study is open for recruitment from June 2001 until May 2008.
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The overall aim is to evaluate the effectiveness, cost-effectiveness and acceptability of treat-
ments for men with localized prostate cancer within the context of a pragmatic randomized 
controlled trial. Specific objectives are as follows:
1) To assess survival at 5, 10 years and 15 years following treatment
2) To investigate a number of short and medium-term outcomes, including: disease pro-
gression (biochemical and clinical), treatment complications, lower urinary tract symptoms, 
psychosocial impact of case-finding and treatment, including generic health status, quality of 
life and sexual function
3) To estimate the resource use and costs of case-finding, treatment and follow-up, and to 
compare costs and outcomes of treatment in terms of survival and health related quality of 
life.
4) To collect material suitable for basic science research, and develop a network for col-
laborative research.
Standard Treatment Against Restricted Treatment (START)191
In this trial, patients with favorable-risk disease are randomized between active surveillance 
and the patient’s choice of standard therapy (surgery, brachytherapy, or external beam). The 
end point is prostate cancer–specific mortality. The trial will be implemented by the Clinical 
Trials Support Unit of the National Cancer Institute of the USA. Randomization should start in 
the beginning of 2007.
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Summary 
The first part of this thesis includes a historical overview (chapter 1) and an introduction 
(chapter 2) to the problems which are encountered by prostate-specific antigen (PSA) screen-
ing for prostate cancer. It provides an introduction to the “European Randomized study of 
Screening for Prostate Cancer (ERSPC)”. It furthermore describes the uncertain effect of the 
screening test, as well as its side-effects, of which overdiagnosis with subsequent overtreat-
ment causes most concern. The scope of this thesis (chapter 3) assumes that the detection 
of low-risk overdiagnosed cancer can at present not be avoided. Therefore, based on current 
literature, including the reports from this thesis, a strategy called active surveillance has been 
developed.
The second part of this thesis deals with effects of screening for prostate cancer. Chapter 4 
compares the preliminary outcome of cancers detected in the screen and the control arm 
of the Rotterdam section of the ERSPC by means of biochemical progression rates. Although 
significantly more cancers were detected in the screen than in the control arm (1,339 vs. 298), 
their clinico-pathological features were more favorable. Furthermore, screened men had 
higher 5-year biochemical progression-free survival rates after surgery (84.4% vs. 58.9% in 
controls), radiotherapy (71.0% vs. 58.0%), and endocrine therapy (40.5% vs. 16.3%). The higher 
biochemical progression-free survival can at least in part be explained by stage migration 
related to lead and length-time. How screening will affect the mortality remains unclear.
Chapter 5 illustrates how PSA screening has changed the characteristics of the disease 
prostate cancer. It provides outcomes of two cohorts of men from two well-defined geo-
graphical areas diagnosed with prostate cancer and exposed to different intensities of pros-
tate cancer screening. A cohort of 822 men from the screen arm of the ERSPC was compared 
to 947 men in a non-screened, non-randomized cohort, who were diagnosed with prostate 
cancer between January 1989 and December 1997 in a geographically neighboring region. 
The five- and ten year overall survival rates were higher in the screened cohort than in the 
non-screened cohort (88.8% versus 52.4%, and 68.4% versus 29.6%, respectively; P<0.001). 
Significant differences in survival were seen for all age-, stage-, and grade subgroups, except 
for metastatic disease at diagnosis. The impact of lead time and overdiagnosis on overall sur-
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vival could not be assessed, but is expected to be the main cause of the observed differences 
between the two cohorts.
Since the beginning of the ERSPC, the use of PSA as a screening tool has become increas-
ingly prevalent in the general population and therefore also in the control arm of the study 
(i.e. contamination). Chapter 6 presents a feasibility study and an explorative simulation of 
the impact of adjusting for contamination and non-compliance according to Cuzick et al. (Stat 
med 1997) applied to the Rotterdam section of the ERSPC. A secondary analysis conducted 
with such adjustments allows to estimate the effect of screening in those men who comply 
with all aspects of screening; it gives an answer to the question “what happens to me if I get 
screened”. The intention to screen analysis allows to judge the effect of a screening program 
applied to the general population. This simulated secondary analysis assumes reductions in 
prostate cancer mortality as endpoints but utilizes actual data of non-compliance and con-
tamination by PSA use in ERSPC Rotterdam. Of the men allocated to the screen arm, 27.1% 
were noncompliant. In the control arm, 6,499 men (30.7%) had their PSA measured by a gen-
eral practitioner for various but undetermined reasons (i.e. contamination). For a scenario in 
which the intention-to-screen analysis was assumed to show a decrease in prostate cancer 
mortality in the screened men of 6.7%, the secondary analysis based on those willing to ac-
cept their randomized allocation resulted in a decrease of 16.1% for those actually screened. 
Adjustment for non-compliance and contamination was shown to be feasible in this prostate 
cancer screening trial. It can therefore be used to carry out a secondary analysis in ERSPC 
Rotterdam and in ERSPC as a whole.
The third part of this thesis provides insight into the risk-stratification of screen-detected pros-
tate cancers. Chapter 7 illustrates that a family history of prostate cancer is an important 
risk factor for finding prostate cancer at biopsy. The clinical presentation and prognosis of 
familial disease remain uncertain. These parameters were evaluated in the first and second 
rounds of ERSPC Rotterdam. Information regarding the family history was obtained by a self-
administered questionnaire from all participants at baseline. In the prevalence screen the 
cancer detection rate in 1,364 men (7.1%) with a positive family history was 7.7% (106 cancers 
in 1,364 screened men with a positive family history) while the positive predictive value of 
the biopsies was 32.2% (154 cancers of 532 biopsies). In 12,803 sporadic cases the detection 
rate was 4.7% and the positive predictive value was 23.6% (p <0.0001 and 0.003, RR 1.63). 
No clinico-pathological differences were found between the two groups in the 1,559 men 
diagnosed in the first and second rounds. The overall biochemical progression-free survival 
rate after a mean follow-up of 56.8 months (range 0 to 129.9) was 76.8%, and was not signifi-
cantly different in familial and sporadic cases (p = 0.840). These findings were consistent for 
the specific treatment modalities as well. Thus, although screened men aged 55 to 75 years 
diagnosed with prostate cancer who have a father or a brother with prostate cancer are at a 
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substantially greater risk, the clinical presentation and prognosis by biochemical progression 
are not different compared to sporadic cases.
Screening for prostate cancer has not only led to a stage migration, but also to a higher 
incidence. A decrease in mortality has occurred in several countries during the same time 
period. Risk stratification of screen-detected cancers at diagnosis has become important for 
the anticipation and interpretation of changing incidence and incidence-to-mortality ratios. 
Chapter 8 contributes to the extreme side of the risk spectrum: the predictors of metastatic 
disease. From 1993 to 1998, 633 men were diagnosed with non-metastatic prostate cancer 
in the prevalence screen of the Rotterdam section of ERSPC. During the median follow-up of 
7.5 years, 41 men developed metastatic disease. After 10 years the metastasis-free survival 
rate was 89.6%, the overall survival 64.7%. In a Cox model 2logPSA, biopsy Gleason score 
and the number of biopsy cores with prostate cancer were independent predictors for the 
development of metastases; the latter only predicted metastases that presented within 60 
months of follow-up. The metastasis-free survival of men with prostate cancer detected in our 
prevalence screen was high. Whether this is related to the beneficial effects of screening or to 
overdiagnosis due to screening (or both) remains unclear. The prognostic factors known for 
clinically diagnosed disease also hold for screen-detected disease.
The stage and grade shift of currently diagnosed prostate cancer has led to a diminished 
prognostic power of the Gleason score system. We investigated the predictive value of the 
amount of high-grade cancer (Gleason growth patterns 4/5) in the biopsy for prostate-specific 
antigen (PSA) and clinical relapse after radical prostatectomy (chapter 9). PSA-tested par-
ticipants (N=281) of ERSPC who underwent radical prostatectomy were analyzed. Besides 
clinical features and serum-PSA, histopathologic features as determined in the diagnostic 
biopsy and matching radical prostatectomy specimen were related to patient outcome. At 
a median follow-up of 7 yr, 39 (13.9%), 24 (8.5%), and 12 (4.3%) patients had PSA≥0.1 ng/
mL, PSA≥1.0 ng/mL, and clinical relapse after radical prostatectomy, respectively. Using Cox 
proportional hazards, PSA level (p=0.002), length of tumor (p=0.040), and length of high-
grade cancer (p=0.006) in the biopsy, but not Gleason score, were independent prognostic 
factors for biochemical relapse (PSA≥0.1 ng/mL) when assessed as continuous variables. In 
radical prostatectomies, the proportion of high-grade cancer (p<0.001) was most predictive 
of relapse (PSA≥0.1 ng/mL). For PSA≥1.0 ng/mL and clinical relapse, the amount of high-
grade cancer, both in the biopsy specimen (p=0.016 and p=0.004, respectively) and radical 
prostatectomy specimen (p=0.002 and p=0.005, respectively), but not Gleason score, was an 
independent predictor. In biopsy and radical prostatectomy specimens of surgically treated 
prostate cancer, the amount of high-grade cancer is superior to the Gleason grading system 
in predicting patient outcome. We propose that, in addition to the Gleason score, the amount 
of Gleason growth patterns 4/5 in the biopsy (whether absolute length or proportion) should 
be included in the pathology report.
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The objective of chapter 10 is to determine what proportion of screen-detected cancers 
are indolent and can be considered for active surveillance. Nomograms provide predictions 
for individual patients based on multivariate analyses of large patient cohorts. These are likely 
to provide the best mechanisms for the selection of candidates for active surveillance strat-
egies, because they are focused on individual patients rather than groups of patients. The 
Kattan et al. nomogram for the prediction of indolent prostate cancer has been validated and 
re-calibrated for use in a screening setting. That nomogram was used to calculate the number 
of men who were predicted to have indolent cancer in a screen-detected cohort from the 
Dutch section of the European Randomized study of Screening for Prostate Cancer (ERSPC). 
Eligibility criteria for nomogram use were: 1) clinical stage T1C or T2 disease, 2) PSA 20 ng/mL 
or less, 3) primary and secondary Gleason grade at most 3 in any biopsy core, 4) positive cores 
50% or less, 5) total cancer in biopsy cores 20 mm or less and 6) benign tissue in all cores 40 
mm or more. Of 1,629 prostate cancers detected in two subsequent screening rounds 825 
were eligible for nomogram use. A total of 485 men (485 / 825 = 59%) were predicted to 
have indolent prostate cancer, which is 30% (485 / 1,629) of all screen-detected cases. Cancers 
found at repeated screening after four years had a higher probability of indolent prostate 
cancer than cases from the prevalence screening (44% vs. 23%; P<.001). With the help of this 
nomogram substantial groups of screen-detected prostate cancers can be identified which 
are likely to be indolent and can therefore be considered for active surveillance.
Opportunistic screening for prostate cancer has resulted in an increasing incidence in the 
Netherlands and many other parts of the world. For ethical, medical, and economic reasons 
it is necessary to decrease overdiagnosis and overtreatment and to define which patients 
can be managed by active surveillance. In the fourth part of this thesis, active surveillance 
was studied as a way out of the overdiagnosis dilemma. For the study in chapter 11, men with 
criteria that reflect current active surveillance studies were selected: those with a biopsy Glea-
son score ≤3+3 in two or fewer cores, with a PSA density <0.2 and a maximum PSA-level of 
15 ng/mL. Clinical stage had to be T1C or T2. Of the 1,014 prostate cancers detected in the 
prevalence screen, 293 men (28.9%) met the criteria for active surveillance. Their mean age 
was 65.7 years and the mean PSA level was 4.8 ng/mL. Radical prostatectomy was elected by 
136 men (46.4%), radiotherapy by 91 (31.1%), and watchful waiting by 64 (21.8%). The mean 
follow-up was 80.8 months. The eight-year prostate cancer-specific survival was 99.2%; the 
overall survival was 85.4%. Nineteen men who chose active surveillance changed to definitive 
treatment during follow-up. Only three men died of prostate cancer, none of these were on 
active surveillance. Our observations provide preliminary validation of the arbitrary selection 
criteria for active surveillance.
Chapter 12 describes the PSA changes in a cohort of men from the ERSPC that initially were 
managed with active surveillance for prostate cancer. In this group, the PSA changes with time 
were studied in 278 patients with histologically proven prostate cancer, clinical stage T1c or 
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T2, a PSA-level 15 ng/mL or less and a biopsy Gleason score less than 8. The choice for watch-
ful waiting was based on patients’ wish or physicians’ advice. PSA slope and PSA doubling time 
(PSA DT) were calculated in patients with three or more PSA test results available (N=233). 
Mean age at diagnosis was 70 years and the median PSA was 3.6 ng/mL. Of the patients 94.2% 
had a Gleason score of 3 + 3 or lower and 44.2% had a negative PSA doubling time or a dou-
bling time longer than 10 years. It can be concluded from this study that in screen-detected 
prostate cancer a considerable subset of men show stable or even decreasing PSA values with 
time, and that this group of men have long PSA doubling time of more than 10 years. These 
males profit from an active surveillance policy with delayed treatment.
The fifth part of this thesis gives a literature overview and puts the described chapters into 
perspective. It furthermore describes the evidence which forms the basis for a prospective 
study which is for a large part based on this thesis: the PRIAS-project (Prostate cancer Research 
International: Active Surveillance), which is described in the epilogue. We hope to establish 
evidence-based guidelines for the management of clinically indolent cancer, which would 
allow to limit active treatment to those who need it and would reduce the harmful side effects 
of early detection. We will make a web-based decision tool available for proper selection and 
active surveillance that will contribute to prevent overtreatment of indolent prostate cancer 
and reduce health care costs. Future candidate prognostic factors can be tested in a carefully 
built database and biorepository. Our study will allow to identify men at risk of ‘unnecessary’ 
active treatment and allow the identification of subgroups who may be offered additional 
psychosocial support. If successful, the results can be incorporated in a modeling analysis of 
cost and effects (MISCAN) of screening policies in the Netherlands.
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Samenvatting 
Deel 1 van dit proefschrift geeft een overzicht van de historie van prostaatkankeronderzoek en 
haar behandeling (hoofdstuk 1). Hoofdstuk 2 geeft een introductie in de gevolgen en de pro-
blemen van vroegopsporing naar prostaatkanker. Het is onbekend of vroegopsporing leidt tot 
een reductie in het aantal prostaatkankerdoden. Wel is duidelijk dat vroegopsoring leidt tot een 
forse toename van het aantal nieuw-gediagnosticeerde prostaatkankers per jaar (incidentie). 
Momenteel is er geen screeningsmethode beschikbaar waarbij alleen de potentieel gevaarlijke 
kankers gedetecteerd worden. In de doelstelling van dit proefschrift (hoofdstuk 3) wordt uit-
gelegd dat de huidige situatie, waarin al deze ongevaarlijke kankers worden gediagnosticeerd, 
voor dit moment wordt geacepteerd. Deze situatie van overdiagnose is de uitgangssituatie van 
dit proefschrift. Overdiagnose leidt dikwijls tot overbehandeling. In dit proefschrift wordt een 
methode beschreven waarbij het gerechtvaardigd is om bij geselecteerde kankers af te wach-
ten met behandelen. Uit de gerandomiseerde screeningstudie voor prostaatkanker (ERSPC) 
is berekend dat ongeveer 50% van de vroeg ontdekte prostaatkankers zeer klein en weinig 
aggressief zijn en waarschijnlijk nooit zullen leiden tot symptomen. Deze kankers zouden dan 
ook niet behandeld moeten worden, tenzij ze tijdens het vervolgen tekenen van groei verto-
nen. Een dergelijk afwachtend beleid wordt ‘active surveillance’ genoemd.
In deel 2 van dit proefschrift wordt het onderzoek beschreven naar de effecten van vroegopspo-
ring naar prostaatkanker. Hoofdstuk 4 vergelijkt de overleving van mannen in de interventie-arm 
van de ERSPC met de controle-arm. Het eindpunt voor deze studie was biochemische progressie. 
In de interventie arm van het Rotterdamse gedeelte van de ERSPC werden 1.339 prostaatkankers 
gevonden, terwijl in dezelfde periode slechts 298 kankers werden gediagnosticeerd in de controle 
arm. De klinische en pathologische parameters waren echter gunstiger in de interventie groep. 
Dit resulteerde ook in een betere biochemische progressie-vrije overleving, zowel na prostatec-
tomie, na radiotherapie als na hormonale behandeling. Deze uitkomsten kunnen in ieder geval 
gedeeltelijk verklaard worden door het feit dat vroegopsporing kankers eerder in hun beloop 
vindt. Uit deze studie kan niet worden geconcludeerd of vroegopsporing de sterfte reduceert.
Hoofdstuk 5 illustreert dat de komst van PSA en het gebruik ervan in het kader van 
vroegopsporing de ziekte prostaatkanker in belangrijke mate heeft veranderd. In dit hoofd-
stuk worden mannen met prostaatkanker uit de interventie-arm van de ERPSC Rotterdam 
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(N=822) vergeleken met een groep mannen met prostaatkanker uit Zeeland welke in dezelfde 
periode werden gediagnosticeerd (N=947). Bekend was dat de intensiteit van PSA vroegop-
sporing in Zeeland laag was. Mannen in het Zeeuwse cohort hadden veel verder gevorderde 
ziekte ten tijde van diagnose. De 10-jaars overleving was significant hoger in de gescreende 
groep dan in het Zeeuwse cohort (68.4% versus 29.6%). Met uitzondering van metastasen op 
afstand bleven deze verschillen ook bestaan na correctie voor leeftijd, stadium en differentia-
tiegraad. Op basis van deze studie is het niet mogelijk om uitspraken te doen over het effect 
van vroegopsporing, maar wel over het veranderde gezicht dat prostaatkanker als gevolg van 
vroegopsporing heeft gekregen.
De uitkomsten van de ERSPC zullen gebaseerd zijn op een intention-to-screen analyse 
waarin de sterfte van de hele groep mannen die gerandomiseerd werd in de interventie arm 
wordt vergeleken met de sterftecijfers van de hele groep mannen in de controle arm. Echter, 
er zijn ook mannen in de interventie-arm die niet bereid zijn deel te nemen aan het hele scree-
ningsalgoritme. Bovendien is sinds het begin van de ERSPC in 1993 het gebruik van de PSA-
test in de algemene bevolking en dus ook in de controle arm van de ERSPC fors toegenomen. 
Hoofdstuk 6 bevat een haalbaarheidsstudie naar het toepassen van een secundaire analyse 
op de ERSPC. In een secundaire analyse wordt gemeten wat het effect is van vroegopsporing 
in die mannen die bereid zijn deel te nemen aan het vroegopsporingsalgoritme. Een derge-
lijke analyse corrigeert voor het gebruik van PSA in de controle arm en het corrigeert voor 
non-participatie in de interventie-arm. Van alle mannen in de interventie-arm nam 27.1% niet 
aan het gehele vroegopsporingsprogramma deel. In de controle-arm liet 30.7% van de deel-
nemers een of meerdere PSA’s bepalen door een huisarts. In een scenario waarin de primaire 
analyse van de ERSPC een sterftereductie zou geven van 6.7%, zou de secundaire analyse op 
16.1% uitkomen voor die mannen die daadwerkelijk gescreend werden. Geconcludeerd kon 
worden dat een dergelijke secundaire analyse van de ERSPC belangrijk en uitvoerbaar is.
Het derde deel van dit proefschrift bevat uitkomsten van onderzoek naar de risico-stratificatie 
van door vroegopsporing gevonden prostaatkankers. Vroegopsporing naar prostaatkanker 
heeft niet alleen geleid tot een stadium migratie, maar ook tot een hogere incidentie. Bovendien 
is de sterfte aan prostaatkanker nagenoeg gelijk gebleven, of zelfs licht gedaald. Het is daarom 
steeds belangrijker geworden om het risico dat iedere kanker met zich meebrengt goed in 
te kunnen schatten. In hoofdstuk 7 is de waarde van een positieve familieanamnese op het 
voorkomen en de prognose van prostaatkankers onderwerp van studie. Op basis van data uit 
de eerste twee onderzoeksrondes van de ERSPC Rotterdam kon worden geconcludeerd dat het 
hebben van een vader en/of een broer een risiscofactor is voor het krijgen van prostaatkanker 
(RR 1.63). Gedurende mediaan 56.8 maanden na diagnose bleek de prognose, afgemeten aan 
de biochemische progressie-vrije overleving, echter niet significant verschillend.
In hoofdstuk 8 worden risicofactoren geidentificeerd van mannen bij wie ten tijde van 
diagnose geen metastasen konden worden aangetoond, maar bij wie zich later in het beloop 
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wel metastasen ontwikkelden. Van 1993 tot 1998 werd bij 633 mannen niet gemetastaseerde 
prostaatkanker gediagnosticeerd. Gedurende een follow-up van 7,5 jaar werd bij 41 van hen 
metastasen gevonden. De 10-jaars metastase-vrije overleving bedroeg 89,6%; de algemene 
overleving 64,7%. In een multivariabel model volgens Cox bleken 2logPSA, biopsie Gleason 
score en het aantal biopten met prostaatkanker per biopsie onafhankelijke voorspellers voor 
het ontwikkelen van prostaatkankermetastasen. Het aantal mannen met prostaatkanker die 
geen metastasen ontwikkelden was opmerkelijk hoog. Het is onduidelijk in hoeverre dit het 
gevolg is van de gunstige effecten van vroegopsporing en in hoeverre van de overdiagnose. 
De geidentificeerde prognostische factoren voor door vroegopsporing gevonden kankers zijn 
dezelfde als die voor klinisch gediagnosticeerde kankers.
De Gleason score is een van de meest belangrijke prognostische factoren voor prostaat-
kanker. Echter, door toedoen van vroegopsporing naar prostaatkanker en de resulterende 
beweging naar laaggradige, laag-stadium prostaatkankers heeft de Gleason score een ge-
deelte van haar kracht als voorspeller verloren. Hoofdstuk 9 beschrijft een studie naar de 
predictieve waarde van de hoeveelheid hoog-gradige (Gleason patroon 4 en 5) prostaat-
kanker in het biopt op de PSA-terugkeer en op de klinische terugkomst van de ziekte. Het 
studiecohort bestond uit 281 mannen uit de ERSPC die een prostatectomie ondergingen. Na 
deze groep mediaan 7 jaar vervolgd te hebben, hadden 39, 24 en 12 mannen een PSA≥0,1 
ng/mL, PSA≥1,0ng/mL en klinische ziekteterugkomst. In een multivariabel Cox model bleken 
PSA, lengte van de tumor en lengte van hooggradige tumor in de biopsie significante voor-
spellers te zijn van ziekteterugkeer. De Gleason score was hier geen significante voorspeller. 
De lengte van hooggradige kanker in het biopt bleek de belangrijkste voorspeller te zijn voor 
de terugkeer van prostaatkanker na een prostatectomie. We stellen dan ook voor dat, naast 
de Gleason score, ook de lengte van Gleason patroon 4/5 in het pathologie rapport vermeld 
zou moeten worden.
Daar de incidentie:mortaliteit ratio voor prostaatkanker sterk is toegenomen, is het be-
langrijk om kankers goed te kunnen classificeren naar risico. Een manier om dit te doen is 
het gebruik van nomogrammen. In hoofdstuk 10 wordt een nomogram gebruikt om te be-
rekenen hoeveel mannen uit het ERSPC cohort indolente ziekte hebben en op basis daarvan 
in aanmerking zouden komen voor het voeren van een afwachtend beleid. Het gebruikte 
nomogram werd afgeleid van het Kattan nomogram en is gevalideerd en ge-recalibreerd met 
behulp van de ERSPC data. Van 1.629 mannen bij wie in de eerste twee rondes prostaatkanker 
werd gevonden, kwamen 825 in aanmerking voor het gebruik van het nomogram. De overige 
mannen hadden ziekteparameters waarbij het onwaarschijnlijk was dat zij indolente ziekte 
zouden hebben. Van de 825 mannen hadden 485 (59%) berekende indolente ziekte. Dit is 
30% van de totale groep mannen. Als kankers in de tweede ronde werden gevonden, dan 
was de kans op indolente ziekte groter dan bij eerste ronde kankers (44% vs 23%; P<.001). Dit 
nomogram kan in de toekomst gebruikt worden om te beoordelen of mannen in aanmerking 
komen voor een afwachtend beleid.
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In het vierde deel van dit proefschrift wordt onderzoek gepubliceerd naar een manier om te 
zorgen dat de overdiagnose die het gevolg is van vroegopsporing niet overgaat in overbehan-
deling met de geassocieerde bijwerkingen. Ethische, medische en financiele argumenten zul-
len de urologische gemeenschap ertoe dwingen om bij iedere nieuwe prostaatkankerpatient 
te evalueren of het mogelijk is om bij de patient af te wachten met het behandelen. In hoofd-
stuk 11 worden selectiecriteria voor zo’n afwachtend beleid toegepast op alle mannen die 
in de eerste ERSPC ronde gedetecteerd werden. Deze selectiecriteria waren: klinisch stadium 
T1C of T2; Gleason score 3+3 of minder; PSA dichtheid 0.2 of kleiner en een maximum PSA van 
15 ng/mL. Van 1.014 mannen kwamen 293 (28.9%) hiervoor in aanmerking. Hun gemiddelde 
leeftijd bedroeg 65,7 jaar en de gemiddelde PSA waarde was 4,8 ng/mL. Van deze mannen 
die in principe in aanmerking gekomen waren voor het afwachtende beleid ondergingen in 
werkelijkheid 136 mannen een prostatectomie, 91 radiotherapie en bij 64 werd daadwerkelijk 
afgewacht. De follow-up was 80.8 maanden. De 8-jaar prostaatkanker-specifieke overleving 
was 99.2%; de algehele overleving 85.4%. Drie mannen overleden aan prostaatkanker; niet 
een uit de afwachtend beleid groep.
Als eenmaal de juiste mannen zijn geselecteerd bij wie afgewacht kan worden met behan-
delen, dan is vervolgens belangrijk om op het juiste moment bij de juiste mannen wel in te 
grijpen. PSA-kinetica spelen hierbij een belangrijke rol. Hoofdstuk 12 beschrijft deze in een 
cohort van 278 mannen met door vroegopsporing gevonden prostaatkanker bij wie werd 
afgewacht met behandelen. Alle mannen hadden T1C/T2, PSA≤15 ng/mL, Gleason score≤3+3 
prostaatkanker. De PSA verdubbelingstijd werd berekend in mannen met tenminste drie PSA-
metingen (N=233). Van deze mannen had 44.2% een PSA verdubbelingstijd langer dan 10 jaar 
of een halveringstijd. Geconcludeerd kon worden dat er een belangrijke groep mannen is die 
zonder dat er ingegrepen wordt, stabiele ziekte hebben en dat er zelfs een aanzienlijke groep 
is bij wie het PSA daalt over de tijd.
Het vijfde deel van dit proefschrift geeft een literatuur overzicht en plaatst de onderzochte 
items in perspectief. Verder geeft het de wetenschappelijke basis weer voor de prosectieve 
studie die het resultaat is van dit proefschrift: de PRIAS studie (Prostate cancer Research 
International: Active Surveillance). Deze internationale studie wordt nader toegelicht in de 
epiloog van dit proefschrift. Wij zijn voornemens om richtlijnen te creeren die gebaseerd zijn 
op wetenschappelijk onderzoek. Verder is het ons doel om de overbehandeling van prostaat-
kanker zoveel mogelijk te beperken zonder daarmee de overlevingscijfers van deze ziekte 
nadelig te beinvloeden. Via deze weg proberen wij de nadelige effecten van vroegopsporing 
naar prostaatkanker te minimaliseren. We creeren een beslisprogramma voor behandelaars 
van prostaatkankerpatienten dat via internet beschikbaar is (www.prias-project.org). Daar-
mee limiteren we ook de kosten van de gezondheidszorg. Bovendien kan een database, een 
serumbank en een weefselbank worden opgebouwd, waarmee verder onderzoek gedaan kan 
worden. Tevens wordt een kwaliteit-van-leven studie geimplementeerd.
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Dankwoord 
‘Hoge toppen, diepe dalen’
Op het moment dat ik dit schrijf kan ik me nog moeilijk voorstellen hoe het is om op een later 
moment dit boekje in mijn handen te hebben. Het schrijven van een proefschrift is voorwaar 
geen sinecure; het kost veel tijd en moeite. Momenten van euforie werden afgewisseld met 
tijden van relatieve somberte. Er zijn een aantal mensen die ik moet bedanken omdat ze een 
bijdrage hebben geleverd aan het huidige proefschrift of omdat ze zelfs een voorwaarde 
waren voor het ontstaan ervan.
Allereerst professor Schröder. Ik ben zo trots en blij dat ik bij u kan promoveren. U heeft me 
laten zien dat integriteit het belangrijkste bezit is voor een wetenschapper. Het is heel mak-
kelijk om dit te verliezen, maar lastig om op te bouwen. Pas in Amerika viel me echt op hoe 
belangrijk u in de afgelopen decaden bent geweest voor de urologie. U heeft me erg vrij 
gelaten in het onderzoek. Dat u mijn promotor bent is een groot voorrecht.
De overige leden van de kleine commissie, te weten professor Bangma, professor Habbema 
en professor Witjes wil ik bedanken voor hun beoordeling van het manuscript en voor het 
zitting nemen in de kleine commissie. Beste Chris, ik hoop op de door jou geleide afdeling 
urologie een goed uroloog te worden.
De kleine commissie wordt aangevuld met professor Horenblas, professor Bosch, Harry de 
Koning en Wytze Hoekstra. Allen hartelijk dank voor het zitting nemen in de commissie. Beste 
Harry, misschien kunnen we nog eens een arctische huskytocht maken?
Dank gaat ook uit naar alle deelnemende mannen aan de ERSPC. In Rotterdam ruim 42,000; 
internationaal ruim 250,000. Zonder hen immers geen proefschrift.
Ik heb het geluk gehad onderdeel te zijn van een leuke en goede onderzoeksgroep. Monique, 
‘vaste tweede’, het is fijn om elkaar met weinig woorden te begrijpen. Dank voor je ‘tips and tricks’. 
Zonder jouw geen ERSPC in zijn huidige vorm. Hoeveel papers gaan we nog samen schrijven?
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Claartje, wat heb jij een ander leven dan ik. Ik heb bewondering voor je doorzettingsver-
mogen! De baby’s kwamen er en die promotie komt er ook!
Tineke en Rodderick, ondanks dat ik maar weinig of geen tijd met jullie heb mogen door-
brengen op het screeningsbureau, ben ik heel blij dat jullie er zijn. Ik ben benieuwd wat jullie 
ervan gaan maken.
Monique en Roderick: PRIAS, let’s make it happen!
Uiteraard ook dank aan alle co-auteurs, zij die het risico wilden lopen bij te dragen aan mijn 
publicaties. Met name veel dank aan professor van der Kwast. Beste Theo, ik vind het heel 
jammer dat de afstand Toronto-Rotterdam te groot is gebleken om in mijn commissie deel te 
nemen. Jouw inbreng in de ERSPC is van onschatbare waarde. Dank voor je gedegen en snelle 
commentaar.
Ries, misschien ontken je het, maar jij bent belangrijk geweest voor mijn promotie. ‘Thin-
king out of the box’ beheers jij als geen ander. Dat levert je soms problemen op, maar bleek 
voor mij enorm waardevol te zijn. Ik weet niet of Amsterdam haalbaar was, maar laten we nog 
vele marathons lopen.
Stijn, via jou ben ik eigenlijk dit onderzoek ingerold. Datte bedaankt zeit da witte. Jouw 
promotie komt vast goed!
De dames van het screeningsbureau, Conja, Marlies, Lakshmi en later ook Naomi, best bijzon-
der dat jullie me 2,5 jaar hebben kunnen pruimen. Begrijp me goed, het is niet altijd makkelijk 
met alleen maar dames om je heen! Vraag maar aan de Ridder.
Ellen, als ik ooit op een plek kom waar ik een secretaresse nodig heb dan wil ik jou!
Dan de paranimfen:
Vis, euhhm, mede danzij jou heb ik een prima onderzoekstijd gehad. Inmiddels niet alleen 
collega’s maar ook goede vrienden. We hebben samen heel wat mooie reisjes gemaakt; met 
name Lapland en Atlanta waren behalve heel interessant, ook gewoon heel erg leuk. Het was 
altijd lachen; mooie verhalen te over. Wat zou onze toekomst in de Urologie ons gaan bren-
gen? Ik ben blij je vandaag aan mijn zijde te hebben.
Luuk, mijn beste herinneringen liggen misschien wel op de fiets, de slechtste ook overi-
gens (Galibier 2005). Jij was daar bijna telkens bij. Het voelt als ‘friends forever’. Geweldig dat 
jij mijn paranimf wilt zijn. Ik zal proberen niet al te veel te klagen.
Zonder het solide fundament dat ik vanuit thuis heb meekregen, ‘nature and nurture’, was 
ik niet geweest wie ik nu ben. Mijn jeugd op het platteland heeft me een hele sterke basis 
gegeven. Marte en Frouke, ik zou jullie voor geen goud willen missen! Papa en mama, ik ben 
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jullie zo dankbaar dat jullie mijn ouders zijn. Als het goed is wordt jullie invloed steeds minder, 
maar jullie blijven de bakens! Dit is ook jullie boekje.
Stijn Roemeling, 2007
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